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Abstract 
P2X7 receptors form non-selective cation channels at the plasma 
membrane and are gated by the binding of extracellular ATP. Prolonged P2X7 
receptor activation also leads to formation of a pore that allows permeation of 
large molecules. Many cell types express P2X7 receptors. Expression is 
particularly high in cells of hematopoietic origin, where they have important 
roles in many biological processes, including release of pro-inflammatory 
cytokines and apoptosis. Furthermore, the properties of P2X7 receptors, 
including their functional expression and pharmacology, exhibit striking species 
differences. However, the underlying molecular bases for these differences are 
not fully understood. 
The gene encoding human P2X7 receptors contains numerous single 
nucleotide polymorph isms (SNP), several of which are non-synonymous (ns-
SNP). Two ns-SNP mutations, H155Y and A348T, were of particular interest 
due to their gain-of function effect on P2X7 receptors. Furthermore, a previous 
study found ATP-induced secretion of cytokines was enhanced in immune cells 
from individuals harbouring the A348T mutation. These two mutations were 
therefore examined in detail. Whole-cell patch-clamp current recordings clearly 
showed both mutations increased agonist-induced maximal currents, with no or 
very mild effect on agonist sensitivity. Cells expressing human P2X7 receptors 
had lower ATP-evoked maximal currents in comparison to the rat receptor. 
Mutations H155Y and A348T change the residues to those in the corresponding 
positions of the WT rat P2X7 receptor. Introduction of reciprocal mutations, 
Y155H and T348A into the rat P2X7 receptor reduced agonist-evoked current 
amplitudes. Substitution of residues surrounding His 155 and Ala348 in the human 
P2X7 receptor with the corresponding residues of the rat P2X7 receptor did not 
result in gain-of-function, with the exception F353L. However, the reciprocal 
mutation L353F in the rat P2X7 receptor had no effect. Taken together, these 
results strongly indicate that residues 155 and 348 are important in determining 
the functional expression of P2X7 receptors. In addition, they reveal that the 
residues at these two positions contribute to the differences in functional 
expression of human and rat P2X7 receptors. 
Further investigations into the functional roles of His 155 and Ala348 were 
performed by studying the effects of mutating to residues with side chains of 
distinct properties. Substitution of His 155 with leucine and aspartic acid reduced 
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ATP-induced current amplitudes, whilst phenylalanine, arginine and alanine had 
no significant effect. Mutation of Ala348 revealed a discernible effect on the 
human P2X7 receptor in that substitution with residues with larger side chains 
reduced, whereas changes to residues with small side chains increased, the 
amplitude of ATP-evoked currents. Immunostaining and biotin labelling revealed 
the H155Y mutation of human P2X7 receptors increased, whilst Y155H of rat 
receptors decreased surface expression. No such effect on surface expression 
resulted from reciprocal mutations at position 348. A human P2X7 receptor 
model, based on the recently determined crystal structure of the zebrafish P2X4 
receptor, indicates that His 155 is in the extracellular region, distant from the 
agonist-binding site and ion-permeating pore, whilst Ala348 is located 
immediately intracellular to the narrowest part of the ion-conducting pathway. 
Therefore, the simple and most consistent explanation for the effects of 
mutating residues at 155 and 348 is that the residue at 155 is important in 
determining receptor surface expression, and the residue at 348 is involved in 
single channel function. 
The monkey P2X7 receptor, which shares 96% sequence homology with 
the human P2X7 receptor, has been functionally characterised, and its 
pharmacological properties were similar to that of the human receptor. The 
monkey P2X7 receptor had a 14-fold higher sensitivity to BzATP over ATP. 
Furthermore, the sensitivity to ATP and BzA TP was slightly lower than in 
comparison to human P2X7 receptors (2.5- and 2-fold, respectively). The 
sensitivity of the monkey P2X7 receptor to the P2X7 receptor antagonists KN-62, 
AZ11645373 and A-438079 was virtually indistinguishable from that of the 
human P2X7 receptor. Therefore the five amino acids in the extracellular 
domain that differ between human and monkey P2X7 receptors do not critically 
interact with these antagonists. The similar pharmacological profiles of human 
and monkey P2X7 receptors suggests the monkey pr?vides a suitable model for 
to investigate P2X7 receptor involvement in human diseases. 
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Chapter 1 
General introduction 
1 
1.1 Purinergic signalling 
1.1.1 History of purinergic signalling 
The first evidence that purines have extracellular actions came in 1929 
when Drury and Szent-Gyrogyi reported that intravenous injection of adenine 
compounds affects the activity of the mammalian heart (Drury and Szent-
Gyorgyi, 1929). In 1972, Burnstock put forward the hypothesis that adenosine 
5'-triphosphate (ATP) acts as a neurotransmitter and accounts for the non-
adrenergic, non-cholinergic responses in the gut and bladder, which he called 
'purinergic' (Burnstock, 1972). In 1978 purinergic receptors were separated into 
two groups, P1 for those activated by adenosine and P2 for those by ATP and 
adenosine 5'-diphosphate (ADP) (Burnstock, 1978). P2 receptors divide into 
two subfamilies based on their structural features and signal transduction 
mechanisms. The P2Y receptor family contains the seven-transmembrane (TM) 
metabotropic G-protein coupled receptors and the P2X receptor family contains 
the two-TM ligand gated ion channels (Abbracchio et al., 2009; Ralevic and 
Burnstock, 1998). The first P2Y receptors were cloned in 1993 (Lustig et al., 
1993; Webb et al., 1993) and the first P2X receptors a year later (Brake et al., 
1994; Valera et al., 1994). 
1.1.2 A TP release 
A TP is a critical source of energy within cells, and therefore the concept 
that a molecule so important to cell physiology could be released into the 
extracellular space was initially difficult for many researchers to comprehend. 
Due to its size and charge, ATP is unable to cross the plasma membrane by 
simple diffusion (Bodin and Burnstock, 2001). AlP is released by cell lysis in 
response to injury, inflammation and traumatic shock (Abbracchio et al., 2009; 
Bodin and Burnstock, 2001; Yegutkin, 2008). A number of cell types release low 
concentrations of ATP under basal conditions and in response to shear stress, 
hypotoniC swelling, hydrostatic pressure, hypoxia and stretching. There are 
numerous ATP release mechanisms under physiological conditions (Abbracchio 
et al., 2009; Bodin and Burnstock, 2001; Yegutkin, 2008). 
Release of ATP in response to nerve stimulation was first shown in 1959 
(Holton, 1959). The idea that ATP acts as a neurotransmitter came from the 
observations made in 1970 that AlP accounts for the non-adrenergic, non-
cholinergic transmission in the gut (Burnstock et aI., 1970). It is now well 
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established that ATP is a neurotransmitter or co-transmitter released with other 
neurotransmitters such as noradrenaline and acetylcholine (Abbracchio et al., 
2009). ATP is synthesised and packaged into vesicles at the presynaptic 
terminals and, upon nerve stimulation, released into the synaptic cleft by 
exocytosis, where it is degraded by ectonucleotidases (see below). 
1.1.3 Ectonucleotidases 
Once released into the extracellular space, ATP is rapidly metabolised by 
ectonucleotidases (Goding et al., 2003; Yegutkin, 2008). There are three 
different families of these enzymes: ecto-nucleoside 5'-triphosphate 
diphosphohydrolase (E-NTPDase), ecto-nucleotide 
pyrophosphatase/phosphodiesterase (E-NPP) and ecto-5'nucleotidase (Figure 
1.1) (Goding etal., 2003; Yegutkin, 2008). 
The E-NTPDase family has eight members, four of which express at the 
cell surface (ENTPDase 1 to 3 and 8). E-NTPDases dephosphorylate both ATP 
and ADP (Figure 1.1). E-NTPDase 1 has been identified as the B-cell activation 
marker, cell activation antigen CD39 and has a wide expression pattern. E-
NTPDase 2 expression is mainly in the mesodermal and endodermal layers, E-
NTPDase 3 in the central nervous system (CNS) and E-NTPDase 8 in the liver 
(Yegutkin, 2008). 
The E-NPP ectonucleotidase family has seven members (E-NPP1 to 7). 
Only E-NPP1 to 3 are capable of hydrolysing nucleotides, and convert ATP into 
adenosine monophosphate (AMP) and pyrophosphate (Figure 1.1). E-NPPs 
can be detected in almost all tissues (Goding et al., 2003; Yegutkin, 2008). 
The ecto-5'-nucleotidase family also has seven members, which 
hydrolyse AMP to adenosine and phosphate (Figure 1.1). Only one member of 
this family, also known as CD73, is located in the outer plasma membrane and 
therefore capable of hydrolysing extracellular AMP (Yegutkin, 2008). 
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~ _______ a _______ _ 
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ATP --+ ADP --+ AMP --+ Adenosine 
\~~ 1 .~Iium.~" 
P2X1_7 A1, 2A, 28, 3 "''''t}. 
\~ 
Figure 1.1 ATP Signalling 
ATP is metabolised to ADP, AMP and adenosine by ectonucleotidase enzymes. 
ATP activates P2X and some P2Y receptors, ADP activates some P2Y 
receptors, and adenosine activated adenosine receptors. (a) E-NPP (b) E-
NTPDase (c) ecto-5'-nucleotidase. This diagram has been adapted from Khakh 
and North, 2006 and Yegutkin, 2008. 
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1.1.4 Purinergic receptors 
AdenosinelP1 receptors 
P1 receptors, more often referred to as adenosine receptors, are 
activated by adenosine. Four members of the P1 receptor family have been 
identified, A1, A2A, A2B and A3 (Burnstock, 2007; Ralevic and Burnstock, 1998; 
von KOgelgen, 2006). They are metabotropic receptors coupling to G proteins, 
resulting in initiation of intracellular signalling cascades. A1 and A3 receptors 
couple to Gilo proteins, leading to inhibition of adenylate cyclase and a fall in 
levels of the second messenger cyclic AMP (cAMP). In contrast, A2A and A2B 
receptors primarily couple to Gs proteins, which stimulate adenylate cyclase and 
cause an increase in cAMP production. Interestingly, A3 receptors can also 
couple to Gq/11 proteins resulting in activation of phospholipase C (PLC) which 
hydrolyses the membrane phospholipid phosphatidylinositol 4,5-bisphosphate 
(PIP2) to produce diacylyglycerol (DAG) and inositol-3-phosphate (IP3). It is 
therefore clear that the actions of adenosine depend on the complement of 
receptors expressed at the plasma membrane of the cell, resulting in diverse 
cellular signalling cascades (Burnstock, 2007; Ralevic and Burnstock, 1998; von 
KOgelgen, 2006). 
P2Y receptors 
To date, eight mammalian P2Y subunits have been identified, P2Y1. 2. 4, 6, 
11-14. Like adenosine receptors, they couple to G proteins (Burnstock, 2007; 
Ralevic and Burnstock, 1998; von KOgelgen, 2006) and can be divided into 
three groups according to the agonists which activate them. P2Y1, 11-13 are 
activated by adenine nucleotides, P2Y2, 4 & 6 are activated by uracil nucleotides 
and P2Y14 is activated by uracil diphosphate (UDP)-sugar derivatives. P2Y1, 2, 4, 
6, 11 & 14 receptor activation stimulates PLC activity via coupling to Gq/11 proteins. 
This leads to conversion of PIP2 to DAG and IP3 and subsequent Ca2+ 
mobilisation from intracellular stores. P2Y11 also couples to Gs proteins, 
resulting in adenylate cyclase activation and an increase in cAMP production. 
Conversely, P2Y2, 4,12,13 receptors couple to Gilo proteins and inhibit adenylate 
cyclase (Burnstock, 2007; Ralevic and Burnstock, 1998; von KOgelgen, 2006). 
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P2X receptors 
Seven P2X receptor subunits have been cloned to date, P2X1-7 (North, 
2002; Ralevic and Burnstock, 1998). P2X receptors form ATP-gated, cation 
selective ion channels at the plasma membrane (North, 2002; Valera et a/., 
1994). The studies presented in this thesis focus on P2X receptors, and 
therefore the following sections will discuss the properties of these receptors in 
more detail. 
1.2 Cloning and tissue distribution of vertebrate P2X subunits 
1.2.1 P2X1 
The first complementary DNA (cDNA) encoding a P2X receptor subunit 
(P2X1) was cloned from the rat vas deferens (Valera et a/., 1994). cDNAs 
encoding the P2X1 subunit were subsequently isolated from human and mouse 
urinary bladders and chicken brain (Soto et a/., 1997; Soto et a/., 2003; Valera 
et a/., 1995). The human gene encoding the P2X1 subunit has been mapped to 
chromosome 17 by in situ hybridisation (Valera et a/., 1995). The rat, human 
and mouse P2X1 subunits are 399 amino acids long, whilst the chicken subunit 
has 392 residues (Soto et a/., 2003; Valera et a/., 1994; Valera et a/., 1995). 
P2X1 messenger RNA (mRNA) has been detected in the spinal cord, 
sensory ganglia, superior cervical ganglia and coeliac ganglia, and in smooth 
muscle of the vas deferens, bladder and peripheral arteries (Collo et a/., 1996; 
Valera eta/., 1994). 
1.2.2 P2X2 
The P2X2 receptor subunit was first cloned from rat pheochromocytoma 
(PC12) cells (Brake et a/., 1994). Human P2X2 cDNA has been cloned from 
pituitary gland, and a number of splice variants were isolated, including P2X2b 
(internal splicing within exon 11), P2X2c (removal of exon 3), and P2X2d 
(inclusion of intron 11) (Lynch et a/., 1999). The rat P2X2 subunit contains 472 
amino acids, and the full-length human P2X2 subunit is one amino acid shorter 
(Brake eta/., 1994; Lynch eta/., 1999). 
P2X2 receptor subunits are widely expressed in the CNS, including the 
thalamus, hypothalamus, preoptic area and spinal cord. They are also found in 
sensory ganglia, superior ganglion, adrenal medulla, bladder, pituitary, vas 
deferens and intestine (Brake et a/., 1994; Collo et a/., 1996; Lynch et a/., 1999). 
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1.2.3 P2X3 
The cDNA for the P2X3 receptor subunit was simultaneously cloned by 
two groups from rat dorsal root ganglion (DRG) (Chen et a/., 1995; Lewis et a/., 
1995). The human, mouse and zebrafish P2X3 receptor subunits have 
subsequently been cloned (Boue-Grabot et al., 2000; Garcia-Guzman et al., 
1997b; Souslova et a/., 1997), and the human P2X3 receptor gene has been 
mapped to region q12 of chromosome 11 (Garcia-Guzman et a/., 1997b). The 
human, rat and mouse P2X3 subunits contain 397 amino acids (Chen et a/., 
1995; Garcia-Guzman et a/., 1997b; Lewis et a/., 1995; Souslova et a/., 1997), 
whilst the zebrafish P2X3 is 410 residues long (Boue-Grabot et al., 2000). 
Despite analysis of numerous tissue types, studies have only shown rat 
P2X3 receptor mRNA in sensory neurones (Chen et al., 1995; Collo et al., 
1996), whilst human P2X3 receptor mRNA is detected in the heart and spinal 
cord (Garcia-Guzman eta/., 1997b). 
1.2.4 P2X4 
The P2X4 receptor subunit was first cloned from rat brain (Bo et al., 
1995; Buell et a/., 1996), and the human, mouse, zebrafish and Xenopus /aevis 
subunits were cloned soon after (Diaz-Hernandez et a/., 2002; Garcia-Guzman 
et a/., 1997a; Juranka et al., 2001; Townsend-Nicholson et al., 1999). The 
human P2X4 receptor gene has been mapped to region q24.32 of chromosome 
12 (Garcia-Guzman et a/., 1997a). The rat, human, mouse and zebrafish P2X4 
subunits have 388 amino acids, and the Xenopus /aevis P2X4 subunits consists 
of 391 residues (Bo et a/., 1995; Buell et a/., 1996; Garcia-Guzman et a/., 
1997a; Townsend-Nicholson et a/., 1999). 
P2X4 receptors have a wide expression pattern. P2X4 receptor mRNA . 
has been detected in the brain, heart, spinal cord, adrenal gland, liver, kidney, 
skeletal muscle, trachea, lung, vas deferens, bladders, testis, thymus, salivary 
gland, sensory ganglia, pancreas, arterial smooth muscle, osteoclasts, kidney 
vascular endothelial cells and human B lymphocytes (Bo et a/., 1995; Buell et 
a/., 1996; Collo et a/., 1996; Garcia-Guzman et a/., 1997a). 
1.2.5 P2Xs 
P2Xs receptor cDNA was cloned from rat celiac ganglia (Collo et a/., 
1996) and heart (Garcia-Guzman et a/., 1996; Haines et a/., 1999). The P2Xs 
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subunit has been also cloned from human and mouse (80 et al., 2003; Cox et 
al., 2001). The human P2Xs subunit gene is located on chromosome 17p13.3 
(Le et al., 1997). The rat and mouse P2Xs subunits are 455 amino acid residues 
long, whilst the full-length human receptor contains 444 residues (80 et al., 
2003; Colla et al., 1996; Garcia-Guzman et al., 1996). 
In situ hybridisation shows little evidence of P2Xs receptor RNA in the 
brain, however mRNA for this receptor could be detected in the spinal cord and 
sensory ganglia (Colla et al., 1996). Southern blot analysis, however, shows 
P2Xs mRNA expression in the brain as well as in heart, spinal cord and adrenal 
gland (GarCia-Guzman et a/., 1996). P2Xs receptors are also expressed in 
satellite skeletal muscle cells (Ryten et al., 2002). 
1.2.6 P2X6 
The P2X6 receptor subunit was first cloned from rat brain (Collo et aI., 
1996; Soto et al., 1996). The human and mouse homologues were 
subsequently cloned from human peripheral lymphocytes (Urano et al., 1997), 
and from mouse skeletal muscle (Nawa et al., 1998), respectively. The human 
P2X6 gene is located on chromosome 22q11 (Urano et al., 1997). The rat and 
mouse subunits are 379 amino acids in length, whilst the human P2X6 
comprises of 431 residues (Colla et a/., 1996; Soto et al., 1996). 
P2X6 receptor mRNA was detected by in situ hybridisation in neurones of 
the CNS, several laminae of the spinal cord, superior cervical ganglion, salivary 
gland, sensory ganglia and bronchial epithelium (Collo et al., 1996). 
Furthermore mRNA for P2X6 was detected by RT-PCR (reverse transcription-
polymerase chain reaction) in the brain, spinal cord, heart, trachea, uterus, 
lungs testis, liver and astrocytes, and in secretory tissues such as the pituitary 
and adrenal gland (Soto et a/., 1996). 
1.2.7 P2X7 
The P2X7 receptor is the main focus of this work, therefore the cloning 
and expression will be discussed in detail in section 1.6. 
1.2.8 Invertebrate P2X subunits 
Genomic analysis indicates P2X subunits are also found in many 
invertebrate species (Fountain and 8urnstock, 2009) (Figure 1.2). The first was 
8 
cloned from Schistosoma mansoni (Agboh et a/., 2004). In 2007, Fountain et a/. 
identified a Dictyoste/ium discoideum P2X receptor. This receptor is localised to 
membranes of the contractile vacuole, an intracellular organelle, and is 
important in regulating cell volume in hypotonic conditions (Fountain et a/., 
2007). A P2X receptor subunit has also been cloned from the green algae 
Ostreococcus tauri (Fountain et a/., 2008). 
1.3 Biophysical properties and functions of P2X receptors 
This section describes the biophysical properties and physiological 
functions of six vertebrate P2X receptors (P2X1-6). These properties of the P2X7 
receptor are discussed in detail in section 1.6. 
1.3.1 P2X1 receptors 
Agonist-evoked currents mediated by P2X1 receptors have fast activation 
and desensitisation kinetics (Figure 1.3) and the recovery from receptor 
desensitisation following agonist removal is slow (North, 2002; Soto et a/., 2003; 
Valera et a/., 1994). 
The generation of P2X1 receptor deficient mice has allowed the roles of 
P2X receptors containing the P2X1 subunit to be determined. The first such 
study showed that disruption of the P2X1 receptor function led to a dramatic 
reduction in fertility of male mice due to reduced contraction of the vas deferens 
in response to sympathetic nerve stimulation, thereby reducing the number of 
sperm in the ejaculate (Mulryan et a/., 2000). The amplitude of bladder detrusor 
muscle contractions in response to nerve stimulation was also reduced in P2X1 
deficient mice, indicating a role for the P2X1 receptor in urinary bladder function 
(Vial and Evans, 2000). Furthermore, a role for the P2X1 receptor in arterial 
vasoconstriction has been studied (Vial and Evans, 2002). It has been shown 
that constriction of mesenteric arteries from P2X1 deficient mice in response to 
sympathetic nerve stimulation is attenuated. However, P2X1 deficient mice had 
normal or only slightly elevated blood pressure, although it has been suggested 
that during increased sympathetic tone the contribution of the P2X1 receptor to 
blood pressure may be altered (Mulryan et a/., 2000; Vial and Evans, 2002). 
Finally, collagen and adrenaline infused into the· jugular vein induced 
intravascular thrombi formation and acute vascular occlusion, and led to death 
of the majority of wild type (VVT) mice (Hechler et a/., 2003). However, P2X1 
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Figure 1.2 Phylogenetic tree showing the relationship between vertebrate 
and invertebrate P2X receptors 
Black lines indicate vertebrate P2X receptor subunits, whilst red lines indicate 
invertebrate P2X receptors. Amoeba and Algae families are highlight grey and 
green respectively. This diagram has been taken from Fountain and Burnstock, 
2009. 
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deficient mice were more likely to survive this treatment. Furthermore, vessel 
wall injury induced by lasers led to localised thrombosis in mesenteric arterioles, 
however the thrombus size was reduced in P2X1 receptor deficient mice. These 
studies have demonstrated a role for the P2X1 receptor in platelet thrombi 
formation (Hechler et al., 2003). 
1.3.2 P2X2 receptors 
Agonist-evoked currents mediated by P2X2 receptors show fast 
activation with little or no desensitisation (Figure 1.3) (Brake et al., 1994; Lynch 
et al., 1999). 
A functional role for the P2X2 receptor has been demonstrated in the 
modulation of ventilation in response hypoxia (Rong et al., 2003). P2X2 receptor 
deficient mice failed to increase their rate and depth of breathing in hypoxic 
conditions. The cells of the carotid body detect arterial P02 , and this information 
is relayed to the respiratory sensors of the brainstem via the carotid sinus 
nerve. However, in a model sinus nerve activity induced by hypoxia was 
impaired in P2X2 deficient mice, indicating an important role for P2X2 receptors 
in this pathway. 
P2X, P2Xs 
rVT -V 
Figure 1.3 Comparison of ATP-evoked currents of P2X receptors 
Whole-cell recordings made from HEK293 cells expressing indicated 
homomeric P2X receptors in response to a 2 s application of 30 f-lM ATP (or 1 
mM for P2X7). This figure has been taken from North, 2002. 
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1.3.3 P2X3 receptors 
Agonist-evoked currents mediated by P2X3 receptors display rapid 
activation, rapid desensitisation (Figure 1.3), and slow recovery from 
desensitisation (Chen et al., 1995; Garcia-Guzman et al., 1997b). 
P2X3 receptors are highly expressed in nociceptive or "pain sensing" 
DRG neurons and there is strong evidence that it contributes to a number of 
pain states including neuropathic and inflammatory pain. Reduction of P2X3 
receptor protein expression using short interfering RNA (siRNA) attenuated 
agonist-induced hyperalgesia (enhanced pain sensation to a normally painful 
stimulus) and tactile allodynia (pain sensation to a normally innocuous stimulus) 
in the partial sciatic ligation model of neuropathic pain (Dorn et al., 2004), 
indicating that P2X3 contributes to neuropathic pain. Interestingly, mice lacking 
the P2X3 receptor subunit display increased thermal hyperalgesia in response 
to chronic inflammation (Souslova et al., 2000). However, in contrast, A-317491, 
a selective inhibitor for P2X3 and P2X2/3 receptors (see section 1.5.2), 
attenuated thermal hyperalgesia in models of inflammatory pain (Jarvis et al., 
2002). P2X3 deficient mice displayed symptoms of urinary bladder hyporeflexia, 
including decreased bladder contractions in response to distension, decreased 
urination and increased bladder capacity, supporting a role for the P2X3 
receptor in controlling the bladder volume reflexes (Cockayne et al., 2000). 
Following cloning of the P2X3 subunit from DRG neurons, Lewis and 
colleagues observed that the properties of af3-methylene-ATP- (af3meATP) 
evoked currents of P2X3 receptors expressed in HEK293 (human embryonic 
kidney 293) cells were different from sensory neurons. They found that agonist-
evoked currents of HEK293 cells co-expressing P2X2 and P2X3 resembled 
those of sensory neurons, and concluded that sensory neurons express P2X2/3 
heteromers (Lewis et al., 1995). 
1.3.4 P2X4 receptors 
Agonist-evoked currents mediated by P2X4 receptors exhibit rapid 
activation and mild desensitisation kinetics (Figure 1.3) (Bo et al., 1995; Buell et 
al., 1996; Garcia-Guzman et al., 1997a; Townsend-Nicholson et al., 1999). 
A functional role for the P2X4 receptor has been described in a number 
of tissues. Schaffer collateral stimulation in the CA 1 region of mouse 
hippocampal slices leads to long-term potentiation (L TP). At these synapses, 
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L TP is reduced in P2X4 deficient mice, thus indicating a role in synaptic 
plasticity (Sim et al., 2006). Studies in the vascular system showed that pre-
constricted arterioles vasodilate in response to administration of ATP 
(Yamamoto et al., 2006). Such vasodilation of arterioles from P2X4 receptor 
deficient mice was suppressed, indicating that P2X4 receptors are important in 
control of vascular tone. Adaptive vascular remodelling describes the decrease 
in vessel diameter in response to a decrease in blood flow. However, in P2X4 
deficient mice, the lumen diameter of the common carotid artery was not 
reduced in response to decreased blood flow, demonstrating a role for P2X4 
receptors in vascular remodelling (Yamamoto et al., 2006). Furthermore, 
following nerve injury, P2X4 receptor expression is increased in spinal cord 
microglia, and administration of antisense oligodeoxynucleotides against the 
P2X4 receptor reduced tactile allodynia (Tsuda et al., 2003). 
1.3.5 P2Xs receptors 
Rat P2Xs receptor mediated currents have fast activation kinetics and 
show little desensitization (80 et al., 2003; Chen et al., 1995; Collo et al., 1996; 
Garcia-Guzman et al., 1996). 
Activation of the P2Xs receptor has been shown to be important in 
skeletal muscle differentiation (Ryten et al., 2002). Following muscle damage, 
skeletal muscle satellite cells undergo differentiation to form new muscle. P2X5 
receptor activation is thought to inhibit satellite cell proliferation and increase 
cell differentiation. Indeed, P2Xs receptor protein was only expressed in the 
satellite cells when they are grown in conditions that promote cell differentiation, 
and not in normal growth media (Ryten et al., 2002). 
1.3.6 P2X6 receptors 
ATP-induced currents in cells expressing P2Xs receptors are fast to 
activate. Currents show little desensitisation, however recovery to baseline is 
slow following agonist removal (Collo et al., 1996; Jones et al., 2004). When 
cDNA encoding the P2Xs receptor was transfected into HEK293 cells, ATP-
evoked currents could only be recorded in less than 5% of the cells (Collo et al., 
1996). Furthermore, ATP-induced P2Xs mediated currents could not be 
detected when expressed in Xenopus oocytes (Soto et al., 1996). However, it 
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has been shown that extensive glycosylation of P2X6 receptors is required for 
receptor function (Jones et al., 2004). 
1.3.7 P2X receptor of invertebrate species 
Disruption of the Dictyoste/ium discoideum P2X receptor orthologue 
Ddp2xA led to cells that were unable to control their volume in hypotonic 
solutions, and cell swelling (Fountain et al., 2007). This is the first evidence 
supporting an intracellular role for P2X receptors and raises the questions of 
what roles intracellular P2X receptors could play in mammalian cell physiology. 
1.4 P2X structure 
The crystal structure of a P2X receptor has recently been solved (Kawate 
et al., 2009). Prior to this, studies utilised site-directed mutagenesis in 
conjunction with biochemical and functional studies to determine the 
stoichiometry and molecular mechanisms of P2X receptors. It has now become 
clear that inferences made from such studies were highly accurate (Browne et 
al., 2010; Evans, 2010; Kawate et al., 2009; Young, 2010). In this section, the 
findings of these structure-function experiments, and how they relate to the P2X 
crystal structure are discussed. 
1.4.1 Crystallisation of the zebrafish P2X4 receptor 
The zebrafish P2X4 receptor crystal structure has been solved in the 
closed state at a resolution of 3.1 A (Kawate et al., 2009). To increase suitability 
for crystallisation, a zebrafish P2X4 construct, with amino (N-) and carboxyl (C-) 
terminal truncations and three mutations (C51 F/N78K1N187R) to reduce non-
native disulphide bond formation and glycosylation, was generated. Importantly, 
this construct was functional, albeit with smaller ATP-induced currents in 
comparison to WT (Kawate et al., 2009). 
1.4.2 P2X receptor subunit topology 
Cloning of the P2X receptor subunits allowed predictions on the subunit 
topology to be made. Based on hydrophobicity analyses, each P2X subunit was 
predicted to contain two TM domains, a large extracellular domain, and 
intracellular C- and N-termini (Valera et 81., 1994). The crystal structure 
confirms this subunit topology (Kawate et al., 2009). The shape of a single P2X4 
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subunit is dolphin-like when viewed parallel to the membrane (Figure 1.4A) 
(Kawate et a/., 2009). 
1.4.3 P2X receptor architecture 
Evidence from biochemical and functional experiments consistently show 
that P2X receptors are trimers. Nicke et a/. used blue native polyacrylamide gel 
electrophoresis (BN-PAGE) followed by Western blotting to show that the native 
P2X1 receptor is a trimer (Nicke et a/., 1998). Furthermore, the use of cross-
linking agents, followed by Western blotting, has shown that P2X receptor 
subunits cross-link into trimers (Barrera et a/., 2005; Nicke et a/., 1998). Imaging 
of antibody-decorated P2X2 receptor by atomic force microscopy indicated that 
this receptor also assembles as a trimer (Barrera et a/., 2005). The subunit 
arrangement of P2X receptors has been studied. Mutations V48C at the 
extracellular end of the P2X2 TM 1, and 1319C at the extracellular end of the 
P2X3 TM2 allowed inter-subunit disulphide bonds to form between the two 
subunit subtypes (Jiang et a/., 2003). Subunits are in a 'head-to-tail' 
arrangement, with contacts made between the TM 1 of one subunit and TM2 of 
another (Jiang et a/., 2003). 
The crystal structure of the zebrafish P2X4 receptor confirmed that P2X 
receptors are trimers (Figure 1.4B) (Kawate et a/., 2009). Detailed study of the 
crystal structure revealed that the TM region has an hour-glass shape and 
comprises six helices (two from each subunit), which are in a left-handed twist. 
The three TM2 domains line the pore and form the ion conducting pathway. The 
TM2 domains cross halfway through the membrane when the channel is closed, 
whereas the three TM1 domains were found to surround the TM2 domains. The 
extracellular regions of the three subunits wrap around each other in a right-
handed twist, and there are extensive subunit-subunit interactions in this 
domain (Kawate et a/., 2009). 
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Figure 1.4 The subunit and trimeric structure of P2X receptors 
(A) The zebrafish P2N subunit is dolphin-like in shape. The a-helices, p-
strands and attached glycans are indicated. Disulphide bonds are numbered 
SS1-5. (8) The structure of the zebrafish P2N receptor viewed parallel to the 
membrane. Each subunit is in different colour and the grey lines represent the 
inner and outer leaflets of the plasma membrane. This figure has been taken 
from Kawate et al., 2009. 
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1.4.4 A TP binding site of P2X receptors 
Analysis of the initial slope of agonist concentration-current response 
curves suggested that P2X receptors are activated by binding of three agonist 
molecules (Bean, 1990; Jiang et a/., 2003). 
The crystal structure of the agonist-binding site is yet to be determined. 
The challenge is intensified by the fact that the large extracellular domain of 
P2X receptors lacks motifs and sequence homology with other proteins that 
bind ATP, for example, the Walker motif (Evans, 2010; Walker et aI., 1982). 
However, extensive site-directed mutagenesis studies have found a number of 
highly conserved residues that are important in ATP binding. 
The phosphate groups of ATP are negatively charged, and therefore site-
directed mutagenesis studies focused on positively charged residues in the 
extracellular domain that could potentially coordinate these groups. Of particular 
importance are residues Lys69, Lys71 , Arg290 and Lys308 (P2X2 numbering), or 
the corresponding residues in P2X1 and P2X4 receptors (Table 1.1), the 
mutation of which reduced the potency of ATP (Ennion et aI., 2000; Jiang et a/., 
2000b; Roberts and Evans, 2007; Roberts et a/., 2008; Zemkova et a/., 2007). 
The aromatic residues in the extracellular domain have been investigated 
with respect to their potential interaction with the adenine ring of ATP. Mutation 
of residues Phe183 or Phe289 (P2X2 receptor numbering) or equivalent residues 
in P2X1 and P2X4 receptors led to a reduction in the potency of ATP, implicating 
an importance in ATP binding (Table 1.1) (Roberts and Evans, 2004; Roberts 
and Evans, 2007; Roberts et a/., 2008; Zemkova et a/., 2007). 
The effect of mutating uncharged polar residues of the extracellular loop 
has also been investigated. Mutation of Thr184 and Asn288 (P2X2 numbering) or 
corresponding residues in P2X1 and P2X4 receptors has been shown to reduce 
the potency of ATP (Table 1.1) (Jiang et a/., 2000b; Roberts and Evans, 2006; 
Roberts and Evans, 2007; Roberts et a/., 2008; Roberts et a/., 2009). 
To further investigate the ATP binding site, Jiang et a/. introduced the 
167C mutation to the P2X2 receptor, and demonstrated inhibition of ATP-evoked 
currents by methanethiosulphate (MTS) compounds with different head group 
properties (different charges and size). The inhibition by negatively charged 
MTS compounds caused a rightward shift in the agonist dose response curve, 
and was overcome by increased ATP concentrations. Consistently, introduction 
of negative groups at this position by site-directed mutagenesis reduced the 
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Table 1.1 Amino acids predicted to be involved in ATP binding 
P2X1 P2X2 P2X4 References 
Lys68 Lys69 LyStlf Ennion et al., 2000, Jiang et al., 2000b, Roberts et al., 2008, Zemkova et al., 2007. 
LysfU Lysfl Lysb!:l Ennion et al., 2000, Jiang et al., 2000b, Roberts et al., 2008. 
PheH:s:, PheHSJ PheHS:' Roberts and Evans, 2004; Roberts et al., 2008; Zemkova et al., 2007. 
ThrHSb ThrHS4 Thr1B6 Jiang et al., 2000b, Roberts and Evans, 2006; Roberts et al., 2008; Roberts et al., 2009. 
Asn29U Asn2BB Asn293 Jiang et al., 2000b, Roberts and Evans, 2006; Roberts and Evans, 2007; Roberts et al., 
2008. 
Phe~!:Il Phe~~!:1 Phe~!:I4 Roberts and Evans, 2004; Roberts et al., 2008; Roberts and Evans, 2007; Zemkova et 
al., 2007. 
Arg29~ Arg~9U Arg29b Ennion et al., 2000; Jiang et al., 2000b; Roberts et al., 2008; Roberts and Evans, 2007; 
Zemkova et al., 2007. 
LysJU!:I LysJU~ LySJ1J Ennion et al., 2000; Jiang et al., 2000b; Roberts and Evans, 2007. 
The eight residues are predicted to be important in ATP-binding. Mutation of these residues reduced in ATP potency at 
P2X1, P2X2 and P2X4 receptors. 
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affinity of the receptor for ATP. These observations indicate that lIe67 is in the 
region of the ATP binding site (Browne et al., 2010, Jiang et al., 2000b). 
Wilkinson et a/. found that the function of K69A or K308A but not 
K69A1K308A P2X2 mutants could be rescued by co-expression with P2X3 
subunits, suggesting that the ATP binding site is located between neighbouring 
subunits rather than within the subunits (Wilkinson et al., 2006). In a separate 
study, double cysteine substitution of Lys68 and Phe291 of the P2X1 receptor, 
residues thought to be involved in ATP binding (see above), resulted in 
formation of trimers, which can be prevented by the presence of ATP. These 
residues are in close proximity, providing further evidence that the ATP binding 
sites are located at interfaces between adjacent subunits (Marquez-Klaka et al., 
2007). 
The structure of the zebrafish P2X4 receptor was solved in the absence 
of ATP, and therefore lacks direct evidence for the location of the ATP binding 
site (Kawate et al., 2009). However, a model of the P2X2 receptor, based on the 
zebrafish P2X4 structure, shows there are inter-subunit grooves which contain 
the eight residues that have been shown to be important determinants of the 
actions of ATP (Lys69, Lys71 , Phe183 and Thr184 from one subunit, and Asn288, 
Phe289, Arg290 and Lys308 from the other; P2X2 numbering; Figures 1.5B and 
1.5C) (Browne et a/., 2010; Kawate et al., 2009). These residues are conserved 
between P2X receptors (Figure 1.6). 
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Figure 1.5 Structural model of the P2X2 receptor 
(A) A single subunit, viewed parallel to the membrane, showing the five 
disulphide bonds present within each subunit. (B) Diagram showing only two 
subunits to show the predicted ATP binding site (arrow), which is formed 
between the two subunits. (C) Predicted ATP binding site, showing the location 
of eight highly conserved residues shown to be important for ATP-induced 
receptor activation from site-directed mutagenesis studies. This figure has been 
taken from Browne et al., 2010. 
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Figure 1.6 Amino acid sequence alignment of human P2X receptor 
subunits. Conserved cysteines are grey, and the 8 residues predicted to bind 
ATP (Table 1.1) are in pink. TM1 and TM2 are indicated. Accession numbers: 
X83688, AF190826, Y07683, Y07684, AF016709, 015547 and Y09561, 
respectively. Aligned using ClustalW. 
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1.4.5 Disu/phide bonds 
The extracellular loop of all mammalian P2X receptor subunits contains 
ten conserved cysteine residues (North, 2002). Clyne et al studied the effects of 
mutating these residues in the P2X2 receptor on ATP sensitivity, ATP-induced 
peak current amplitude, zinc potentiation and the effects of extracellular pH 
(Clyne et al., 2002). Ennion and Evans mutated each of these ten cysteines in 
P2X1 receptor. If the mutated cysteine was usually involved in disulphide bond 
formation, mutational effects or the free cysteine, if accessible, would be 
labelled by MTSEA-biotin (2-aminoethyl methanethiosulfonate hydrobromide-
biotin). Using these approaches, the two studies concluded that Cys 113_Cys 164, 
Cys 124_Cys 147, Cys 130_Cys 158, Cys214_Cys224 and Cys258_Cys267 (P2X2 
numbering) disulphide bonds exist (Ennion and Evans, 2002; Clyne et al., 2002; 
Kawate et al., 2009). The crystal structure of the zebrafish P2X4 receptor shows 
these combinations of cysteines do indeed form disulphide bonds (Figure 1.4A 
and 1.5A) (Browne et al., 2010; Clyne et al., 2002; Ennion and Evans, 2002; 
Kawate et al., 2009). In addition, disruption of Cys261_Cys270 disulphide bond, or 
Cys 117_Cys 165 and any other disulphide bond, disrupts P2X1 receptor trafficking 
to the cell surface (Ennion and Evans, 2002). 
The ten cysteine residues conserved among mammalian P2X receptors 
are not present in Dictostelium discoideum P2X receptors (with one exception) 
(Fountain et al., 2007). Despite this, ATP-evoked currents of HEK293 cells 
expressing this P2X receptor can be recorded, showing that disulphide bonding 
is not essential for P2X receptor function (Fountain et al., 2007). 
1.4.6 Transmembrane region 
The roles of the TM 1 and TM2 domains in ion permeation have been 
investigated. Studies into the modification of introduced cysteines in the TM2 
region of the P2X2 receptor by thiol-reactive compounds and ions indicate that 
residues in this region are located in the ion permeation pathway (Browne et al., 
2010; Li et al., 2008). For example, mutants T336C and T339C are modified 
much faster when the channel is open than in the closed state (Li et al., 2008). 
Cadmium (Cd2+) is a thiol-reactive metal with a similar radius to sodium and 
requires 3 cysteine residues for tight binding. Cd2+inhibited ATP-evoked 
currents of T336C mutant only when the channel was in the open state, 
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suggesting that the region surrounding Thr336 lines the ion conducting pore (U 
et a/., 2008). 
Mutations in the TM2 domain have been shown to affect the 
spontaneous gating, unitary conductance and outward rectification of the P2X2 
receptor (Cao et a/., 2007; Cao et a/., 2009). Mutations introduced between 
residues Asn333 and Ser340 produced spontaneous channel activity. 
Furthermore, mutation of residues Asn333, Thr336 and Ser340 to positively 
charged residues increased the amplitude of outward currents, indicating these 
side chains are important in ion permeation. Almost any amino acid substituted 
at Thr336 results in spontaneous activity of the channel, suggesting that 
movement of this residue is crucial for channel opening (Cao et a/., 2009). 
Residues in the TM1 domain were mutated to cysteine, however ATP-
evoked currents of relatively few mutants were modified by MTS reagents, 
suggesting that this domain does not line the ion permeation pathway (Browne 
et a/., 2010; Jiang et a/., 2001; U et a/., 2008). When Val48 (TM1) and lIe328 
(TM2) are both mutated to cysteine they are able to form a disulphide bond, 
leading to inhibition of ATP-evoked currents, which can be recovered by 
reducing agents. V48C becomes more accessible to MTS reagents when the 
channel is open, suggesting that movement of this part is important for gating of 
the ion channel (Jiang et a/., 2001). Furthermore, a chimera in which TM1 of 
P2X2 receptor was replaced with that of P2X1 receptor displayed increased 
af3meATP sensitivity (P2X2 receptor are insensitive to af3meATP), showing that 
the TM1 domain has an important influence on the gating properties of the ion 
channel (Haines et a/., 2001). 
The crystal structure of the zebrafish P2X4 receptor shows that the 
narrowest part of the ion permeating pathway is at residue Ala344 (Thr336 of rat 
P2X2) (Kawate et a/., 2009). This finding is consistent with structure-function 
studies (U et a/., 2008). The extracellular boundary is composed of residues 
Leu340 and Asn341 (lIe332 and Asn333 in rat P2X2), whilst the cytoplasmic gate is 
residues Ala347 and the Leu346 (Thr339 and Leu338 in rat P2X2, respectively). A 
model of the rat P2X2 receptor, based on the crystal structure of the zebrafish 
P2X4 receptor, predicts that Val48 and lIe328 are in close proximity, in line with the 
structure-function data (Browne et a/., 2010; Jiang et a/., 2001). 
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1.4.7 Channel opening 
A crystal structure of a protein is a snapshot in time, and, in the case of 
the zebrafish P2X4 structure, this snapshot is in the closed state (Kawate et aI., 
2009). However, the information gained from structure-function studies and the 
crystal structure allows predictions on the possible opening mechanism of the 
P2X receptor following agonist binding. Browne et al. predict that due to the 
positioning of Thr336, Thr339 and Ser340, channel opening is likely to involve a 
~50o anti-clockwise rotation of the TM2 domain and a steepening of the angle at 
which the TM2 domain crosses the membrane (Browne et aI., 2010). Cysteine 
mutation of ASp349 of the P2X2 receptor lead to ATP-induced currents that were 
completely blocked by MTSEA (Rassendren et al., 1997a). ASp349 is at the 
intracellular end of TM2, indicating that the intracellular parts of TM2, which are 
spread out in the closed state, must undergo substantial movement during 
channel opening (Browne et al., 2010; Rassendren et al., 1997a). 
1.5 P2X Pharmacology 
1.5.1 P2X receptor agonists 
The physiological agonist for P2X receptors is ATP. All P2X receptors 
respond to ATP in the low micromolar ()lM) range with the exception of P2X7 
that has a much lower sensitivity (Table 1.2). There are currently no P2X 
receptor subtype specific agonists. Several ATP analogues, however, show 
distinct potencies between receptor subtypes, although the difference is often 
limited. 
apmeATP most potently activates P2X receptors containing P2X1 and 
P2X3 subunits (Table 1.2). In contrast, the P2X2 receptor is relatively insensitive 
to apmeATP, thereby making this ATP analogue a useful tool for distinguishing 
these subtypes. apmeATP acts as a partial agonist at human and mouse P2X4 
receptors, and antagonises the rat P2X4 receptor (ICso 4.6 ~lM) (Jones et al., 
2000). apmeATP activates the human P2Xs receptor, albeit with a relatively low 
potency, and is without effect at rat P2Xs and P2X6 and P2X7 receptors at 
concentrations up to 100 )lM (Collo et al., 1996; Surprenant et al., 1996). 
Benzoyl-benzoyl-ATP (BzATP), another ATP analogue (Table 1.2), is a more 
potent agonist at P2X7 receptors than ATP (Surprenant et al., 1996; Young et 
aI., 2007). BzATP, however, should not be used as a P2X7 receptor specific 
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Table 1.2 Potencies of P2X receptor agonists and antagonists 
P2X ECso (~M) ICso (~M) 
receptor ATP upmeATP BzATP Suramin PPADS 
hP2X1 0.06*, 1, 0.8, 0.9 0.2*,2.2 0.002*,0.7 1-5,0.9* 1-5, 1.8* Bianchi et al., 1999; Ennion et 
rP2X1 1 0.7 <10 <30, 0.09, 0.1 al., 2000 ; Evans et a/ .. 1995. 
rP2X2 1.4*, 7.7, 60 <100*, »100 5.5*,23 1-5,33* 1-5,3.8* Bianchi et al., 1999; Brake et al., 
1994 ; Evans et a/., 1995. 
hP2X3 0.3* 0.7* 0.08* <100* 5.1* Bianchi et al., 1999; Chen et al., 
rP2X3 0.3*, 0.5, 1.2 0.5* 0.03* 0.8*,3 3.6*, 1.5 1995 ; Lewis et a/., 1995. 
rP2X2/3 0.5* 3.4* 0.65* 0.8* 1.3* Bianchi et al., 1999. 
hP2~ 0.5*, 1.4 8.3*, 19 0.5* <100* <100*,9.6 Bianchi et al., 1999; Bo et al., 
rP2~ 5.5,10 >100 >100 >100 1995; Jones et a/., 2000. 
mP2~ 2.3 7.1 >100 10.5 
hP2Xs 4.1 160 5.7 2.9 0.2 Bo et a/., 2003; Colla et al., 
rP2Xs 15 >100 4 2.6 1996. 
rP2Xs 12 >100 >100 >100 Colla et al., 1996. 
hP2X7 96* <100* 4.7* <100* 4.6* Bianchi et al., 1999; Surprenant 
rP2X7 123,115 3.6,7 et al., 1996; Young et a/., 2007. 
mP2X7 936 285 
- ---
--
-_.-~-
*indicates ECso values obtained using an intracellular calcium assay, as opposed to patch clamp recording. 
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agonist as it activates other P2X receptor subtypes such as P2X1, P2X3 
receptors in the nanomolar range (Table 1.2) (Bianchi et al., 1999). 
1.5.2 P2X receptor antagonists 
Pharmaceutical companies are making a huge effort to synthesise novel, 
potent and subunit selective P2X receptor antagonists, as reflected by the large 
number of recently patented compounds (Gunosewoyo and Kassiou, 2010). 
This section summarises the compounds that have been fully characterised. 
Suramin was identified as an inhibitor of aj3meATP-evoked responses in 
the mouse vas deferens (Dunn and Blakeley, 1988). This compound inhibits a 
number of P2X receptors (Table 1.2) and P2Y receptors (Ralevic and 
Burnstock, 1998), making it of limited use in P2X receptor studies. 
There are three analogues of suramin with improved selectivity and/or 
potency (NF023, NF279 and NF449). NF023 potently and reversibly inhibits 
P2X1 receptors in a competitive manner with no effect on maximal current (Soto 
et al., 1999). Of the receptor subtypes tested, NF023 is selective for P2X1 
receptors over P2X2, P2X3 and P2X4 receptors. NF279 was reported as a 
potent P2X receptor antagonist when it was shown to antagonise a~meATP­
evoked smooth muscle contractions of rat vas deferens (Damer et al., 1998). 
The compound blocks P2X1 and P2X2 receptors with a high potency and is also 
effective at P2X3 receptors (Rettinger et al., 2000). The P2X4 receptor is 
relatively insensitive to NF279, with 300 ~M only resulting in approximately 40% 
inhibition (Damer et al., 1998). NF279 has so far been shown to be without 
effect on a1A-adrenoceptors, adenosine A1 and A2B, histamine H1, muscarinic 
M3 and nicotinic receptors (Soto et al., 1999). Finally, NF449 has been reported 
as a highly potent P2X1 receptor antagonist, and inhibits P2X1 receptors in the 
picomolar range (Hulsmann et al., 2003; Rettinger et al., 2005). 
PPADS (pyridoxyl-5'-phosphate-6-azo-phenyl-2,4-disulphonate) blocks a 
number of P2X receptor subtypes (Table 1.2), however, it is relatively ineffective 
at P2X4 and P2X6 receptors (Collo et al., 1996; Jones et al., 2000). It was 
initially identified as a P2X receptor antagonist by showing that it can block P2X 
receptor mediated responses in rat vas deferens (Lambrecht et al., 1992). 
However, PPADS is now classed as a non-selective P2 antagonist since it can 
also block P2Y receptor responses (Ralevic and Burnstock, 1998). 
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Several analogues of PPADS that have been synthesised display 
increased potency. The first of these analogues, MRS2220, is a selective and 
reversible P2X1 receptor antagonist (lGso 10 JlM) (Jacobson et a/., 1998). It is 
approximately 6-fold less potent at P2X3 receptors (IGso 58 JlM), and shows no 
antagonistic properties at P2X2 and P2X4 receptors. Unlike PPADS, MRS2220 
has no effect at P2Y1, P2Y2, P2Y4 or P2Ys receptors as well as P1 receptors. 
The PPADS analogue PPNDS is also an antagonist at P2X1 receptors, with 6 
times greater potency than PPADS (IGso 14 nM) (Lambrecht et a/., 2000). 
IPsl, a diinosine pentaphosphate, is a potent antagonist at P2X1 
receptors (IGso 3 nM) (King et a/., 1999). The compound can also block P2X3 
receptors, albeit with approximately a 900-fold lower potency (IGso 2.8 ~lM), and 
is ineffective at P2X2 receptors. In contrast, IPsl potentiates P2X4 receptor 
responses (EGso 2 nM) (King et a/., 1999). 
2'3'-O-(2,4,6-trinitrophenyl)-substituted nucleotides have been described 
as potent antagonists at P2X1, P2X3 and P2X2/3 receptors (Virginio et a/., 1998). 
The trinitrophenyl analogue of ATP (TNP-ATP) potently inhibits P2X1, P2X3 and 
P2X2/3 receptors mediated responses (IGso - 1 nM) (Virginio et a/., 1998). A 
similar potency is seen with trinitrophenyl analogues of ADP, AMP and GTP, 
but TNP-adenosine is ineffective. These compounds show a much lower 
potency of inhibiting P2X2, P2X4, P2X4 and P2X7 receptors (IGso > 1 JlM) 
(Burgard et a/., 2000). 
A-317491 is a highly potent and selective inhibitor of P2X3 and P2X2/3 
receptors. P2X3 receptors expressed in 1321 N1 cells are blocked by the S-
enantiomer of A-317491 with a Ki of 22 nM (92 nM and 9 nM for rat P2X2/3 and 
human P2X2/3 respectively) (Jarvis et a/., 2002). The compound exhibits high 
affinity for P2X3 and P2X2/3 receptors compared to P2X1, P2X2, P2X4, P2X7 and 
P2X2 receptors. Of these, A-317491 shows the highest affinity for P2X1 
receptors (IGso 11 JlM), and is >100-fold less potent than at P2X3 and P2X2/3 
receptors. A-371344, the R-enantiomeric form of A-317491, is significantly less 
potent than A-317491. A-317491 antagonises P2X2/3 mediated responses in a 
competitive manner. Radioligand binding studies show that [3H] A-317491 can 
specifically label the P2X3 subunit (Jarvis et a/., 2004). 
When comparing receptor sensitivity to agonists or antagonists between 
studies, a number of factors should be taken into account. Firstly, the sensitivity 
of the assay used requires consideration. For example, the EGso for the human 
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P2X1 receptor was reported to be 0.002 J-lM using an Ca2+ uptake assay 
(Bianchi et al., 1999), and 0.7 J-lM in a study using electrophysiology (Evans et 
al., 1995) (Table 1.2). The composition of the recording solutions should also be 
taken into account. For example, the P2X7 receptor mediated currents are 
inhibited by extracellular divalent cations and protons (see section 1.6.5) 
(Rassendren et al., 1997; Surprenant et al., 1996; Virginio et a/., 1997). 
Furthermore, current facilitation should be considered. For example, P2X7 
receptor mediated currents undergo facilitation when agonist application is 
prolonged or repeated (see section 1.6.6), and the receptor is more sensitive to 
agonist in the fully facilitated state (Roger et a/., 2008). In terms of antagonist 
potency, IC50 values depend on the concentration of agonist used, and the 
antagonist incubation time, both of which must be considered when comparing 
values between different studies. 
P2X7 receptor pharmacology is discussed in section 1.6.5. 
1.6 The P2X7 receptor 
Prolonged application of ATP to macrophages results in cell 
permeabilisation, and this remarkable property was thought to result from 
activation of a receptor that was distinct from P2X and P2Y receptors, and was 
therefore named the P2Z receptor (Oi Virgilio, 1995). However, molecular 
cloning and functional characterisation of the rat P2X7 receptor indicated that 
prolonged activation of the P2X7 receptor led to cell permeabilisation. Therefore 
the P2Z receptor is a member of the P2X receptor family (Surprenant et a/., 
1996). The P2X7 receptor has now been cloned from human macrophages, 
mouse microglial cells, guinea pig brain and dog heart (Chessell et a/., 1998; 
Fonfria et al., 2008; Rassendren et aI., 1997; Roman et al., 2009; Surprenant et 
a/., 1996), as well as zebrafish and Xenopus laevis (L6pez-Castej6n et a/., 
2007; Paukert et a/., 2002). The gene for the human P2X7 receptor (P2RX7) is 
located on chromosome 12q24 (Buell et a/., 1998). The mammalian P2X7 
subunit is 595 amino acid residues in length, with the exception of guinea-pig 
P2X7, which is one residue shorter (Chessell et al., 1998; Fonfria et a/., 2008; 
Rassendren et al., 1997; Roman et al., 2009, Surprenant et a/., 1996). 
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1.6.1 P2X7 receptor tissue and cellular distribution 
P2X7 receptors are expressed in cells of hematopoietic origin, including 
monocytes, macrophages, Band T lymphocytes, mast cells and microglia 
(Boumechache et a/., 2009; Lister et a/., 2007; Solie et a/., 2001). Northern 
blotting has detected P2X7 mRNA in the rat brain, lung, microglia, thymus, 
spleen, macrophages, pancreas, liver, heart and thymus (Collo et al., 1997; 
Rassendren et al., 1997). Furthermore, both osteoclasts, osteoblasts, lung, vas 
deferens, DRG and salivary glands have also been shown to express P2X7 
receptors (Gartland et a/., 2003; Ke et a/., 2003; Nicke, 2008). 
Expression of P2X7 receptors by neurons is a matter of continuing 
debate. Initial studies found little evidence of P2X7 receptor RNA or protein in 
adult peripheral or central nerves (Collo et al., 1997). However, a number of 
immunohistochemical experiments using antibodies against a C-terminal 
epitope of the P2X7 receptor have shown expression in presynaptic terminals of 
neurons (Deuchars et a/., 2001; Armstrong et a/., 2002; Sperlagh et a/., 2002). 
However, the specificity of P2X7 receptor antibodies has been brought into 
question by Sim et a/. who analysed the expression of the P2X7 receptor in the 
brain and found that antibodies targeting different epitopes of the receptor 
showed different patterns of immunoreactivity. P2X7 receptor immunoreactivity 
in neurons from either P2X7 knock out (KO) mouse was unchanged and 
Western blots from mouse brain showed bands of the expected size for P2X7 
protein in both WT and KO mice (Sim et al., 2004). 
In the study by Sim et a/., both published P2X7-deficient mouse lines 
were used, one generated by Glaxo by the insertion of a /acZ transgene into 
exon 1, and the other by Pfizer by the insertion of a neomycin cassette into 
exon 13. However, a splice variant of the P2X7 receptor (P2X7(k)), which is 
functional in terms of both agonist-evoked current and dye uptake, has recently 
been identified (Nicke et a/., 2009). This variant has an alternative N-terminus 
and TM1 domain, and peR, SOS-PAGE and BN-PAGE have shown it escapes 
gene deletion in the Glaxo KO mouse strain. Furthermore, cerebella from the 
Pfizer P2Xr deficient mouse was shown by RT-PCR to express the P2Xr 
specific sequences between Ala 1737 and Ala 1795 (downstream of the deleted 
sequence), but not the deleted sequence (Sanchez-Nogueiro et al., 2005). A 
possible reason is that a splice variant that escapes deletion in the Pfizer KO 
mouse strain exists, although none of the currently identified splice variants 
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provide an explanation for these observations (Nicke et al., 2009). It is therefore 
clear that further investigations into the neuronal expression of the P2X7 
receptor are required, and that such splice variants complicate studies that use 
P2X7 receptor KO mice to study the role of the receptor in health and disease. 
1.6.2 Biophysical properties of P2X7 receptors 
Like other members of the P2X family, the P2X7 receptor is a ligand 
gated ion channel and upon ligand binding, the channel opens allowing the 
passage of small cations including Ca2+. P2X7 receptor mediated currents show 
relatively slow activation kinetics and no desensitisation (Figure 1.3) (North, 
2002; Rassendren et al., 1997; Surprenant et al., 1996). The currents are 
carried by cations, and P2X7 receptors show little evidence of chloride 
permeability, as evidenced by a lack of effect on reversal potentials when 
internal chloride is replace by aspartate (Rassendren et al., 1997). P2X7 
receptor mediated currents are linearly dependent on membrane potential and 
reverse close to 0 mV (Rassendren et al., 1997; Surprenant et al., 1996). 
Electrophysiological experiments have shown that· repeated or prolonged 
activation of the rat P2X7 receptor leads to increased permeability of the large 
monovalent cation N-methyl-D-glucamine (NMDG), and fluorescent dyes such 
as YO-PRO-1 or ethidium (Et+) can be seen to enter cells expressing the P2X7 
receptor (Rassendren et al., 1997; Surprenant et al., 18996; Virginio et aI., 
1999). Deletion of an 18-amino acid juxamembrane cysteine-rich domain of the 
rat P2X7 receptor led to loss of NMDG permeability, whilst agonist-evoked YO-
PRO-1 uptake was unaffected, suggesting the NMDG and dye permeation 
pathways are different (Jiang et al., 2005). 
The molecular mechanism of dye uptake is still contentious. One idea is 
that the ion channel itself dilates, whereas an alternative hypothesis is that 
activation of the P2X7 receptor leads to activation of a distinct protein that forms 
the dye-uptake pathway. In 2006 Pelegrin and Surprenant provided evidence 
that pannexin-1 forms the P2X7 receptor mediated dye-uptake pathway 
(Pelegrin and Surprenant, 2006). Pannexin-1 is often referred to as a hemi 
channel because of structural similarity to connexins. mRNA for pannexin-1 was 
shown to be present in monocytes, macrophages, astrocytes and cell lines (e.g. 
HEK293 and HeLa) by RT-PCR. When over-expressed with P2X7 receptors in 
HEK293 cells, pannexin-1 could interact with P2X7 receptors. Furthermore, 
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siRNA targeting pannexin-1 and a pannexin-1 mimetic peptide inhibited ATP-
induced dye uptake without effect on the ionic currents. HEK293 cells 
expressing pannexin-1 were shown to constitutively take up Et+, however, cells 
co-expressing pannexin-1 and P2X7 receptors required ATP application to take 
up Et+. Therefore it has been proposed that pannexin-1 is the large pore-
forming molecule that opens upon P2X7 receptor activation, and that the P2X7 
receptor negatively regulates pannexin-1 (Pelegrin and Surprenant, 2006). 
1.6.3 Molecular and biochemical properties 
P2X7 receptors share the membrane topology of P2X receptors, as 
discussed in section 1.4. The unique structural feature of the P2X7 receptors is 
that its C-terminus is much longer than that of the other P2X receptors and is 
important for pore formation (Surprenant et al., 1996). P2X subunits can 
assemble into homomeric receptors, but also interact with P2X1-6 subunits to 
form heteromeric receptors (Murrell-Lagnado and Qureshi, 2008; Torres et aI., 
1999). Evidence suggests native P2X7 receptors form homotrimers 
(Boumechache et al., 2009; Nicke, 1998), however there is also evidence that 
P2X7 receptors can interact with P2X4 receptors and functionally influence each 
one other (Guo et al., 2007). 
1.6.4 P2X7 receptor trafficking 
Cell surface expression of the P2X7 receptor is under tight regulation. For 
example, P2X7 receptor mRNA levels are similar between monocytes and 
macrophages, however differentiation from monocytes to macrophages occurs 
in parallel with an increase in P2X7 receptor surface expression (Gudipaty et al., 
2001). 
The P2X7 receptor C-terminus contains residues/motifs important for its 
surface expression (Murrell-Lagnado and Qureshi, 2008). Point mutations within 
residues 551-581 prevent P2X7 receptor expression at the plasma membrane 
(Smart et al., 2003). In particular, mutation of Arg578 and Lys579 does not alter 
protein expression, but abolishes surface expression, suggesting this dibasic 
motif is important for P2X7 receptor trafficking (Denlinger et al., 2003). 
Furthermore, immunocytochemistry using an antibody against a C-terminal 
epitope has shown mutation 1568N in the human P2X7 receptor disrupts 
trafficking to the plasma membrane (Wiley et al., 2003). 
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Palmitoylation is the reversible covalent linkage of a fatty acid palmitate 
group to cysteine side chains of proteins, resulting in increased hydrophobicity. 
Mutation of the cysteines within residues 371-377, 477-506, 572-573 or 572-
573 in the C-terminus disrupted [3H]-palmitic acid binding and led to retention of 
P2X7 receptor in the endoplasmic reticulum (ER) and targeting to Iysosomes 
(Gonnord et al., 2009). Furthermore, disruption of palmitoylation reduced 
association of the receptor with detergent-resistant membranes. The study 
therefore demonstrates palmitoylation is important for P2X7 surface expression 
and its association with lipid rafts. 
1.6.5 P2X7 receptor pharmacology 
P2X7 receptor agonists 
As described in section 1.5.1, the physiological agonist for P2X7 receptor 
is ATP. However, the P2X7 receptor has a much lower sensitivity to ATP in 
comparison to other members of the P2X family, and requires concentrations in 
the submillimolar range for activation (Surprenant et al., 1996; Young et al., 
2007). BzA TP is a more potent agonist at P2X7 receptors than ATP itself and 
therefore this unique property is a useful tool for distinguishing P2X7 receptor 
responses from other P2X receptors (Anderson and Nedergaard, 2006). 
In addition to ATP and BzATP, P2X7 receptors can be activated by the 
covalent attachment of ADP-ribose at Arg 125 (Adriouch et al., 2007). ADP-
ribosylation involves transfer of the ADP-ribose group from nicotinamide 
adenine dinucleotide to the P2X7 receptor by ADP-ribosyltransferases. In the 
structural model, this residue is in close proximity to the predicted ATP binding 
site described in section 1.4.4 (Adriouch et al., 2007; Browne et al., 2010). 
P2X 7 receptor antagonists 
Oxidised ATP (oATP) was initially identified as an inhibitor of P2X7 
receptor mediated responses in J774 cells, including ATP-induced dye uptake 
and plasma membrane depolarisation, blebbing and cell swelling (Murgia et al., 
1993). The compound, however, is of limited use as high concentrations and 
prolonged incubation (hrs) are required for complete inhibition and the 
compound also inhibits ectonucleotidases enzymes and P2X1 and P2X2 
receptors (Evans et al., 1995; Murgia et al., 1993). 
32 
Calmidazolium potently inhibits BzA TP-evoked currents mediated by rat 
P2X7 receptor (ICso 13 nM), however it does not affect BzA TP-induced YO-
PRO-1 uptake (Virginio et al., 1997). Inhibition is non-competitive, and recovery 
is partial and slow. Calmidazolium has no action at P2X2 and P2X2/3 receptors 
(Virginio et al., 1997). 
KN-62, an isoquinoline derivative, inhibits ATP-induced Et+ uptake in 
cells expressing the human P2X7 receptor, but shows only partial antagonism 
when BzATP is used as an agonist (Humphreys et al., 1998). In contrast, KN-62 
completely inhibits human P2X7 receptor mediated currents whether ATP or 
BzA TP is the agonist. Interestingly, KN-62 fails to inhibit the rat P2X7 receptor. 
KN-62 is widely used as a Ca2+/calmodulin-dependent protein kinase II 
(CaMKII) inhibitor. However, KN-04, a KN-62 structural analogue lacking 
CaMKII inhibitor activity, can also effectively block the human P2X7 receptor, 
indicating inhibition of CaMKII activity is not involved in inhibition of the human 
P2X7 receptor by KN-62 (Humphreys et al., 1998). 
A series of KN-62 related compounds have been synthesised by 
modifying the phenylpiperazine residues in an attempt to produce a more potent 
P2X7 receptor antagonist (Baraldi et al., 2003). The majority of the compounds 
blocked ATP-evoked Ca2+ influx in the nanomolar range, the most potent 
(compound 63) with an ICso of 1.3 nM (Baraldi et al., 2003). 
Another analogue of KN-62, A-438079, was identified as a P2X7 receptor 
antagonist via high throughput screening of a compound library and structure-
activity relationship studies (Nelson et al., 2006). Unlike KN-62, A-438079 acts 
in a competitive manner. The compound inhibits rat P2X7 receptor with an ICso 
of 320 nM, as determined by Ca2+ influx assay. A-438079 has weak or no 
antagonistic activity at P2X1, P2X2, P2X2/3 , P2X4, P2Y1 and P2Y2 receptors, a 
range of G-protein coupled receptors, enzymes, transporters and ion channels 
(McGaraughty et al., 2007). 
Brilliant blue G (BBG) has been described as a selective inhibitor of the 
P2X7 receptor (Jiang et al., 2000a). The compound inhibits the rat P2X7 
receptor (ICso 10 nM) more potently than human P2X7 receptors (ICso 265 nM). 
The inhibition was voltage independent, and non-competitive. BBG was found 
to prevent BzATP-induced YO-PRO-1 uptake and membrane blebbing in 
HEK293 cells expressing rat P2X7 receptor. BBG is far less potent as an 
antagonist at other P2X receptors; it is ineffective at P2X1, P2X3, P2X2/3 and 
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P2Xlls receptors, but inhibits P2X2 receptor, albeit with a lower potency (ICso 1.4 
IlM). (Jiang et al., 2000a). 
High throughput screening has revealed a series of cyclic imides that 
potently inhibit P2X7 receptor activation-dependent Et+ uptake in THP-1 cells, a 
human acute monocytic leukemia cell line (Alcaraz et al., 2003). The action of 
one of these cyclic amides, AZ11645373, has been fully characterised (Stokes 
et al., 2006). This compound is a potent inhibitor of ATP or BzATP-induced 
responses mediated by human P2X7 receptors (agonist-induced current, Ca2+ 
influx, YO-PRO-1 uptake and interleukin-1 J3 (IL-1 J3) release) with ICso/kB values 
of 5-90 nM. Inhibition was non-surmountable, indicating a non-competitive 
inhibitory mechanism. The compound, however, only weakly inhibits rat P2X7 
receptors, with 10 IlM inhibiting agonist-induced currents by 40-50%. 
AZ11645373 has no agonistic or antagonistic action at P2X1, P2X2, P2X3, 
P2X2/3 receptors (Stokes et al., 2006). 
A-740003 is another new highly potent and selective antagonist at P2X7 
receptors (Honore et al., 2006). This inhibitor is less species-specific than KN-
62 and BBG, blocking rat and human P2X7 receptors in the nM range (ICso 18 
nM and 40 nM, respectively). Schild analysis shows a slope close to unity, 
indicating competitive antagonism. A-740003 displays high specificity for P2X7 
receptors, with concentrations up to 100 IlM having no effect on P2X1, P2X2, 
P2X2/3 , P2X4, P2Y1 and P2Y2 receptors (Honore et al., 2006). 
Emodin has recently been identified as a P2X7 receptor antagonist (Liu 
et al., 2010). The compound is an anthraquinone derivative that has been 
isolated from Rheum officinale Baill (common name Chinese rhubarb). Emodin 
is able to inhibit BzA TP-evoked currents in HEK293 cells expressing the rat 
P2X7 receptor (ICso 3 IlM), and is much less potent in inhibiting rat P2X4 
receptors (ICso >30 IlM). Moreover, emodin is able to reduce ATP-evoked 
macrophage cell death, Et+ dye uptake and BzA TP-induced Ca2+ influx (Liu et 
al.,2010). 
Modulators of P2X7 
P2X7 receptors are inhibited by extracellular protons and divalent cations 
such as Ca2+, Mg2+, Zn2+ and Cu2+ (Rassendren et a/., 1997; Surprenant et a/., 
1996; Virginio et al., 1997). The inhibition is voltage independent, therefore 
disfavouring an open channel block mechanism (Virginio et al., 1997). For many 
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years it has been thought that the tetra-anionic form of ATP (ATp4-) activates 
P2X7 receptors, and the presence of divalent cations lowers the ATp4-
concentrations. However, inhibition of P2X7 receptors by protons, Zn2+ and Cu2+ 
is at least in part due to their direct interaction with the receptor via allosteric 
modulation. Residues His62 and Asp 197 are shown to be critical for Zn2+ and 
Cu2+ inhibition of P2X7 receptors (Liu et al., 2008). Similarly, several residues in 
the extracellular domain have been identified that contribute to inhibition by 
extracellular protons, with the most critical being ASp197 (Liu et al., 2009). 
1.6.6 Regulation by interacting proteins 
Tyrosine phosphatase 
A proteomic study has identified several proteins that interact with the 
P2X7 receptor, including laminin 0.3, integrin P2, p-actin, a-actinin, supervillin, 
MAGuK, three heat shock proteins, phosphatidyl-inositol 4-kinase, and receptor 
protein tyrosine phosphatase-p (RPTP-P) (Kim et al., 2001). The same study 
showed that repeated stimulation of rat P2X7 receptors lead to rapid rundown in 
the current amplitude. This was preventable by application of phosphatase 
inhibitors or substitution of the phosphorylation site Tyr343 with phenylalanine in 
TM2. Therefore this rundown is thought to be due to dephosphorylation of P2X7 
receptor by RPTP-P (Kim et al., 2001). 
Calmodulin 
Binding of Ca2+ to calmodulin (CaM) induces a conformational change, 
revealing a hydrophobic patch, which allows hydrophobic and salt bridge 
interactions with target proteins (Saimi and Kung, 2002). CaM acts as a Ca2+ 
sensor for a number of ion channels, and modulates their activity. The rat P2X7 
receptor sequence contains a CaM binding sequence in the C-terminus (IIe541 _ 
Arg557) (Roger et al., 2008). It has been demonstrated, using co-
immunoprecipitation, that P2X7 receptors and CaM can interact, and that 
mutations 1541T and S552C disrupt this interaction. ATP-evoked currents 
amplitudes were decreased by expression of a dominant negative CaM mutant. 
Therefore the study suggests that binding of CaM to the rat P2X7 receptor 
increases current amplitudes and augments Ca2+ entry into cells (Roger et al., 
2008). 
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Agonist-evoked P2X7 receptor currents undergo facilitation in response 
to prolonged or repeated receptor activation (Roger et al., 2008). CaM inhibition 
by CaM inhibitory binding peptide, expression of a dominant negative CaM 
mutant, or intracellular Ca2+ chelation reduce current facilitation, demonstrating 
that rat P2X7 receptor current facilitation is in part dependent on Ca2+/CaM 
(Roger et al., 2008). 
1.6.7 Physiological functions of P2X7 receptors 
Cytokine release 
IL-1 f3 is a pro-inflammatory cytokine and is synthesised in response to 
inflammatory stimuli (e.g., lipopolysaccharide, or LPS). Proteolytic cleavage of 
the inactive precursor pro-IL-1 f3 by caspase-1 is required to produce the mature, 
active IL-1 f3 (Ferrari et al., 2006). ATP-induced IL-1 f3 release by LPS-primed 
human macrophages is completely inhibited by oATP (Ferrari et aI., 1997a). 
ATP-dependent release of IL-1f3 is completely absent in LPS-primed 
macrophages from P2X7 receptor deficient mice, despite high levels of pro-IL-1 f3 
(Solie et al., 2001). Furthermore, ATP-evoked IL-1f3 release from human LPS-
primed monocytes expressing the functionally impaired E496A P2X7 mutant 
receptor was reduced in comparison to WT subjects (Sluyter et al., 2004b). 
Moreover, ATP-induced IL-18 release from LPS-primed human monocytes from 
subjects homozygous carrying the E496A mutation is also reduced in 
comparison to WT subjects (Sluyter et al., 2004a). These studies show a critical 
role for P2X7 receptors in release of IL-1 f3 and IL-18. 
Production of reactive oxygen species 
A role for P2X7 receptor in reactive oxygen species (ROS) generation 
has been demonstrated. SzATP-induced ROS production (measured indirectly 
as H20 2) in primary rat microglia was abolished by PPADS, SSG and oATP 
(Parvathenani et aI., 2003). Furthermore, ATP-induced ROS production by 
mouse macrophage RAW264.7 cells was reduced by KN-62 (Noguchi et al., 
2008; Parvathenani et al., 2003). Inhibition of nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase, a generator of ROS at the plasma membrane, by 
apocyanin, suppresses SzA TP-induced H20 2 production by rat microglia, and 
ATP-induced ROS generation by RAW264.7 cells (Noguchi et al., 2008; 
Parvathenani et al., 2003). p38 mitogen-activated protein kinase (p38 MAPK) is 
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activated by NADPH oxidase. The p38 MAPK inhibitor SS203580 reduced 
SzATP-induced H20 2 production by rat microglia (Parvathenani et al., 2003). 
Furthermore, ATP- and SzATP-induced activation of p38 MAPK was reduced 
by KN-62 and SSG in RAW264.7 cells (Noguchi et al., 2008). Therefore, P2X7 
dependent ROS production is via activation of the NADPH oxidase/p38 MAPK 
pathway. 
A reduction in P2X7 expression using siRNA knock-down reduced ATP-
induced apoptosis (Noguchi et al., 2008). Moreover, ATP-induced apoptosis 
was reduced by the antioxidant propyl gallate. Taken together, these studies 
suggest that the P2X7 receptor mediates ROS production as a result of 
activation of NADPH oxidase and p38 MAPK, leading to apoptosis (Noguchi et 
al., 2008; Parvathenani et al., 2003). 
Cell death 
Cells death occurs via necrosis or apoptosis (Guimaraes and Linden, 
2004). Necrosis is characterised by swelling of the cytoplasm, organelle 
destruction and plasma membrane disruption, ultimately resulting in discharge 
of the cytoplasmic contents into the extracellular space and inflammation. 
Apoptosis is highly controlled, and characterised by cell shrinkage, membrane 
blebbing, maintenance of organelle integrity, DNA condensation and 
fragmentation, and finally, removal of cell by phagocytosis (Guimaraes and 
Linden, 2004). Activation of P2X7 receptors can cause cell death via necrosis or 
apoptosis (Ferrari et al., 1999; Mackenzie et al., 2005). 
ATP-induced DNA fragmentation does not occur in cells that do not 
express P2X7 receptors, and can be prevented by P2X7 receptor antagonist 
oATP (Ferrari et al., 1999). Furthermore, chromatin condensation can be 
prevented by inhibition of caspase activity. However, caspases are also 
involved in necrotic cell death, as caspase inhibitors can reduce ATP-induced 
lysis of these cells (Ferrari et al., 1999). 
Activation of the P2X7 receptor induces rapid morphological changes 
such as membrane blebbing that occurs within 1 min of activation of P2X7 
receptor (Mackenzie et al., 2005). Activation of P2X7 receptor has also been 
shown to induce cytoskeletal rearrangements, including F-actin redistribution, 
focal adhesions disassembly and redistribution of a-tubulin. P2X7 receptor 
activation can evoke depolarisation and swelling of mitochondria. However, if 
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the activation is within mins, membrane blebbing and mitochondrial disruption 
are reversible, and cytochrome c, which initiates apoptosis, is not released. 
Therefore, Mackenzie et al. have called this phenomenon "pseudoapoptosis" 
(Mackenzie et al., 2005). 
Cell growth and proliferation 
A role for the P2X7 receptor in cell proliferation has been demonstrated. 
Baricordi et al. observed that LG14 B-Iymphoblastic cells and K562 leukemic 
cells over-expressing P2X7 receptor were able to proliferate under serum-
deprived conditions, whilst mock transfected cells were not (Baricordi et al., 
1999). Proliferation was preventable by apyrase, an ATP-hydrolysing enzyme. 
Furthermore, the luciferin-Iuciferase assay revealed that these cells release 
ATP. The study indicates that cells release ATP in an autocrine/paracrine 
fashion, leading to cell proliferation (Baricordi et al., 1999). Therefore, 
depending on growth conditions, P2X7 receptor can promote cell growth or 
death. 
Investigations to identify the mechanisms by which the P2X7 receptor 
mediates both cell growth and death have been performed. Under basal and 
serum-deprived conditions, cells expressing P2X7 receptors are able to 
proliferate (Adinolfi et al., 2005). HEK293 cells expressing P2X7 receptors have 
high mitochondrial potentials, high Ca2+ concentrations in the mitochondria, and 
a high intracellular ATP concentration. The mechanism put forward is that under 
serum-free conditions, basal release of ATP activates the P2X7 receptor and 
causes leak of Ca2+ into the mitochondria. The resulting increase in metabolic 
activity and ATP levels allows the cells to proliferate even when growth factors 
are lacking. However, application of supra-maximal concentrations of ATP is 
thought to lead to P2X7 receptor-mediated increase in mitochondrial Ca2+ 
concentrations, collapse in mitochondrial potential, mitochondrial fragmentation 
and cell death (Adinolfi et al., 2005). 
Bone remodelling 
Normal bone remodelling involves both osteoclast and osteoblast 
activities. Osteoclasts are multinucleated cells, resulting from the fusion of 
mononucleated phagocytes and are responsible for bone resorption. 
Osteoblasts are the cells responsible for depositing new bone. P2X7 receptor 
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deficient mice have reduced total and cortical bone content, reduced periosteal 
circumference and bone formation, and increased bone resorption (Ke et al., 
2003). Furthermore, inhibition of the P2X7 receptor by oATP or a P2X7 receptor 
blocking monoclonal antibody prevents fusion of human mononucleated 
phagocytes into multinucleated osteoclasts (Gartland et al., 2003). Taken 
together, these studies reveal an important role for P2X7 receptors in bone 
remodelling. . 
Neuronal functions 
Despite the challenges in interpreting immunohistological data of P2X7 
receptor expression in the brain, there is functional evidence that activation of 
P2X7 receptors modulate synaptic transmission by promoting vesicular release 
of neurotransmitters (Armstrong et al., 2002; Deuchars et al., 2001; Sperlagh et 
al., 2002). For example, Deuchars et al. have shown that application of BzATP 
to sympathetic preganglionic neurons of the spinal cord leads to depolarisation 
of the neurons, which can be prevented by BBG (2 JlM) and the glutamate 
antagonists NBQX and AP-5 (Deuchars et al., 2001). A separate study found 
that application of BzA TP to rat hippocampal slices led to depression of 
transmission at mossy fibre-CA3 synapses (Armstrong et al., 2002). Kukley et 
al. made similar findings, however this study also showed that BzA TP-evoked 
depression of synaptic transmission at the mossy fibre-CA3 synapses was not 
different in the hippocampus of mice lacking the P2X7 receptor (Kukley et al., 
2004). Furthermore, the same study showed that BzATP-induced inhibition of 
synaptic transmission in this region of the hippocampus could be prevented by 
pre-application of an A1 receptor antagonist (Kukley et al., 2004). 
It is clear that the study of P2X7 receptor expression and function in 
neurons is complex (Anderson and Nedergaard, 2006). Lack of P2X7 receptor 
selective and specific agonists, antagonists and antibodies has hindered 
progress in this field. SzATP activates non-P2X7 receptors with a very similar, 
or even higher, potency (Table 1.2). Unique to P2X7 receptors is that BzA TP is 
a more potent agonist at P2X7 receptors than ATP, and so is only a useful tool 
for identifying P2X7 receptor responses when its potency is compared to that of 
ATP. BSG is a rodent P2X7 receptor selective antagonist with an ICso of 10 nM. 
However, BBG can also inhibit other P2X receptors at~lM concentrations (Jiang 
et a/., 2000a). 
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Neuron-glial interactions 
Duan et al. have shown that ATP or BzATP induces a significant 
increase in release of [14C]-glutamate and [3H]-D-aspartate from preloaded 
astrocytes. This can be potentiated by removal of divalent cations from the 
extracellular solution and blocked by oATP, suggesting a role for P2X7 
receptors in mediating neurotransmitter release from astrocytes (Duan et al., 
2003). 
There is also evidence supporting a role for P2X7 receptors in neuron-
glial communications. DRG nerve stimulation caused release of ATP, which 
activated P2X7 receptors on satellite glial cells which release tumour necrosis 
factor-a (Zhang et al., 2007). The same group have shown that the tonic activity 
of P2X7 receptors inhibited expression of P2X3 receptors in DRG (Chen et a/., 
2008). The underlying mechanism is thought to involve activation of P2X7 
receptor-dependent release of ATP from satellite glial cells and activation of 
P2Y1 receptors on DRG neurons by ATP (or possibly ADP), and inhibition of 
expression of P2X3 receptors (Chen et al., 2008). 
NF-KB activation 
NF-KB is a transcription factor that resides in the cytoplasm in an inactive 
complex with its inhibitory subunit IKB (Grossmann et al., 1999). 
Phosphorylation of IKB induces a conformational change allowing binding of 
ubiquitin and subsequent degradation. The active NFKB then translocates into 
the nucleus and binds to target genes. A role for the P2X7 receptor in NF-KB-
DNA complex formation has been suggested (Ferrari et al., 1997b). Application 
of ATP to mouse microglial N9 cells induced NF-KB-DNA complex formation. 
This was prevented by oATP, and did not occur in N9 clones that lack P2X7 
receptor (Ferrari et al., 1997b). Target genes of NF-KB include those which 
encode inflammatory and chemotactic cytokines and cytokine receptors 
(Grossmann et al., 1999). 
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1.6.8 Pathological functions 
Inflammatory diseases 
Rheumatoid arthritis describes a disease of the joint in which 
inflammation leads to destruction of cartilage and bone (Choy and Pabayi, 
2001). Arthritic symptoms (paw swelling and inflammation) can be induced in 
mice by intraperitoneal injection of four mAbs against type II LPS (Labasi et al., 
2002). It was found that in P2X7 receptor deficient mice the incidence of these 
symptoms and the severity of cartilage destruction were reduced (La basi et al., 
2002). This suggests a role for the P2X7 receptor is a potential therapeutic 
target for the treatment of arthritis. 
Neurodegenerative diseases 
Alzheimer's disease is characterised by formation of J3-amyloid plaques 
and loss of cerebral cortex neurons (Apolloni et al., 2009). In a transgenic 
mouse model of Alzheimer's disease (tg2576 with an amyloid precursor protein 
K670N/M671 L mutation), or a rat model of Alzheimer's disease (induced by 
intrahippocampal J31-42 injection), P2X7 receptor immunoreactivity was shown in 
close proximity to J3-amyloid plaques, and localised to microglia (McLarnon et 
al., 2006; Parvathenani et al., 2003). Furthermore, P2X7 protein expression was 
up regulated in the hippocampus in both these models of Alzheimer's disease 
(McLarnon et al., 2006; Parvathenani et aI., 2003). Loss of rat hippocampal 
neurons following J31-42 injection was shown by reduced immunoreactivity of 
NeuN (neuronal marker), and was attenuated by SSG (Ryu and McLarnon, 
2008). Taken together, these studies suggest that an increase in P2X7 receptor 
expression in the hippocampus contributes to neuronal death in Alzheimer's 
disease. 
Multiple sclerosis (MS) is an autoimmune disease in which the immune 
system attacks myelin in the CNS, leading to oligodendrocyte cell death, 
demyelination, and axonal damage (Apolloni et al., 2009). Experimental 
autoimmune encephalomyelitis (EAE) describes a model of MS, in which 
injection of MOG35-55 (synthetic myelin oligodendrocyte glycoprotein peptide 35-
55) results in neuronal demyelination in the CNS. Involvement of the P2X7 
receptor in MS was demonstrated in studies of the EAE mice model, in which 
ATP- and SzA TP-induced demyelination and oligodendrocyte cell death is 
dramatically attenuated by oATP or SSG (Matute et al., 2007). Studies of EAE 
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in P2X7 receptor deficient mice show conflicting results. One investigation found 
axonal damage was greater in P2X7 receptor deficient mice (Witting et a/., 
2006). This was supported by another study showing P2X7 receptor deficient 
mice had higher clinical scores for EAE (Chen and 8rosnan, 2006). In contrast, 
Sharp et al. found that incidence of EAE, as well as axonal damage, was 
reduced in mice lacking the P2X7 receptor (Sharp et al., 2008). Therefore, the 
role of P2X7 receptors in MS requires further investigation. 
Pain 
Hyperalgesia and allodynia are characteristic of chronic pain, and can 
occur because of neuronal injury (neuropathic pain) or inflammation 
(inflammatory pain). P2X7 receptor deficient mice lacked thermal and 
mechanical hyperalgesia following partial ligation of the sciatic nerve. 
Furthermore, following intraplantar injection of Freund's Complete Adjuvant to 
induce inflammation, these mice failed to display mechanical hyperalgesia 
(Chessell et al., 2005). 
The role of P2X7 receptor in nociception has also been demonstrated 
using P2X7 receptor antagonists. A-740003 and A438079 (see section 1.6.5) 
dose-dependently reduced allodynic responses following sciatic or spinal nerve 
injury as well as pain responses following intraplantar injection of carrageenan 
or formalin to induce inflammation (Honore et al., 2006; McGaraughty et al., 
2007). 
Chronic lymphocytic leukaemia 
Chronic lymphocytic leukaemia (Cll) is a hemopoietic tumour caused by 
monoclonal expansion of 8 lymphocytes, and as a result, CD5+ 8 lymphocytes 
accumulate in the circulation (Matutes et al., 1994). Progression of Cll is slow 
in patients with the indolent form and rapid in patients with the evolutive form of 
the disease. 80th P2X7 receptor protein expression and ATP-induced Ca2+ 
influx responses were lower in lymphocytes from patients with the indolent 
compared to the evolutive variant of the disease (Adinolfi et al., 2002). As 
described above, expression of the P2X7 receptor in leukemic cells allows 
proliferation under serum free conditions (Baricordi et al., 1999). The results 
therefore suggest higher P2X7 receptor expression may correlate with the more 
severity of Cll (Adinolfi et al., 2002). The prevalence of the E496A 
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polymorphism is greater in Cll patients than healthy controls (Wiley et al., 
2002, but see Zhang et al., 2003). The study also found agonist-induced Et+ 
uptake and apoptosis were reduced in lymphocytes from Cll patients 
homozygous or heterozygous for the polymorphism. This suggests the P2X7 
receptor is required to remove lymphocytes from circulation via apoptosis, and 
that loss of receptor function results in lymphocyte accumulation in the 
circulation (Wiley et al., 2002). 
The two studies describe different roles for P2X7 receptor in ClL. Both 
interpretations, however, are supported by a report that Cll survival was longer 
for patients heterozygous for the E496A polymorphism than WT subjects 
(Thunberg et al., 2002). However, a separate study could not detect this 
association (Zhang et al., 2003). 
Killing intracellular mycobacteria 
One role of macrophages is to engulf pathogens, such as bacteria, 
thereby removing them from the extracellular space. Application of ATP to 
bacille Calmette-Guerin (BCG)-infected macrophages leads death of the 
intracellular mycobacteria via fusion of phagosomes containing BCG with 
Iysosomes (Fairbairn et al., 2001). Neither ATP-dependent BCG death, nor 
phagosome-lysosome fusion occurs in macrophages from P2X7 deficient mice 
(Fairbairn et al., 2001). Furthermore, ATP-induced killing of BCG-infected 
macrophages from individuals heterozygous for the T357S or E496A 
polymorphisms is severely reduced in comparison to WT (Saunders et al., 
2003; Shemon et al., 2006). Studies of two separate cohorts of individuals from 
Southeast Asia show that the E496A polymorphism is associated with extra 
pulmonary tuberculosis (Fernando et al., 2007). However, this finding is not 
supported by a study of a separate cohort in the Chinese Han population (Xiao 
et al., 2009). 
Affective mood disorders 
Association studies have identified chromosome 12q24.31, which 
encompasses the P2RX7 gene, as a susceptibility locus for bipolar disorder 
(Barden et al., 2006; Shink et al., 2005) and major depressive disorder (lucae 
et al., 2006). One single nucleotide polymorphism (SNP) of the human P2XR7 
gene, 1405A>G, which leads to the Q460R mutation, was found to be 
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associated with bipolar disorder and major depressive disorder (Barden et al., 
2006; lucae et al., 2006; McQuillin et al., 2008). This polymorphism has been 
shown have little, if any, effect of the functional expression of the P2X7 receptor 
(see section 1.6.9) (Cabrini et al., 2005; Roger et aI., 2010a). However, the SNP 
1405A>G lies in a haplotype with three gain-of-function SNPs of P2RX7 
(489C>T, 853G>A and 1068G>A) (Stokes et al., 2010). Two recent studies, 
however, cannot confirm SNP 1405A>G is associated with bipolar disorder 
(Green et al., 2009; Grigoroiu-Serbanescu et al., 2009), and there is currently 
no clear insight into how SNPs of the P2RX7 gene could cause increased 
susceptibility to bipolar disorder and major depressive disorder. 
Due to the implication of the P2X7 receptor in a number of diseases, as 
described above, pharmaceutical companies are keen to develop drugs to 
target the receptor, and P2X7 receptor antagonists have now reached clinical 
trials (Guile et a/., 2009). The first compound to enter clinical trials was 
developed by AstraZeneca (AZD9056) (Astbury et al., 2007), which has 
undergone phase II studies to test the efficacy of the compound for treatment of 
rheumatoid arthritis, osteoarthritis of the knee and chronic obstructive 
pulmonary disease (www.clinicaltrials.gov; www.astrazeneca.com). Pfizer are 
also undertaking phase II studies to investigate their P2X7 receptor antagonist 
CE-224535 as a treatment for rheumatoid arthritis (www.clinicaltrials.gov). 
1.6.9 Single nucleotide polymorphisms 
There are extensive SNPs within the P2RX7 gene. SNP mutations are 
either synonymous (no change in amino acid sequence) or non-synonymous 
(mutation of amino acid sequence). A number of non-synonymous SNP (ns-
SNP) mutations have been identified in patients with mood disorders (Barden et 
al., 2006; lucae et al., 2006; McQuillin et al., 2008) or altered pathophysiology 
. of Cll (Wiley et al., 2002). This section focuses on some of the ns-SNP 
mutations previously studied. The research of ns-SNP mutations is important for 
two reasons. Investigation of these naturally occurring mutations can provide 
information into, how the P2X7 receptors operate at the molecular level, and 
such information can in turn help understand the molecular mechanisms 
responsible for the associated diseases. 
The first ns-SNP studied in terms of it's effect on human P2X7 receptor 
function is 1513A>C, which has an allele frequency of 0.08-0.23 (Barden et aI., 
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2006; Cabrini et al., 2005; Gu et al., 2001; lucae et al., 2006; Shemon et al., 
2006; Stokes et al., 2010; Wiley et al., 2002). This SNP leads to mutation 
E496A in the C-terminus of the receptor. 
Results from experiments using two different heterologous expression 
systems show significant discrepancies. BzA TP-induced Ca2+ influx was absent 
in HEK293 cells expressing the E496A mutant (Cabrini et al., 2005). Likewise, 
agonist-induced E( uptake in HEK293 cells expressing the E496A mutant and 
in monocytes, B- and T-Iymphocytes and NK cells from subjects homozygous 
for the E496A SNP was severely reduced or abolished (Denlinger et al., 2005; 
Gu et al., 2001; Saunders et al., 2003; Wiley et al., 2002). However, Boldt et al. 
found ATP-induced currents were unaltered by this mutation (Boldt et al., 2003). 
A further ns-SNP is 489C> T, has an allele frequency of 0.44-0.5 (Barden 
et al., 2006; Cabrini et al., 2005; Shemon et al., 2006; Stokes et al., 2010). This 
SNP introduces the H155Y mutation in the extracellular domain of the receptor. 
ATP-evoked Ca2+ influx was found to be increased in lymphocytes of Cll 
patients carrying this mutation (Cabrini et al., 2005). 
A third ns-SNP is 1068G>A, and has an allele frequency of 0.37-0.41 
(Barden et al., 2006; Cabrini et al., 2005; Lucae et al., 2006; Stokes et al., 
2010). This polymorphism results in mutation A348T. A recent study have 
demonstrated that monocytes and erthrocytes isolated from subjects 
homozygous for the mutation exhibit increased ATP-dependent Et+ uptake in 
comparison to those from WT subjects (Stokes et al., 2010). Furthermore, LPS-
primed monocytes from these subjects release more Il-1P in response to ATP. 
The 946G>A SNP has an allele frequency of 0.01-0.013 and results in a 
R307Q mutation of the P2X7 receptor (Shemon et al., 2006; Stokes et al., 
2010). One study found ATP-induced Et+ uptake was abolished in lymphocytes 
from R307A heterozygous subjects (Gu et al., 2004). Mutation of the equivalent 
residue in the rat P2X2 receptor reduced the ATP sensitivity (Jiang et al., 
2000b). It is possible this residue plays a role in ATP binding (see section 
1.4.4). 
Another ns-:SNP is 1096C>G, which has a minor allele frequency of 0.04-
0.1 (Barden et aI., 2006; Cabrini et al., 2005; lucae et al., 2006; Stokes et al., 
2010; Shemon et al., 2006), introduces T357S mutation. ATP induced Et+ 
uptake by lymphocytes, monocytes and macrophages from subjects 
polymorphic for the T357S mutation is reduced. Furthermore, in heterologous 
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systems, both ATP-evoked currents and Et+ uptake are impaired by the 
mutation (Shemon et al., 2006). 
The final ns-SNP, 1729T>A has a minor allele frequency of 0.02-0.04, 
resulting in the 1568N mutation (Stokes et al., 2010; Wiley et al., 2003; Shemon 
et al., 2006). When expressed in HEK293 cells, the 1568N mutant was non-
functional in terms of ATP-induced Et+ uptake. Moreover, lymphocytes from 
subjects polymorphic for the 1568N mutation had reduced ATP-evoked Ba2+ 
uptake. The impaired function appeared to be due to a reduction in cell surface 
expression of the receptor as shown by flow cytometry and immunofluorescent 
staining (Wiley et al., 2003). 
Many of the studies into the effects of SNP mutations have used 
lymphocytes and macrophages from patients. However, Roger et al. studied 
twelve ns-SNP mutations identified in patients with mood disorders and Cll, by 
introducing the point mutations in the human P2X7 receptor and performing 
functional studies upon expression in HEK293 cells (Barden et al., 2006; lucae 
et al., 2006; Roger et al., 2010a; Wiley et a/., 2002). Five mutations (V76A, 
R117W, l 191 P, T357S and E496A) reduced ATP-evoked currents and rate of 
Et+ uptake, whilst two (Q460R and H521 Q) had no effect. Using the same 
techniques, H155Y and A348T increased, whilst G150R, E186K and 1568N 
abolished receptor function (Roger et al., 2010a). 
1.6.10 Species differences in P2X7 receptors properties 
Five mammalian P2X7 receptor orthologues have been cloned and 
functionally characterised. These are, in order of the date they were cloned: rat, 
human, mouse, guinea pig and dog (Chessell et al., 1998; Fonfria et al., 2008; 
Rassendren et al., 1997; Roman et al., 2009; Surprenant et al., 1996). 
Functional characterisation of the cloned P2X7 receptors has revealed a 
number of striking species differences, which are discussed below. 
Agonist potency 
One difference is that the human P2X7 receptor is less sensitive to ATP 
(10-fold) and BzA TP (25-fold) than the rat P2X7 receptor (Rassendren et al., 
1997). The mouse P2X7 receptor is the least sensitive to both ATP and BzA TP 
in comparison to the rat or human P2X7 receptor (Hibell et al., 2000; Young et 
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aI., 2007). The dog P2X7 receptor is equally sensitive to ATP and BzATP as the 
human P2X7 receptor (Roman et al., 2009). 
The sensitivity of the P2X7 receptor to agonist depends on the 
experimental conditions. P2X7 receptors become more sensitive to agonist 
when the extracellular divalent cation concentration is lowered, or after the 
receptors are fully facilitated (see sections 1.6.5 and 1.6.6). Furthermore, EC50 
values calculated from data obtained using different assays . can differ 
significantly (Hibell et al., 2001). Therefore, comparisons between the 
sensitivities of different P2X7 receptor species orthologues to agonist should be 
under the same experimental conditions. 
There are also differences between human and rat species in terms of 
the P2X7 receptor mediated dye uptake pathway. The maximal uptake of YO-
PRO-1 elicited by BzATP is greater by cells expressing the rat P2X7 receptor in 
comparison to the human receptor (Rassendren et al., 1997). 
Activation and deactivation kinetics 
The kinetics of the P2X7 receptor activation and deactivation differ 
between species. The human, rat and mouse P2X7 receptor are activated by 
BzATP very rapidly (within 1 s). However, the ATP- or BzATP-evoked current 
onset at dog P2X7 receptor was much slower, and failed to reach the maximum 
within 2 s (Chessell et al., 1998; Roman et al., 2009). The deactivation kinetic of 
the rat P2X7 receptor is considerably slow in external solution containing low 
concentrations of divalent cations, and progressively prolonged upon repeated 
agonist applications (Surprenant et al., 1996). However, the deactivation of 
human and mouse P2X7 receptors is much quicker, and does not change 
dramatically with repeated agonist applications (Chessell et al., 1998; 
Rassendren et al., 1997). 
Antagonist sensitivity 
BBG is a potent antagonist at rat P2X7 receptor (see section 1.6.5); 
however, it has an approximately 20 times lower potency at human P2X7 
receptors (Jiang et al., 2000a). 
KN-62 is a potent antagonist at human P2X7 receptors (Gargett and 
Wiley, 1997) (see section 1.6.5). Interestingly, KN-62 fails to inhibit rat P2X7 
receptors (Humphreys et al., 1998). By constructing human and rat P2X7 
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receptor chimeras, this species difference has been shown to depend on the 
extracellular part of the receptor (Humphreys et al., 1998). 
AZ11645373, is a potent antagonist at human and dog P2X7 receptors. 
However, it is less potent at mouse and guinea pig P2X7 receptors, and has low 
potency at rat P2X7 receptors (Michel et al., 2009; Stokes et al., 2006). 
Introduction of F95L mutation in human P2X7 receptor, which changes residue 
95 in rat P2X7 receptor, reduces the potency of AZ11645373 (Michel et al., 
2008; Michel et al., 2009). 
Current facilitation 
Repeated or prolonged activation of P2X7 receptors leads to an increase 
in current amplitude or facilitation (see section 1.6.6). The facilitation for rat 
P2X7 receptors is much faster than human P2X7 receptors. Facilitation of the rat 
P2X7 receptor has a Ca2+/CaM-dependent component (Roger et al., 2008), 
which is absent for the human P2X7 receptor as the latter does not contain a 
CaM binding site and does not associate with CaM. (Roger et al., 201 Ob). 
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1.7 Aims of the study 
There are numerous ns-SNP mutations of the human P2X7 receptor, and 
two of these, H 155Y and A348T, were of particular interest due to their gain-of-
function effect. The molecular bases for these effects are not fully understood. 
In addition, these two mutations change residues in the human P2X7 receptor to 
the corresponding ones in the rat P2X7 receptor. The properties of P2X7 
receptors, including their functional expression and pharmacology, exhibit 
striking species differences. Therefore, the overall aim of the study was to 
investigate the molecular mechanisms responsible for the gain-of-function and 
whether the residues at these two positions contribute to the species-dependent 
properties. The specific objectives of this study, therefore, were: 
1. To examine the gain-of-function effects of H 155Y and A348T mutations 
singly or in combination, and determine the influence of side chains with 
different properties at position 155 and 348 (chapter 3). 
2. To explore differences in functional expression of human and rat P2X7 
receptors, and particularly to determine the effects of introducing 
reciprocal mutations Y155H and T348A on the rat P2X7 receptor (chapter 
4). 
3. To investigate the possible contribution of other non-conserved residues 
in the microdomains surrounding His 155 and Ala348 to the functional 
expression and species-specific expression of the human and rat P2X7 
receptors (chapter 5). 
4. The number of functional channels at the cell surface and the single 
channel properties (unitary conductance and open probability) together 
determine the functional expression of an ion channel. Therefore the 
effects of mutations at residues 155 and 348 on the total protein and 
surface expression of human and rat P2X7 receptors was determined 
(chapter 6). 
5. To characterise the monkey P2X7 receptor in terms of sensitivity to 
agonists and antagonists, and compare its properties to those of the 
human P2X7 receptor (chapter 7). 
To address these aims, WT or mutant P2X7 receptors were expressed in 
HEK293 cells, and receptor function was assessed by whole-cell patch-
clamp recordings, and protein subcellular distribution and surface 
expression by immunocytochemistry and biotin labelling. 
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Chapter 2 
Materials and methods 
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2.1 Chemicals, reagents and solutions 
2.1.1 Chemicals and reagents 
Chemicals and reagents were purchased at the appropriate grade from 
Sigma, unless otherwise stated. 
2.1.2 Solutions 
All solutions were prepared using Milli-Q deionised water and are shown 
in Table 2.1. Solutions used for DNA and tissue culture were sterilised by 
autoclaving or syringe filtering (0.22 IJm). 
2.1.3 Enzymes 
Opn I restriction enzyme, PfuUltra DNA polymerase and Benzonase 
nuclease were purchased from Promega, Stratagene and Sigma, respectively. 
2.1.4 DNA purification kits 
The QIAprep Spin Miniprep and Midiprep kits were purchased from 
Qiagen. 
2.1.5 Antibodies, streptavidin beads, biotin, SeA kit and protein markers 
Antibody suppliers are shown in Table 2.2. EZview red streptavidin 
affinity gel beads were purchased from Sigma. EZ-Iink sulfo-NHS-LC biotin and 
the bicinchoninic acid (BCA) Protein Assay kit were purchased from Pierce. 
Prestained protein markers (6-175 kDa) were purchased from New England 
Biolabs. 
2.1.6 E. coli strains and growth media 
Competent Escherichia coli (E. Coli) cells (a-Select bronze efficiency) 
used for site-directed mutagenesis were purchased from BioLine. Competent E. 
coli cells (DH5a strain) used for plasmid amplification were prepared as 
described in section 2.2.1, using cells originally purchased from GIBCOBRL. E. 
coli growth medium was purchased from Sigma (Table 2.1). 
2.1.7 Cell culture media and transfection reagents 
HEK293 cells were kindly provided by Prof. Annmarie Surprenant 
(University of Manchester). Dulbecco's modified Eagle's medium (DMEM) + 
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Glutamax™-1, foetal bovine serum (FBS), trypsin/ethylenediaminetetraacetic 
acid (EDTA), OPTI-MEM®-I serum reduced media and Lipofectamine™ 2000 
were purchased from Invitrogen (Table 2.1). 
2.1.8 Plasmids and oligonucleotides 
Prof. Annmarie Surprenant (University of Manchester) kindly provided 
the cDNAs encoding the human or rat P2X7 receptor with a C-terminal 
EYMPME (EE) tag and the cDNA encoding enhanced green fluorescent protein 
(eGFP). The gene encoding the Macaca Mullata P2X7 receptor (LOC722096, 
www.ensembl.org) with a C-terminal EE tag was synthesised by Epoch Biolabs 
and cloned into KpnllNotl digested pcDNA3.1 (+) vector. Primers were custom 
made by Sigma. Amino acid sequences were aligned using online ClustalW 
software. 
2.2 Molecular biology methods 
2.2.1 Bacterial cell culture and transformation 
Preparation of competent E. coli cells 
The protocol for the preparation of competent E. coli cells was adapted 
from a method described previously (Hanahan, 1983). DH5a E. coli cells (stock 
stored at -80°C) were spread onto an LB agar plate (Table 2.1) without 
antibiotics and single colonies were grown overnight at 37°C. A single colony 
was used to inoculate 5 ml of LB growth media (Table 2.1) and was cultured 
overnight at 37°C with shaking (250 revolutions per minutes (rpm»). A sample of 
this culture (0.5 ml) was diluted in 100 ml of LB growth media and cultured 
overnight at 37°C with shaking (250 rpm). Cells were collected by centrifugation 
(2000 x g for 10 min at 4°C). After removal of the supernatant, the cell pellet 
was resuspended in 20 ml of chilled 0.1 M CaCI2 , and cells were pelleted again 
. by centrifugation (2000 x g for 10 min at 4°C). Following removal of the 
supernatant, cells were resuspended in 4 ml of chilled transformation buffer 
(Table 2.1). The cells were then aliquoted and stored at -80°C. 
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Table 2.1 Solutions and media 
E. coli growth media, transformation buffer and antibiotics 
LB growth media 10 gIl tryptone; 5 gIl yeast extract; 5 gIl NaCI. 
LB agar plate LB media supplemented with 15 gIl agar, autoclaved, 
cooled to - 60°C, then supplemented with 100 !-Ig/ml 
ampicillin or 50 !-Ig/ml kanamycin, if required. 
Transformation 0.1 M CaCb; 15% glycerol (v/v). 
buffer 
Ampicillin 50 mglml ampicillin, dissolved in water, filter sterilised 
(0.22 !-1m), stored -20°C. 
Kanamycin 10 mglml kanamycin, dissolved in water, filter sterilised 
(0.22 !-1m), stored -20°C. 
DNA preparation 
Buffer P1 50 mM Tris-HCI, pH B.O; 10 mM EDTA; 100 !-Ig/ml RNase 
(resuspension A, stored at 4°C. 
buffer) 
Buffer P2 (lysis 200 mM NaOH; 1 % sodium dodecyl sulphate (SDS) 
buffer) (w/v). 
Buffer P3 3.0 M potassium acetate, pH 5.5. 
(neutralisation 
buffer) 
Buffer QBT 750 mM NaCI; 50 mM MOPS, pH 7.0; 15% isopropanol 
( equilibration (v/v); 0.15% Triton® X-1 00 (v/v). 
buffer) 
Buffer QC (wash 1 M NaCI; 50 mM MOPS, pH 7.0; 15% isopropanol (v/v). 
buffer) 
Buffer QF (elution 1.25 M NaCI; 50 mM Tris-HCI, pH B.5; 15% isopropanol 
buffer) (v/v). 
Buffer EB (elution 10 mM Tris-HCI, pH B.5. 
buffer) 
BufferN3,PE Recipes unknown, purchased from Qiagen. 
DNA gel electrophoresis 
TAE buffer 40 mM Tris-Oac; 0.114% glacial acetic acid (v/v); 1 mM 
EDTA; pH B.O. 
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1 % agarose gel 1 % agarose (w/v) dissolved in TAE. 
EtBr 10 mg/ml EtBr dissolved in water. 
6 x DNA loading 0.25% bromophenol blue (w/v); 40% sucrose (w/v) , 
buffer stored at 4°C. 
Polymerase chain reaction (PCR) 
10 x PfuUltra DNA 100 mM KCI; 100 mM (NH4hS04; 200 mM Tris-HCI, pH 
polymerase buffer 8.8; 20 mM MgS04; 1% Triton® X-100; 1 mg/ml nuclease-
free BSA, stored -20°C. 
dNTPs 2 mM dATP; 2 mM dCTP; 2 mM dGTP; 2mM dTTP, 
stored -20°C. 
Tissue culture and transfection 
HEK293 culture DMEM + Glutamax™-1, supplemented with 10% FBS 
media (v/v). 
Trypsin/EDTA 0.5 g/I trypsin; 0.2g/1 EDTA4Na; 0.8 g/I NaCI in PBS. 
Phosphate buffered 137.93 mM NaCI; 2.67 mM KCI; 8.06 mM Na2HP04; 1.47 
saline (PBS) mM KH2P04. 
Biotin labelling 
PBS 138 mM NaCI; 2.7 mM KCI; 8.1 mM Na2HP04; 1.5 mM 
KH2P04; 0.1 mM CaCI2; 1 mM MgCI2, pH 8.0. 
PBS/glycine 100 mM glycine dissolved in PBS. 
EZ-link sulfo-NHS- 0.5 mg/ml EZ-Iink sulfo-NHS-LC biotin in PBS. 
LC biotin 
RIPA lysis buffer 150 mM NaCI; 20 mM Tris-HCI, pH 7.4; 1 mM CaCb; 1 
mM MgCI2. 
Protease inhibitor 1.5 jJg/ml chymotrypsin; 0.8 jJg/ml thermolysin; 1 mg/ml 
papain; 1.5 jJg/ml pronase; 15 jJg/ml pancreatic extract; 
0.2 jJg/ml trypsin; made in RIPA buffer. 
Benzonase 10 U/jJl benzonase in 50% glycerol (v/v); 20 mM Tris-HCI, 
nuclease pH8.0; 20 mM NaCI; 2 mM MgCI2. 
2 x Electrophoresis 12% SDS; 20% glycerol; 100 mM Tris-HCI, pH 6.8; 4 mM 
buffer EDTA; 0.1 % bromophenol blue. 
BCA assay 
BCA reagent A Sodium carbonate; sodium bicarbonate; bicinchoninic 
acid; sodium tartrate in 0.1 M sodium hydroxide. 
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BCA reagent B 4% cupric sulphate. 
SOS-polyacrylamide gel electrophoresis (SOS-PAGE) 
SOS-PAGE running. 25 mM Tris; 192 mM glycine; 0.1 % SOS (w/v). 
buffer 
Towbin transfer 25 mM Tris; 192 mM glycine; 10% methanol (v/v). 
buffer 
Tris-buffered 10 mM Tris-HCI, pH8.0; 150 mM NaCI; 0.05% Tween-20 
saline-Tween (v/v). 
(TBST) 
Non-fat milk 5% skim milk powder (w/v) dissolved in TBST. 
blocking buffer 
Immunocytochemistry 
PBS 137 mM NaCI; 2.7 mM KCI; 0.01 M phosphate buffer, pH 
7.4. 
Zamboni's fixative 15% (v/v) picric acid; 5.5% (v/v) formaldehyde in PBS. 
Antibody dilution 2% (v/v) Triton® X-1 00 in PBS. 
buffer 
Blocking solution 5% (v/v) goats serum in antibody dilution buffer. 
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Table 2.2 Antibody suppliers and dilutions 
Primary antibodies 
Antibody Supplier Western blotting Immunocytochemistry 
Rabbit Bethyl 1:5000 1 :1000 
anti-EE 
Mouse Santa 1:2000 N/A 
anti-GFP Cruz 
Secondary antibodies 
Bovine Santa 1:5000 N/A 
anti- Cruz 
rabbit-
HRP 
Bovine Santa 1:2000 N/A 
anti- Cruz 
mouse-
HRP 
Goat anti- Invitrogen N/A 1 :2000 (rat P2X7) 
rabbit 1 :4000 (human P2X7) 
Alexafluor 
488 
Antibodies were diluted in blocking solution (Table 2.1). HRP: horseradish 
peroxidise. 
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Heat shock transformation 
Plasmid DNA (10-100 ng) or 1 IJI of PCR product was mixed with 50 IJI of 
thawed competent E. coli cells and incubated on ice for 30 min. Cells were heat 
shocked at 42°C for 45 s and returned to ice for 2 min. Prewarmed (37°C) LB 
growth media was then added (950 IJI) and incubated for 1 hr at 37°C with 
shaking (250 rpm). A sample of the culture (100 IJI) was spread on a LB agar 
plate containing 100 IJg/ml ampicillin (or 50 IJg/ml kanamycin for eGFP) and 
incubated overnight at 37°C to allow colonies to grow. Plates were stored at 
4°C. 
2.2.2 DNA preparation 
Small scale isolation of plasmid DNA 
For small-scale isolation of plasmid DNA (up to 20 IJg), the QIAprep Spin 
Miniprep kit was used (see Table 2.1 for solutions) according to the suggested 
protocol and as follows. LB growth media (5 ml) containing 100 IJg/ml ampicillin 
(or 50 IJg/ml kanamycin for eGFP) was inoculated with a single colony of 
transformed E. coli cells and incubated overnight at 37°C with shaking (250 
rpm). Cells were collected from 3 ml of the cell culture by centrifugation (14,000 
x g for 4 min at room temperature (RT)) and resuspended in 250 IJI of chilled 
buffer P1 by vortexing. Cells were lysed under alkaline conditions by adding 250 
IJI of buffer P2 and gently inverting the tube. Buffer N3 was added (350 IJI) and 
cell debris was cleared by centrifugation (12,000 x g for 10 min at RT). The 
supernatant was then applied to a QIAprep spin column, containing a silica 
membrane, and centrifuged (12,000 x g for 1 min at RT). Follow-through was 
discarded and the column was washed with 0.75 ml of buffer PE, followed by 
further centrifugation (12,000 x g for 1 min at RT). Follow-through was 
discarded and DNA was eluted by adding 50 IJI of prewarmed (37°C) elution 
buffer (buffer EB) to the column and allowing 1 min incubation. Purified DNA 
was collected from the column by centrifugation (12,000 x g for 1 min at RT). 
Plasmid DNA was stored at -20°C until use. 
Large scale isolation of plasmid DNA 
For larger scale isolation of plasmid DNA (up to 100 IJg), the Qiagen 
Midiprep kit was used (see Table 2.1 for solutions) according to the suggested 
protocol, which was as follows. LB growth media (10 ml) containing 100 IJg/ml 
57 
ampicillin, or 50 IJg/ml kanamycin for eGFP, was inoculated with a single colony 
of transformed E. coli cells and incubated for 8 hrs at 37°C with shaking (250 
rpm). This culture was diluted in 90 ml of LB growth media containing 100 IJg/ml 
ampicillin or 50 IJg/ml kanamycin and grown overnight at 37°C with shaking 
(250 rpm). Cells were harvested by centrifugation (6,000 x 9 for 15 min at 4°C). 
After removal of the supernatant, cells were resuspended in 4 ml of buffer P1 by 
vortexing and lysed under alkaline conditions by adding 4 ml of buffer P2 and 
gently inverting the tube. After a 5 min incubation at RT, the lysate solution was 
neutralised by adding 4 ml of buffer P3 and then incubated on ice for 15 min. 
Cell debris was cleared by two centrifugation steps (13,000 x 9 for 45 min in 
total at 4°C). The supernatant was then applied to the QIAGEN-tip 100, which 
had been pre-equilibrated with 4 ml of buffer QBT, and allowed to enter by 
gravity flow. The tip was washed with 20 ml of buffer QC. DNA was eluted with 
5 ml buffer QF and precipitated by adding 3.5 ml of isopropanol. Precipitated 
DNA was collected by centrifugation (5,000 x 9 for 60 min at 4°C). Supernatant 
was removed and the DNA pellet washed with 2 ml 70% ethanol (v/v) and 
centrifuged (13,000 x 9 for 10 min at 4°C). Supernatant was removed; the pellet 
was air-dried for 10 min and dissolved in 200 IJI of buffer EB. Plasmid DNA was 
stored at -20°C until use. 
2.2.3 Analysis of DNA by gel electrophoresis 
DNA samples were analysed by agarose gel electrophoresis. A 1 % 
agarose gel solution (Table 2.1) was made by heating in a microwave. When 
cooled to approximately 60°C, EtBr was added (Table 2.1) to a final 
concentration of 0.5 IJg/ml, and the solution was poured into a pre-assembled 
gel cast with a comb inserted, and left to solidify. A 6 IJI DNA sample was 
prepared (1 IJI of plasmid; 1 IJI 6 x DNA loading buffer (Table 2.1); 4 IJI water). 
Samples were loaded into the wells, with an additional well for the 1 kb DNA 
markers. Gel electrophoresis was carried out at 70 V for 90 min, and 
intercalated Et was detected by fluorescence under UV light using a gel doc 
XR quantity system (Biorad, UK). To quantify the DNA yield, a sample of DNA 
(1 IJI) was diluted 100-fold in buffer EB. A spectrophotometer (Eppendorf) was 
used to measure A26o, and used to calculate the DNA concentration (1 A260 = 50 
~g/ml of DNA). To check DNA purity the ratio of the absorbance at 260 and 280 
nm (A26o/28o) was measured. A260128o of 1.8 indicates pure DNA. 
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2.2.4 Site-directed mutagenesis 
Site-directed mutagenesis was used to introduce point mutations. The 
primers were designed to encode the desired mutation (Table 2.3). Each primer 
was 22- 41 bases in length with the mutated base approximately in the middle, 
and had a melting temperature of ~78°C. The PCR reaction mix contained 0.75 
1-/1 of each primer (10 I-/M), 2 1-/1 of 10 x PfuUltra DNA polymerase buffer (Table 
2.1), 2.5 1-/1 of 2 mM dNTP mix (Table 2.1), 0.5 1-/1 (50 ng) of template plasmid 
DNA, 0.5 1-/1 of PfuUltra high-fidelity DNA polymerase, and was adjusted to 25 1-/1 
using sterile deionised water. PCR was performed using an Eppendorf 
thermocycler. The first step, 95°C for 60 s, denatured the double stranded DNA, 
and was followed by 18 cycles, each comprising 3 steps of 95°C for 50 s, 60°C 
for 50 s and then 68°C for 20 min. A further incubation of 68°C for 20 min was 
allowed, and the samples were maintained at 4°C until collection. 
A Opn I digestion step is necessary. Opn I restriction enzyme (10 U) was 
mixed with the PCR sample by pipetting, and incubated at 37°C for 60 min to 
digest the methylated, non-mutated parental DNA template. 
PCR product was transformed into competent E. coli cells (section 2.2.1), 
and small scale isolation of plasmid DNA was performed (section 2.2.2). The 
presence of the desired mutation was confirmed using commercial DNA 
sequencing services (University of Leeds or Geneservice). 
The following mutations in the human P2X7 receptor were made by other 
members of the lab: H155Y and A348T. 
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Table 2.3 Primer sequences for site-directed mutagenesis 
Mutation name 5' to 3' sequences 
Human P2X7: 
V1531 forward primer GACCGGAAGGTGTATAGTGCATGAAGGG 
V1531 reverse primer CCCTTCATGCACTATACACCTTCCGGTC 
V154P forward primer GGAAGGTGTGTACCGCATGAAGGGAACCAGAAG 
V154P reverse primer CTTCTGGTTCCCTTCATGCGGTACACACCTTCC 
V154Y forward primer GGAAGGTGTGTATACCATGAAGGGAACCAG 
V154Y reverse primer CTGGTTCCCTTCATGGTATACACACCTTCC 
H 155Y forward primer GGAAGGTGTGTAGTGTATGAAGGGAACCAGAAGA 
H 155Y reverse primer TCTTCTGGTTCCCTTCATACACTACACACCTTCC 
H 155F forward primer GAAGGTGTGTAGTGTTTGAAGGGAACCAGAAG 
H 155F reverse primer CTTCTGGTTCCCTTCAAACACTACACACCTTC 
H 155R forward primer GAAGGTGTGTAGTGCGTGAAGGGAACCAGAAG 
H 155R reverse primer CTTCTGGTTCCCTTCACGCACTACACACCTTC 
H 1550 forward primer GAAGGTGTGTAGTGGATGAAGGGAACCAGAAG 
H1550 reverse primer CTTCTGGTTCCCTTCATCCACTACACACCTTC 
H 155N forward primer GAAGGTGTGTAGTGAATGAAGGGAACCAGAAG 
H 155N reverse primer CTTCTGGTTCCCTTCATTCACTACACACCTTC 
H155A forward primer GAAGGTGTGTAGTGGCTGAAGGGAACCAGAAG 
H 155A reverse primer CTTCTGGTTCCCTTCAGCCACTACACACCTTC 
H 155L forward primer GAAGGTGTGTAGTGCTTGAAGGGAACCAGAAG 
H155L reverse primer CTTCTGGTTCCCTTCAAGCACTACACACCTTC 
E 1560 forward primer GGTGTGTAGTGCATGACGGGAACCAGAAG 
E1560 reverse primer CTTCTGGTTCCCGTCATGCACTACACACC 
E156Y forward primer GGTGTGTAGTGCATTACGGGAACCAGAAG 
E 156Y reverse primer CTTCTGGTTCCCGTAATGCACTACACACC 
G157Q forward primer GTGTAGTGCATGAACAGAACCAGAAGACCTG 
G157Q reverse primer CAGGTCTTCTGGTTCTGTTCATGCACTACAC 
N158K forward primer GTGCATGAAGGGAAGCAGAAGACCTGTG 
N 158K reverse primer CACAGGTCTTCTGCTTCCCTTCATGCAC 
Q 159R forward primer GTGCATGAAGGGAACCGGAAGACCTGTGAAG 
Q 159R reverse primer CTTCACAGGTCTTCCGGTTCCCTTCATGCAC 
A348G forward primer CTTCGGTCTGGCCACTGTGTTCATCG 
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A348G reverse primer CGATGAACACAGTGGCCAGACCGAAG 
A348F forward primer CTTCGGGCTAGCCTTTGTGTTCATCGACTTCC 
A348F reverse primer GGAAGTCGATGAACACAAAGGCTAGCCCGAAG 
A348M forward primer CTTCGGGCTAGCCATGGTGTTCATCGACTTCC 
A348M reverse primer GGAAGTCGATGAACACCATGGCTAGCCCGAAG 
F350C forward primer GCTAGCCGCTGTGTGCATCGACTTCCTCATCG 
F350C reverse primer CGATGAGGAAGTCGATGCACACAGCGGCTAGC 
F353L forward primer GTGTTCATCGACTTACTCATCGACACTTACTCCAG 
F353L reverse primer CTGGAGTAAGTGTCGATGAGTAAGTCGATGAACAC 
L3541 forward primer GTGTTCATCGACTTCATCATCGACACTTACTCCAG 
L3541 reverse primer CTGGAGTAAGTGTCGATGATGAAGTCGATGAACAC 
D356N forward primer GACTTCCTCATCAACACTTACTCCAGTAACTGCTG 
D356N reverse primer CAGCAGTTACTGGAGTAAGTGTTGATGAGGAAGTC 
Rat P2X7: 
Y155H forward primer GCAGGTGTATACCTCACGACCAGAAGAG 
Y155H reverse primer CTCTTCTGGTCGTGAGGTATACACCTGC 
T348A forward primer CTATTTCGGTTTGGCCGCCGTGTGTATTGAC 
T348A reverse primer GTCAATACACACGGCGGCCAAACCGAAATAG 
L353F forward primer GTGTGTATTGACTTCATCATCAACACGTATGCC 
L353F reverse primer GGCATACGTGTTGATGATGAAGTCAATACACAC 
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2.2.5 Mammalian cell culture and transfection 
Maintenance of HEK293 cells 
HEK293 cells were used to express WT and mutant P2X7 receptors. 
Cells were maintained in culture media (Table 2.1) at 37°C and 5% CO2 , and 
under humidified conditions. 
Cells were passaged every 3-4 days by trypsinisation. Solutions used are 
shown in Table 2.1, and volumes of solutions used are shown in Table 2.4. 
When cells were confluent, the culture media was removed and cells were 
washed with PBS. Trypsin/EOTA was added and cells were incubated at 37°C 
for 1-2 min to lift the cells. An equal volume of culture media was added and 
cells were collected by centrifugation. Cells were replated in new dishes 
containing fresh culture media at a ratio of 1:5 or 1:10. 
Preparation of HEK293 frozen cell stocks 
Frozen cells kept in a liquid nitrogen cryostat were thawed quickly in a 
37°C incubator and added to a 25cm2 culture flask containing 5 ml of culture 
media. Following overnight incubation, the culture media was replaced to 
remove the dimethylsulphoxide (OMSO) in the freezing solution. Cells were 
grown to confluency and maintained as described above. 
To replenish frozen stocks, cells with a low passage number were frozen 
in liquid nitrogen. Confluent cells from a 75cm2 flask were collected by 
trypsinisation as described above. The cell pellet was resuspended in 1 ml FBS 
containing 10% OMSO (v/v) and divided between 2 freezing vials. The vials 
were placed in a box containing isopropanol, kept at -80aC overnight, and then 
transferred to a liquid nitrogen cryostat. 
Table 2.4 Solution or media volumes used for tissue culture 
35 mm dish 25 cm~ flask 75 cm L flask 
PBS (ml) 1 5 10 
Trypsin/EOTA (ml) 0.5 1 2 
Culture media (ml) 2 5 15 
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Transient transfection 
In order to express P2X7 receptors, HEK293 cells were transiently 
transfected with plasmid DNA using Lipofectamine ™ 2000, according to the 
manufacturer's recommendations. Cells were transfected in 35 mm dishes at 
50-80% confluency (-106 cells). Plasmid DNA (1 IJg for P2X7 encoding plasmid, 
and 0.1 IJg for eGFP, if required) was diluted in 100 IJI of OPTI-MEM®-I. 
Lipofectamine ™ 2000 reagent (3 IJI per 1 IJg plasmid) was diluted in 100 /-11 of 
OPTI-MEM®-I and incubated for 5 min at RT. The plasmid and Iipofectamine™ 
2000 mixes were combined and incubated for 20 min at RT to allow DNA-
liposome complex formation and, after adding 800 IJI of culture media, was 
transferred to the cells. 
2.2.6 Biotin labelling and Western blotting 
Biotin labelling 
HEK293 cells prepared in 35 mm dishes were co-transfected (as 
described above) with P2X7 receptor (or pcDNA3.1 vector as a negative control) 
and eGFP as an internal control for possible variations in cell preparation, 
transfection efficiency and sample handling, and used 48 hrs later. Two 35 mm 
dishes of cells were used for each sample. Cells were washed four times with 
chilled PBS (Table 2.1) and incubated in 1 ml of 0.5 mg/ml EZ-link sulfo-NHS-
LC biotin (Table 2.1) for 30 min at 4°C. PBS/glycine (1 ml; Table 2.1) was then 
added and the cells collected by centrifugation (16,000 x g for 15 s at RT). The 
cell pellet was washed 4 times with 1 ml PBS/glycine and the same 
centrifugation step applied each time, and finally resuspended in 0.5 ml RIPA 
lysis buffer supplemented with protease inhibitor and 20 U benzonase nuclease 
(Table 2.1). After being cleared by centrifugation (15,000 x g for 10 min at 4°C), 
the lysate was transferred to a new tube. 
Protein concentrations were determined using the BCA assay (Table 2.1) 
and bovine serum albumin (BSA) as standard. A sample of the cell lysate was 
diluted at 1:1 using RIPA lysis buffer supplemented with protease inhibitors 
(RIPAlPI). 200 IJI of BCA reagent (2% reagent B in reagent A) plus 10 IJI of 
samples or standards were added to each wells of 96-well plates. The plate was 
placed on a mixer for 1 min at RT and then incubated for 30 min at 37°C before 
the AS40 values were taken using a POLARstar OPTIMA plate reader (BMG 
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Labtech). A standard curve was produced, from which the protein 
concentrations of the samples were determined. 
Cell lysate was diluted in RIPAIPI to a protein concentration of 1 ~lg/~ll. 
For analysis of total expression of the P2X7 receptor, a sample was taken and 
an equal volume of 2 x electrophoresis buffer (Table 2.1) added (protein 
concentration 0.5 ~g/~I). The sample was then boiled for 2 min. For analysis of 
surface expression of the P2X7 receptor, 300 I-Ig of cell lysate was mixed with 
50 1-11 of EZview red streptavidin affinity gel beads and incubated overnight at 
4°C. Beads were collected by centrifugation (2,000 x g for 2 min at 4°C) and 
washed 4 times with 1 ml RIPA lysis buffer and the same centrifugation step 
applied each time. The beads were resuspended in 50 1-11 of 1 x electrophoresis 
buffer and the samples boiled for 5 min. These protein samples were subject to 
Western blotting analysis as described below. 
Western blotting 
Proteins were separated using 1.5 mm thick 12% resolving gels. The 
resolving gel solution (Table 2.5) was prepared and applied to pre-assembled 
gel casts. After a layer of water was applied onto the top of gel solution, the gel 
was allowed to set at RT for 30 min. The water layer was removed and a 4% 
stacking gel solution (Table 2.5) added. A 10-lane comb was inserted and the 
gel left to set at RT for 30 min. 
The gel was placed in the electrophoresis tank and the tank filled with 
SOS-PAGE running buffer (Table 2.1). After clearance by centrifugation (16,000 
x g for 1 min at RT), equal amounts of total protein sample (10 1-11 (5 I-Ig) or 20 1-11 
(10 I-Ig» and equal amounts of biotin labelled protein sample (20 1-11) prepared as 
described above were added to each well alongside 6 1-11 of prestained protein 
markers. Samples were run through the stacking gel for 30 min at 80 V to form 
condensed bands. The voltage was then increased to 120 V. 
Proteins were transferred to a Protran nitrocellulose membrane (pore 
size 0.45 I-Im) under semi-dry transfer conditions. The gel, blotting paper and 
membrane were soaked in Towbin transfer buffer (Table 2.1) and stacked on 
the anode plate from the bottom: 2 layers of blotting paper, nitrocellulose 
membrane, gel, then 2 more layers of blotting paper. The stack was rolled with 
a 5 ml pipette tip to remove trapped air bubbles, and the cathode plate placed 
on the top. A constant current of 1 mAlcm2 was applied for 2 hrs. 
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The membrane was then rinsed in TBST (Table 2.1) and incubated in 5% 
non-fat milk (Table 2.1) for 1-2 hrs at RT to block non-specific protein binding. 
The membrane was then cut between the 30 kOa and 46 kOa protein markers. 
The top part was incubated in rabbit anti-EE containing solution and the bottom 
part in mouse anti-GFP antibody containing solution (Table 2.2), overnight at 
4°C. The membranes were washed 4 times, each time for 5 min, with TBST. 
The top part was then incubated in HRP-conjugated bovine anti-rabbit IgG 
(Table 2.2), and the bottom part in HRP-conjugated bovine anti-mouse IgG 
(Table 2.2) for 1 hr at RT. Again, the membranes were washed 4 times, each 
time for 5 min, with TBST. 
Table 2.5 Reagents used for 50S-PAGE gel preparation 
Gel 30% 1.5 M Tris- 0.5 M Tris- 10% 10% TEMEO H2O 
acrylamide HCI, pH8.8 HCI, pH APS SOS (1-1 1) (ml) 
(ml) (ml) 6.8 (ml) (1-1 1) (1-1 1) 
12% 3.2 2 80 80 3.2 2637 
4% 0.408 0.6 24 24 2.4 1342 
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Protein detection by enhanced chemilluminescence 
The membrane was placed on a layer of cling film and incubated in 
SuperSignal West Pica or Femto chemilluminescent substrate solution (Pierce) 
for 5 min at RT to allow the chemilluminescent signals to develop. Excess 
substrate solution was removed and the membranes covered in cling film and 
exposed to X-ray films (Kodak) for a period of 5 s to 2 min, depending on the 
signal strength. A number of films were exposed to the membrane for range of 
exposure times to ensure that the bands were not saturated due to over-
exposure and that any differences in signal strength between bands could be 
detected. Band intensities were quantified using a gel doc XR quantity system 
(Biorad). 
2.2.7Immunostaining 
HEK293 cells prepared in 35 mm dishes were transfected (as described 
above) with 1 I-'g of plasmid and, 24 hrs later, re-plated onto cover slips, and 
incubated for further a 24 hrs. Cells were washed with PBS before being fixed in 
Zamboni's fixative (Table 2.1) at RT for 30 min. Cells were permeabilised and 
blocked for 1 hr in the blocking solution (Table 2.1) at RT, and then incubated in 
blocking solution containing rabbit anti-EE primary antibody (Table 2.2) at 4°C 
overnight. After 5 PBS washes, the cells were incubated in blocking solution 
containing Alexa Fluor 488 anti-rabbit IgG secondary antibody (Table 2.2) for 2 
hrs at RT. Following 5 washes in PBS, cover slips were mounted onto 
microscope slides using Antifade Reagent (Molecular Probes) and stored at 
4°C. A Zeiss AxioVert 200M confocal microscope and LSM510 software were 
used to capture the fluorescent images. 
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2.3 Recording of P2X7 receptor mediated currents 
2.3.1 Principle of whole-cell patch-clamp recording 
The patch-clamp recording technique is a powerful tool for the study of 
ion channel activity (Hamill et al., 1981). A recording pipette, which is a blunt-
ended glass capillary with a tip of approximately 1 IJm, was filled with saline 
solution and placed onto the cell membrane. Light suction was applied to the 
pipette to form an electrically tight, gigaohm seal with the cell membrane. This is 
the cell-attached configuration (Figure 2.1A), and, from this point, a number of 
patch-clamp configurations are achievable. In this study, the whole-cell 
configuration was used, which enabled the membrane potential to be held at the 
desired values and the ionic currents through all the ion channels at the cell 
membrane to be measured. To obtain the whole-cell configuration, further 
suction was applied to rupture the patch of membrane beneath the pipette tip so 
that the contents of the pipette were in physical contact with the interior of the 
cell while the tight seal was intact (Figure 2.1A). A reference electrode was 
placed in the extracellular solution to form an electrical circuit. Activation of ion 
channels allows ions to move through the open channels along their 
electrochemical gradients and forms ionic currents. Figure 2.18 shows a 
schematic of the patch-clamp set-up. 
2.3.2 Solutions used for P2X7 receptor recordings 
Standard extracellular solution contained: 147 mM NaGI, 2 mM KGI, 1 
mM MgGI2, 2 mM GaGI2, 10 mM HEPES and 13 mM glucose. Divalent cations 
strongly inhibit P2X7 receptors (see section 1.6.5). P2X7 receptors and 
particularly the human P2X7 receptor, the main subject of the study, exhibit a 
low sensitivity to ATP. It is difficult to obtain maximal current responses in 
standard extracellular solution, unless high concentrations of ATP are used 
(Roger et al., 2010a). Therefore, unless otherwise stated in the Figure legend, 
current recordings were made in low divalent extracellular solution, which 
contained: 147 mM NaGI, 2 mM KGI, 0.3 mM GaGI2 , 10 mM HEPES and 22 mM 
glucose. The composition of pipette or intracellular solution was: 145 mM NaGI, 
10 mM EDTA and 10 mM HEPES. 80th extracellular and intracellular solutions 
were adjusted to pH 7.3 using 5 M NaOH and the osmolality was in the range of 
300-315 mOsm. ATP stock solution (100 mM) was prepared in extracellular 
67 
A 
Cell-attached configuration 
8 
RSC-160 system 
/ 
Whole-cell configuration 
RFeedback 
)------'----+ ADC 
Vcmd 
Extracellular 
solution 
Reference 
electrode 
Intracellular solution Cell 
Figure 2.1 Whole-cell patch-clamp configuration and recording set-up 
(A) The cell is placed in extracellular solution. The recording pipette, filled with 
intracellular solution, is manoeuvred to be form a gigaohm seal between the 
pipette and the cell membrane (cell-attached configuration). Suction is applied 
to rupture the membrane patch underneath the tip of the recording electrode, 
(whole-cell attached configuration). (8) The recording electrode is in physical 
contact with the inside of the cell, and the reference electrode is in contact with 
the extracellular solution. The voltage command (Vcmd) determines the voltage 
between the recording and reference electrode, and can be held at desirable 
values via a feedback resistor. The analogue/digital converter (ADC) converts 
analogue signals to digital signals or vice verse. The RSC-160 system was 
used to change the extracellular solutions. 
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solution and adjusted to pH 7.3 with 5 M NaOH, whilst BzATP stock solution 
(100 mM) was prepared in water. Stock solutions of antagonists (KN-62, 
AZ11645373 and A-438079, all 10 mM) were prepared in DMSO. In some 
experiments, where P2X7 (particularly rat P2X7) receptor mediated currents 
showed substantial run-down with repeated agonist applications, 100 /-tM bpV 
(bisperoxovanadium, an tyrosine phosphatase inhibitor) was used (Kim et al., 
2001 a). bpV stock solutions (50 mM) were prepared in water. 
2.3.3 Preparation of cells for patch-clamp recording 
HEK293 cells prepared in 35 mm petri dishes were co-transfected with 
plasmid encoding the P2X7 receptor and eGFP, as described in section 2.2.5. 
Cells were plated onto glass coverslips 24 hrs following transfection, and used 
18-48 hrs later. 
2.3.4 Preparation of recording and reference electrodes 
The recording pipettes were made from borosilicate glass capillaries with 
an outer diameter of 1.5 mm and an inner diameter of 1.12 mm (World 
Precision Instruments). Pipettes were pulled in two stages using a vertical puller 
(PP-830, Narishige Scientific Instruments) to a tip of approximately 1 j.lm, and 
had a resistance of 3-5 MO in recording solutions. The pipettes were back-filled 
with intracellular solution and mounted onto a headstage (EPC-10, HEKA) via 
an AgCI coated Ag wire, which was connected to a HEKA EPC10 amplifier. The 
reference electrode was a silver chloride pellet, which was immersed in the 
extracellular solution and connected to the ground via the head stage. 
2.3.5 Patch-clamp recording 
Single, eGFP positive (identified under UV light) HEK293 cells were 
chosen for recordings. The recording pipette was lowered into the bath solution 
and the resistance was determined using a 5 mV test pulse. The pipette was 
manoeuvred until it is just in contact with the cell and a slight increase in the 
recording pipette resistance was detected. Negative pressure was then applied 
to form a gigaohm seal. The transient capacitative currents were compensated. 
Further suction was applied to break-through to the whole-cell configuration, as 
indicated by appearance of relatively slow capacitative currents. Series 
resistance and cell capacitance were measured and only the cells with series 
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resistance of <10 MO were used for recordings. The cells were held at -60 mV, 
and agonists and antagonists were applied for individually indicated durations 
using a rapid solution changer (RSC-160, Biological Sciences Instruments). 
As described in previous studies (Roger eta/., 2008; Roger et al., 
2010b), a sub-maximal concentration of agonist was repeatedly applied (4 s 
every min or for 1 min with an 1 min interval) until the current amplitude was no 
longer increased. This was indicated by no change in the amplitude of currents 
subsequently evoked by 3 consecutive 4 s applications. 
To obtain an agonist-dose response curve, 4 s applications of increasing 
concentrations of agonist were made at 1 min intervals, after the receptor was 
facilitated as described above. To measure antagonist concentration-dependent 
inhibition of agonist-evoked currents, antagonists were applied to the patched 
cells for 4 min (1 min for A-438079) before the currents were evoked by 4 s 
application of ATP. In the case of A-438079, A-438079 was also present during 
4 s application of ATP. To measure the effect of antagonists on the ATP-dose 
response curve, ATP dose-response curves were obtained as described above, 
before and after a 4 min application of antagonist. 
The peak current amplitudes were measured and converted to current 
density (pA/pF). For agonist dose-responses, the agonist concentration evoking 
half of the maximal response (EC50) was determined by the least-square fit of 
the data from individual cells to the following Hill equation: 
I/IMAX= [AtH/([AtH+EC50tH} (1 ) 
or: 
(2) 
where I is the current evoked by the agonist concentration [A] and nH is the Hill 
coefficient. IMAX respresents the maximal response. For antagonist dose-
inhibition curve, the antagonist concentration producing half of the maximal 
inhibition (IC50) was determined by the least-square fit of the data from 
individual cells to the following Hill equation: 
I = 100 [IC5otH/([B]nH+[IC50]nH} (3) 
where I is the residual current in the presence of the antagonist concentration 
[B] as a percentage of the current in the absence of antagonist and nH is the Hill 
coefficient. Where the inhibition was incomplete, the IC50 value was determined 
by using the following equation: 
1= (100-C) [IC50]nH/([B]nH+[IC5otH} + C (4) 
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where C is the antagonist-sensitive current component and the other 
parameters remain the same as in the equation 3. Sensitivity to agonist or 
antagonist was determined by calculating pECso (-log10 of the ECso value), or 
plCso (-log10 of the ICso) values, respectively. Dose response curves shown in 
the figures were fit to the mean current for all the cells recorded. 
2.4 Statistical analysis 
Origin software (version 7.5) was used for analysis of the data and 
preparation of figures. All data are presented as mean ± standard error of the 
mean (SEM). The number of independent experiments is indicated by 'n'. 
Comparisons were made using unpaired or paired Student's t-test. A probability 
(p) value of <0.05 was considered significant. 
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Chapter 3 
Effect of mutations H155Y and A348T on human P2X7 
receptor function 
72 
3.1 Introduction 
H155Y and A348T are ns-SNP mutations of the human P2X7 receptor 
and were originally identified in patients with major depressive disorder and/or 
bipolar disorder (Barden et al., 2006; Lucae et al., 2006). Genetic linkage 
studies have so far shown that these SNPs are not associated with these 
conditions, however they are frequently co-inherited with Q460R, a 
polymorphism associated with affective mood disorders (see section 1.6.8) 
(Barden et al., 2006; Lucae et al., 2006; McQuillin et al., 2008; Stokes et aI., 
2010). 
Previous studies have indicated both the H155Y and A348T mutations 
confer gain-of-function of the human P2X7 receptor. The mutations increased 
either agonist-induced Et+ dye uptake or Ca2+ influx (Cabrini et al., 2005; Roger 
et al., 2010; Stokes et al., 2010), and ionic currents (Roger et al., 2010; Stokes 
et aI., 2006). 
These observations suggest that the residues at positions 155 and 348 
may be important in the functional expression of the P2X7 receptor. A model of 
the human P2X7 receptor (Figure 3.1), based on the recently solved zebrafish 
P2X4 structure, predicts His 155 is located in the head region of the extracellular 
domain (Kawate et al., 2009; Roger et al., 2010a). In contrast, the model 
predicts Ala348 is located within TM2, on the intracellular side of the gate. In this 
chapter, the functional importance of residues His 155 and Ala348 on human P2X7 
receptor function were investigated in detail using site-directed mutagenesis 
and whole-cell patch-clamp recording. 
The results of this study have been presented in agonist dose-response 
curves, and the results have been analysed in terms of the maximal current 
amplitudes, the EC50 values and the Hill coefficients in order to gain insight into 
the functional effects of the P2X7 receptor mutations, as well as the underlying 
mechanisms. A mutational effect on the maximal current amplitude may be 
caused by a change in the number of functional receptors expressed at the cell 
surface, or the single channel properties of the receptor. The EC50 value is a 
measure of the receptor sensitivity to agonist. Changes to the sensitivity of the 
receptor to agonist could reflect an alteration to agonist binding affinity, or to the 
conformational changes that lead to channel gating. A change in the Hill 
coefficient reflects a change in the cooperativity of ligand binding, with an 
increased Hill coefficient indicating increased cooperativity of binding. 
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Figure 3.1 Structural model of the human P2X7 receptor showing the 
location of His 155 and Ala348 
The model is based in the crystal structure of the zebrafish P2~ receptor 
(Kawate et al., 2009). (A) The trimeric complex showing the three subunits in 
green, red and blue. Lys64 and Lys31\ residues thought to form part of the 
agonist binding site, are pink and yellow, respectively. His 155 and Ala348 are 
orange. Viewed parallel to the membrane. (B) Structure surrounding His 155, 
viewed from the extracellular side along the symmetrical axis. (C) Structure 
surrounding Ala348, viewed from the intracellular side along the symmetrical 
axis. These figures were kindly provided by Prof. Steve Baldwin and Dr. Lin-
Hua Jiang. 
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3.2 Results 
3.2.1 Effect of the H155Y mutation on agonist-evoked currents 
To investigate the effect of the H155Y mutation on human P2X7 receptor 
function, agonist-evoked whole-cell currents were recorded from HEK293 cells 
expressing WT or mutant receptors. 
Cells expressing the WT human P2X7 receptor responded to increasing 
concentrations of ATP in a dose-dependent manner (Figures 3.2A and B), with 
a maximal current amplitude of 268 ± 12 pNpF (n = 29), an EC50 of 397 ± 19 
IJM (n = 30) (pEC50 3.42 ± 0.02, n = 30) and a Hill coefficient of 2.08 ± 0.06 (n = 
30). Cells expressing the H155Y mutant responded to ATP with a maximal 
current amplitude of 391 ± 19 pA/pF (n = 10), which is approximately 50% 
greater than that of WT (p<0.001; Figure 3.2C). Furthermore, the receptor 
sensitivity to ATP (EC50 313 ± 14 IJM, n = 10) was slightly, yet significantly, 
increased (pEC5o 3.51 ± 0.02, n = 10; p<0.05; Figure 3.2D), but the Hill 
coefficient was unaltered (2.03 ± 0.07, n = 10; p>0.05; Figure 3.2E). 
The effect of the H 155Y mutation on BzA TP-evoked current responses 
was investigated (Figure 3.3). The mutation significantly increased the maximal 
current amplitude from 244 ± 4.5 pNpF (n = 4) for WT to 392 ± 51 pNpF (n = 4) 
for the H155Y mutant (p<0.05; Figure 3.3C). The EC50 values were 36 ± 4.7 ~lM 
(n = 4) for WT and 27 ± 6.6 ~M (n = 4) for H155Y. The mutation did not alter 
receptor sensitivity to BzA TP (pEC50 4.46 ± 0.05, n = 4 for WT, and 4.60 ± 0.11, 
n = 4 for H155Y; p>0.05; Figure 3.3D) or the Hill coefficient (2.06 ± 0.27, n = 4 
for WT and 2.09 ± 0.14, n = 4 for H155Y; p>0.05; Figure 3.3E). 
3.2.2 Effect of the H155Y mutation on antagonist inhibition 
KN-62 is a potent antagonist at human P2X7 receptors (see section 
1.6.5; Humphreys et al., 1998). The effect of the H 155Y mutation on inhibition of 
ATP-evoked currents by KN-62 was investigated (Figure 3.4). KN-62 potently 
inhibited ATP-induced currents mediated by the WT receptor in a concentration 
dependent manner, with an IC50 of 127 ± 38 nM (n = 3). KN-62 showed similar 
inhibition of ATP-evoked currents mediated by the H155Y mutant (IC5o 129 ± 20 
nM, n = 3). There was no difference in the potency of KN-62 at WT or mutant 
receptors (plC5o 6.93 ± 0.12, n = 3 for WT, and 6.90 ± 0.06, n = 3 for H155Y; 
p>0.05; Figure 3.4C). The inhibition in both cases was largely irreversible 
(Figure 3.4A). 
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Figure 3.2 Effect of the H155Y mutation on ATP-evoked currents 
(A) Representative AlP-evoked currents recorded from a HEK293 cell 
expressing WT (hP2X7 WT; left) or mutant H155Y human P2X7 receptors (right) 
at -60 mV. lhe black bars indicate the 4 s ATP application of the concentration 
shown, and ATP was applied at 1 min intervals. The dashed line indicates the 
maximal current for the WT receptor. (8) Mean AlP dose-response curves 
summarising the data from experiments shown in A: WT (squares) or H155Y 
(triangles). Smooth lines show the best fits to the Hill equation. (C) Mean 
maximal current amplitudes (lMAX). (D and E) pEC50 and Hill coefficients 
calculated using the least-square fit to the Hill equation. The number of cells 
recorded is indicated in the bars. * p<0.05, *** p<0.001, compared to WT. 
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Figure 3.3 Effect of the H155Y mutation on BzATP-evoked currents 
(A) Representative BzATP-evoked currents recorded from a HEK293 cell 
expressing WT (left) or mutant H155Y human P2X7 receptors (right) at -60 mV. 
The dashed line indicates the maximal current for the WT receptor. (B) Mean 
BzA TP dose-response curves summarising the data from experiments shown in 
A: WT (squares) or H155Y (triangles). Smooth lines show the best fits to the Hill 
equation. (C-E) Mean maximal current amplitudes (IMAX), pEC50 and Hill 
coefficients. The number of cells recorded is indicated. * p<0.05, compared to 
WT. 
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Figure 3.4 Effect of the H155Y mutation on antagonism of human P2X7 
receptor responses by KN-62 
(A) Representative currents evoked by 1 mM ATP recorded in the absence 
(control) and presence of indicated concentrations of KN-62 from a HEK293 cell 
expressing WT (left) or mutant H 155Y human P2X7 receptors (right) at -60 mV. 
Washout was 20 min. (8) Mean KN-62 dose-inhibition curves summarising the 
data from experiments shown in A: WT (squares) or H155Y (triangles). Smooth 
lines show the best fits to the Hill equation using 2 parameters. (C-D) Mean 
plCso and Hill coefficients. The number of cells recorded is indicated. No 
significant differences were detected. 
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3.2.3 Effect of the A348T mutation on agonist-evoked currents 
The effect of the A348T mutation on human P2X7 receptor function was 
also investigated, firstly using ATP as the agonist (Figure 3.5). The mutation 
conferred a significant increase in the maximal current amplitude (268 ± 12 
pA/pF, n = 29 for WT, and 324 ± 17 pA/pF, n = 12 for A348T; p<0.05; Figure 
3.5C). The EC50 values were 397 ± 19 IJM (n = 30) for WT, and 354 ± 26 IJM (n 
= 12) for A348T. The mutation did not affect the sensitivity of the receptor to 
ATP (pEC5o 3.42 ± 0.02, n = 30 for WT, and 3.46 ± 0.03, n = 12 for A348T; 
p>0.05; Figure 3.50). Furthermore, the mutation conferred a small, yet 
significant decrease in the Hill coefficient (2.08 ± 0.06, n = 30 for WT, and 1.80 
± 0.08, n = 12 for A348T; p<0.05; Figure 3.5E). 
These experiments were also performed using BzA TP as the agonist 
(Figure 3.6). The maximal current amplitude was significantly increased (244 ± 
4.5 pA/pF, n = 4 for WT, and 447 ± 72 pA/pF, n = 3 for A348T; p<0.05; Figure 
3.6C). EC50 values were 36 ± 4.7 IJM (n = 4) for WT, and 31 ± 3.9 IJM (n = 3) for 
A348T. The sensitivity to BzATP was not changed; pEC50 and Hill coefficients 
were 4.46 ± 0.05 and 2.06 ± 0.27 for WT (n = 4), and 4.51 ± 0.05 and 1.94 ± 
0.14 for the mutant (n = 3; p>0.05; Figures 3.60 and E). 
3.2.4 Effect of the double mutation H155YIA348T on A TP-evoked currents 
The effect of the double mutation H 155Y/A348T on human P2X7 receptor 
function was investigated using ATP as the agonist (Figure 3.7). The maximal 
current amplitude was significantly increased in comparison to WT, and H155Y 
and A348T mutations alone (268 ± 12 pA/pF, n = 29 for WT, and 473 ± 31 
pA/pF, n = 7 for H155Y/A348T; p<0.001; Figure 3.7C). The EC50 values were 
397 ± 19 IJM (n = 30) for WT, and 360 ± 47 IJM (n = 7) for H155Y/A348T. There 
was no effect on the sensitivity to ATP (pEC50 3.42 ± 0.02, n = 30 for WT, and 
3.47 ± 0.06, n = 7 for H155Y/A348T; p>0.05; Figure 3.70). The Hill coefficient 
was decreased by the double mutation (2.08 ± 0.06, n = 30 for WT, and 1.73 ± 
0.09, n = 7 for H155Y/A348T; p<0.05; Figure 3.7E). 
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Figure 3.5 Effect of the A348T mutation on ATP-evoked currents 
(A) Representative ATP-evoked currents recorded from a HEK293 cell 
expressing WT (left) or mutant A348T human P2X7 receptors (right) at -60 mV. 
The dashed line indicates the maximal current for the WT receptor. (8) Mean 
ATP dose-response curves summarising the data from experiments shown in A: 
WT (squares) or A348T (triangles). Smooth lines show the best fits to the Hill 
equation. (C-E) Mean maximal current amplitudes (I MAX) , pEC50 and Hill 
coefficients. The number of cells recorded is indicated. * p<0.05, compared to 
WT. 
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Figure 3.6 Effect of the A348T mutation on BzATP-evoked currents 
(A) Representative BzA TP-evoked currents recorded from a HEK293 cell 
expressing WT (left) or mutant A348T human P2X7 receptors (right) -60 mV. 
The dashed line indicates the maximal current for the WT receptor. (B) Mean 
BzA TP dose-response curves summarising the data from experiments shown in 
A: WT (squares) or A348T (triangles). Smooth lines show the best fits to the Hill 
equation. (C-E) Mean maximal current amplitudes (IMAX), pEC50 and Hill 
coefficients. The number of cells recorded is indicated. * p<0.05, compared to 
WT. 
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Figure 3.7 Effect of the double H155Y/A348T mutation on ATP-evoked 
currents 
(A) Representative ATP-evoked currents recorded from a HEK293 cell 
expressing WT (left) or mutant H155Y/A348T human P2X7 receptors (right) at 
-60 mY. The dashed line in black indicates the maximal current for the WT 
receptor, and in grey indicates the representative maximal currents for the 
H155Y (Figure 3.2A) and A348T (Figure 3.5A) single mutants. (8) Mean ATP 
dose-response curves summarising the data from experiments shown in A: WT 
(squares) or H155Y/A348T (circles). Smooth lines show the best fits to the Hill 
equation. (C-E) Mean maximal current amplitudes (IMAX), pEC50 and Hill 
coefficients. The number of cells recorded is indicated. * p<0.05, *** p<0.001, 
compared to WT. II p<0.05, 11l1li p<0.001 compared to H155Y/A348T. 
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3.2.5 Effect of substituting His155 with other residues on ATP-evoked 
currents 
To further study the functional role of His 155 in the human P2X7 receptor 
and particularly the role of the side chain, His 155 was mutated to phenylalanine, 
arginine, aspartic acid, alanine and leucine. The mutational effects on ATP-
evoked currents were investigated, and the results are shown in Figure 3.8. 
Mutations H1550 and H155L led to a reduction in ATP-induced maximal 
currents (293 ± 13 pA/pF, n = 28 for WT, and 214 ± 25 pA/pF, n = 5; p<0.05 and 
171 ± 29 pA/pF, n = 5; p<0.001 for H1550 and H155L, respectively; Figure 
3.8C). The EC50 values were 348 ± 14 jJM (n = 28) for WT, and 228 ± 29 jJM (n 
= 6) for H 155R. The sensitivity to ATP was not altered by any of the mutations, 
with the exception of H155R (pEC5o 3.47 ± 0.02, n = 28 for WT, and 3.66 ± 
0.06, n = 6 for H155R; p<0.001; Figure 3.80). The H155A mutation significantly 
altered the Hill coefficient (1.89 ± 0.04, n = 28 for WT, and 2.20 ± 0.09, n = 5 for 
H155A mutant; p<0.01; Figure 3.8E). 
,3.2.6 Effect of substituting Val154 and GIU156 with tyrosine on ATP-evoked 
currents 
To further determine the specificity of tyrosine at position 155, positions 
154 and 156 in the human P2X7 receptor were mutated to tyrosine (V154Y and 
E156Y; Figure 3.9). In comparison to WT (293 ± 13 pA/pF, n = 28), mutation 
V154Y had no effect on the ATP-induced maximal current (260 ± 15 pA/pF, n = 
5; p>0.05), whilst mutation E156Y resulted in a significant reduction (137 ± 30, n 
= 6; p<0.001; Figure 3.9C). The EC50 value was 348 ± 14 jJM (n = 28) for the 
WT receptor. The pEC50 and Hill coefficient values for the WT receptor were 
3.47 ± 0.02 and 1.89 ± 0.04 (n = 28), respectively, and were not significantly 
altered by the V154Y or E1560 mutations (p>0.05; Figures 3.9 0 and E). 
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Figure 3.8 Effect of substituting His 155 on AlP-evoked currents 
(A) Representative ATP-evoked currents recorded from a HEK293 cell 
expressing WT or indicated mutant human P2X7 receptors at -60 mV. The 
dashed line indicates the maximal current for the WT receptor. (8) Mean ATP 
dose-response curves summarising the data from experiments shown in A: WT 
(squares) or mutant (triangles). Smooth lines show the best fits to the Hill 
equation. (C-E) Mean maximal current amplitudes (IMAX), pEC50 and Hill 
coefficients. The number of cells recorded is indicated. * p<0.05, ** p<0.01, *** 
p<0.001, compared to WT. 
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Figure 3.9 Effect of substituting Val154 and Glu 156 with Tyr on ATP-evoked 
currents 
(A) Representative ATP-evoked currents recorded from a HEK293 cell 
expressing WT or indicated mutant human P2X7 receptors at -60 mV. The 
dashed line indicates the maximal current for the WT receptor. (8) Mean ATP 
dose-response curves summarising the data from experiments shown in A: wr 
(squares) or mutant (triangles). Smooth lines show the best fits to the Hill 
equation. (C-E) Mean maximal current amplitudes (I MAX) , pEC50 and Hill 
coefficient. The number of cells recorded is indicated. *** p<0.001, compared to 
WT. 
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3.2.7 Effect of substituting Ala348 with other residues on A TP-induced 
currents 
Residue Ala348 in human P2X7 receptor was substituted with other 
residues to study the importance of the side chain at this position (Figure 3.10). 
Ala348 was mutated to glycine, phenylalanine or methionine. In comparison to 
WT (257 ± 13 pA/pF, n = 18), the ATP-induced maximal currents were 
significantly increased by the A348G mutation (394 ± 19, n = 4; p<0.001; Figure 
3.10C). The ECso value was 392 ± 16 IJM (n = 18) for WT, and 280 ± 25 IJM, (n 
= 4) for A348G. The A348G mutation conferred an increase in sensitivity to AlP 
(pECso 3.41 ± 0.02, n = 18 for WT, and 3.56 ± 0.04, n = 4 for A348G; p<0.01; 
Figure 3.100). Conversely, A348F and A348M significantly decreased the 
maximal current amplitude (143 ± 42 pA/pF, n = 4; p<0.01 and 178 ± 55 pA/pF, 
n = 5; p<0.05, respectively), and decreased the pECso (3.26 ± 0.05, n = 4; 
p<0.01, and 3.25 ± 0.07, n = 4; p<0.01, respectively; Figure 3.100). Only A348F 
altered the Hill coefficient (2.14 ± 0.06, n = 18 for WT and 1.71 ± 0.11, n = 4 for 
A348F; p<0.01; Figure 3.1 OE). 
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(A) Representative ATP-evoked currents recorded from a HEK293 cell 
expressing WT or indicated mutant human P2X7 receptors at -60 mV. The 
dashed line indicates the maximal current for the WT receptor. (8) Mean ATP 
dose-response curves summarising the data from experiments shown in A: WT 
(squares) or mutant (triangles). Smooth lines show the best fits to the Hill 
equation. (C-E) Mean maximal current amplitudes (IMAX), pEC50 and Hill 
coefficients. The number of cells recorded is indicated. * p<0.05, ** p<0.01, *** 
p<0.001, compared to WT. 
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3.3 Discussion 
In this chapter the effects of two ns-SNP mutations, H155Y and A348T, 
on human P2X7 receptor functional expression were examined in detail. Both 
mutations conferred an increase in maximal current amplitudes, with little effect 
on agonist sensitivity. The size of the side chain at residue 348 is an important 
determinant of the functional expression of the receptor. 
The H 155Y mutation conferred an increase in maximal currents evoked 
by ATP or BzA TP (Figures 3.2 and 3.3), confirming previous results (Roger et 
al., 2010a), and consistent with studies showing increased Et+ uptake and Ca2+ 
influx (Cabrini et al., 2005; Roger et al., 2010a). The A348T mutation also 
enhanced ATP- and BzA TP-induced maximal currents (Figures 3.5 and 3.6), 
consistent with previous work (Roger et aI., 2010a) and in agreement with 
another study using patch-clamp (Stokes et al., 2010) or dye uptake assays 
(Roger et a/., 2010a; Stokes et al., 2010). 
The importance of the side chain at 155 was examined by mutating 
His 155 to other residues (Figure 3.8). Replacing the positively charged histidine 
with negatively charged aspartic acid (H155D) or hydrophobic leucine (H155L) 
reduced the maximal current. However, mutating to phenylalanine (differs from 
tyrosine by the lack of an OH group), arginine (similar properties to histidine) or 
alanine (smaller than tyrosine) had no such effect. Therefore, the particular 
residue at 155 is critical in determining human P2X7 receptor function, however 
of the residues examined, only sUbstitution with tyrosine conferred gain-of-
function. 
The effect of mutating His155 on ATP sensitivity was modest (H155Y and 
H155R) or lacking (H155F, H155A, H115L and H155D; Figures 3.2 and 3.8), 
and sensitivity to KN-62 was unaltered (Figure 3.4). These results suggest 
mutating His 155 has little effect on the conformation of the ligand binding sites. 
Indeed, in the dolphin-like human P2X7 receptor structural model (Figure 3.1), 
His155 is located in the head region and distant from both the proposed ATP 
binding site and ion permeating pathway (Kawate et a/., 2009; Roger et a/., 
2010a). Therefore, mutation of His 155 is unlikely to influence the ligand-bind site 
or single channel properties of the receptor. 
The importance of the side chain at 348 on human P2X7 receptor 
functional expression was also investigated (Figure 3.10). Mutating the small, 
hydrophobic alanine to threonine or glycine (also small) increased ATP-evoked 
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maximal currents, whilst mutating to methionine or phenylalanine (both bulky) 
had the opposite effect. The human P2X7 receptor model predicts Ala348 is 
located in the TM2, and on the intracellular side of the channel gate (Figure 
3.1). The zebrafish P2X4 structure shows the TM2 region forms the ion 
permeating pathway (Kawate et al., 2009). The TM2 a-helices are spread out 
on the intracellular side of the gate, and are predicted to undergo substantial 
movement during channel opening (Browne et al., 2010; Kawate et al., 2009). 
Such conformational changes may be affected by mutations at Ala348 . 
Considering this location, and the dependence of maximal current on the side 
chain size, mutation of Ala348 may affect the single channel properties of the ion 
channel. To examine these possibilities, single channel recordings are required. 
Altered surface expression is another possibility and is examined in chapter 6. 
The double mutation H155Y/A348T further enhanced ATP-evoked 
maximal currents in comparison to single mutations (Figure 3.7). These ns-SNP 
mutations are frequently co-inherited with Q460R, an SNP mutation that has 
been associated with affective mood disorders (Barden et al., 2006; Lucae et 
al., 2006; McQuillin et al., 2008; Stokes et al., 2006). Q460R has little 
mutational effect on the functional expression of the human P2X7 receptor 
(Roger et al., 2010a), however, co-inheritance with H155Y and A348T SNP 
mutations may have a significant effect on the pathophysiology of affective 
mood disorders (~abrini et al., 2005; Roger et al., 2010a; Stokes et al., 2010). 
Indeed, Stokes et al. have shown that agonist-induced secretion of IL-1 ~ by 
monocytes from subjects polymorphic for the A348T mutation is increased 
(Stokes et al., 2010). 
This study has shown that His 155 and Ala348 are important for the 
functional expression of the human P2X7 receptor, and are likely to be via 
different mechanisms (single channel properties for Ala348 , and a mechanism 
yet to be determined for His 155). 
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Chapter 4 
Species differences between human and rat P2X7 
receptor functional responses 
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4.1 Introduction 
The cloning and characterisation of the human and rat P2X7 receptors 
has revealed striking differences in their functional expression (Rassendren et 
al., 1997; Surprenant et al., 1996) (see section 1.6.10). It is important to 
determine the differences in P2X7 receptors properties between species. 
Pharmacological characterisations of P2X7 receptors are frequently performed 
following heterologous expression of the rat P2X7 receptor. Information from 
such work will be of limited use if the agonist and antagonist properties of P2X7 
receptors are very different. Furthermore, a large body of information gained on 
the physiological and pathophysiological roles for the P2X7 receptor has been 
from laboratory animal studies. Inferring functional roles for the human P2X7 
receptor should bear in mind the differences in receptor properties between 
species. 
It is clear that the rat P2X7 receptor is more sensitive to ATP and BzA TP 
than the human receptor (Rassendren et al., 1997; Roman et al., 2009). 
However, differences between the two species in terms of P2X7 receptor 
mediated response to agonists are less well described. A previous study found 
that cells expressing the rat P2X7 receptor have a higher BzA TP-induced 
maximal uptake of YO-PRO-1 dye than those expressing the human P2X7 
receptor, however, surprisingly there was no significant difference in maximal 
BzATP-evoked currents (Rassendren et al., 1997). 
Studies described in chapter 3 show that mutations H155Y or A348T of 
the human P2X7 receptor confer an increase in agonist-evoked maximal 
currents. Similar gain-of-function effects of these mutations on agonist-induced 
Ca2+ influx or dye uptake have also been reported (Cabrini et al., 2005; Roger 
et al., 2010a, Stokes et al., 2010). These two mutations change the residues at 
155 and 348 positions to those of the WT rat P2X7 receptor. The particular 
residues at position 155 and 348 are therefore hypothesised to be important in 
determining the functional expression of the P2X7 receptor, and particularly the 
difference between the human and rat species. Thus, in this chapter, the 
currents in HEK293 cells expressing human or rat P2X7 receptors evoked by 
ATP and BzA TP were re-examined. In addition, the reciprocal mutations, 
Y155H and T348A, of the rat P2X7 receptor were introduced by site-directed 
mutagenesis, and their effects on rat P2X7 receptor-mediated agonist-evoked 
currents was determined. 
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4.2 Results 
4.2.1 Comparison of human and rat P2X7 receptor mediated currents 
The functional expression of human and rat P2X7 receptors were 
compared. WT human and rat P2X7 receptors were expressed in HEK293 cells 
and their current responses to ATP were compared by whole-cell patch-clamp 
recording. Figure 4.1 shows the results. Cells expressing the human P2X7 
receptor responded to ATP with a maximal current amplitude of 281 ± 18 pA/pF 
(n = 5), an ECso of 304 ± 49 IJM (n = 5), and a Hill coefficient of 2.03 ± 0.13 (n = 
5). Cells expressing the rat P2X7 receptor responded with larger maximal 
current amplitudes (458 ± 27 pA/pF, n = 5; p<0.001; Figure 4.1 C). The EC50 
value was 110 ± 6.1 IJM (n = 5), and the rat receptor was more sensitive to ATP 
than the human (pEC5o 3.96 ± 0.02, n = 5, and 3.54 ± 0.07, n = 5, respectively; 
p<0.001; Figure 4.1 D). The Hill coefficient was higher for the rat P2X7 receptor 
(2.67 ± 0.18, n = 5; p<0.05; Figure 4.1 E). 
Figure 4.2 shows the dose-response curves constructed using BzA TP as 
the agonist. Cells expressing the rat P2X7 receptor responded to BzA TP with a 
maximal current amplitude (282 ± 21 pA/pF, n = 12), and this was not 
significantly different to the human receptor (234 ± 24 pA/pF, n = 11; p>0.05; 
Figure 4.2C). The ECso values were 1.9 ± 0.1 ~M (n = 12) for the rat receptor, 
and 31 ± 3.7 ~M (n = 11) for the human. The rat P2X7 receptor was more 
sensitive to BzATP (pEC5o 5.72 ± 0.02, n = 12) than the human receptor (pEC50 
4.53 ± 0.05, n = 11; p<0.001; Figure 4.2D). The Hill coefficient was greater for 
the rat than the human receptor (3.59 ± 0.28, n = 12 and 2.73 ± 0.29, n = 11, 
respectively; p<0.05; Figure 4.2E). 
The maximal current amplitudes recorded from cells expressing the 
human P2X7 receptor were not significantly different whether ATP or BzATP 
were used as the agonist (281 ± 18 pA, n = 5 for ATP, and 234 ± 24 pA/pF, n = 
11 for BzA TP; p>0.05). However, the maximal current amplitudes recorded form 
cells expressing the rat P2X7 receptor were significantly smaller when BzA TP 
was used as the agonist (458 ± 27 pA/pF, n = 5 for ATP, and 282 ± 21 pA/pF, n 
= 12 for BzATP; p<0.001). These results indicate that BzATP is a full agonist at 
the human P2X7 receptor, but only a partial agonist at the rat receptor. Note that 
these experiments were not performed in parallel. 
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Figure 4.1 AlP-evoked human and rat P2X7 receptor mediated currents 
recorded in low divalent extracellular solution 
(A) Representative ATP-evoked currents recorded from a HEK293 cell 
expressing WT human (left) or rat P2X7 receptors (right) at -60 mV. The dashed 
line indicates the maximal current for human P2X7 receptor. (8) Mean AlP 
dose-response curves summarising the data shown in A: human (squares) or 
rat (circles). Smooth lines show the best fits to the Hill equation. (C-E) Mean 
maximal current amplitudes (IMAX), pEC50 and Hill coefficients. The number of 
cells recorded is indicated. * p<O.05, *** p<O.001, compared to the human P2X7 
receptor. 
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Figure 4.2 BzATP-evoked human and rat P2X7 receptor mediated currents 
recorded in low divalent extracellular solution 
(A) Representative 8zATP-evoked currents recorded from a HEK293 cell 
expressing WT human (left) or rat P2X7 receptors (right) at -60 mV. The dashed 
line indicates the maximal current for human P2X7 receptor. (8) Mean ATP 
dose-response curves summarising the data shown in A: human (squares) or 
rat (circles). Smooth lines show the best fits to the Hill equation. (C-E) Mean 
maximal current amplitudes (IMAX), pECso and Hill coefficients. The number of 
cells recorded is indicated. * p<0.05, *** p<0.001, compared to the human P2X7 
receptor. 
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4.2.2 Effect of the Y155H mutation on agonist-induced current responses 
of the rat P2X7 receptor 
In chapter 3 it was shown that the H155Y mutation confers increased 
ATP-evoked maximal current amplitudes (Figure 3.2). This mutation changes 
the residue at 155 to that of the WT rat P2X7 receptor. The ATP-evoked current 
amplitudes mediated by the rat P2X7 receptor were higher than the human 
receptor (Figure 4.1). Therefore, the effect of the reciprocal mutation Y155H on 
rat P2X7 receptor function was investigated. Using low divalent cation 
extracellular solution (Figure 4.3), cells expressing the WT rat P2X7 receptor 
responded to ATP with a maximal current amplitude of 444 ± 24 pA/pF (n = 10), 
and an ECso of 104 ± 5.2 IJM (n = 10). The Y155H mutation conferred a 
reduction in maximal current amplitude (211 ± 25 pA/pF, n = 7; p<0.001; Figure 
4.3C) and in sensitivity to ATP (ECso 286 ± 10 IJM, n = 7) (pECso 3.99 ± 0.02, n 
= 10 for WT, and 3.55 ± 0.02 for Y155H, n = 7 for Y155H; p<0.001; Figure 
4.30). The Hill coefficient was unaltered (2.54 ± 0.07, n = 10 for WT and 2.40 ± 
0.13, n = 7 for Y155H; p>0.05; Figure 4.3E). 
These experiments were repeated using standard extracellular solution 
(Figure 4.4). Cells expressing the WT rat P2X7 receptor responded to ATP with 
a maximal current amplitude of 411 ± 21 pA/pF (n = 5), which was reduced to 
189 ± 37 pA/pF (n = 5; p<0.001) by the Y155H mutation (Figure 4.4C). The 
ECso value was 1470 ± 33 IJM (n = 5) for WT, and 2513 ± 114 IJM (n = 4) for 
Y155H. The mutation conferred a significant decrease in sensitivity to ATP 
(pECso 2.83 ± 0.01, n = 5 for WT, and 2.60 ± 0.02, n = 4 for Y155H; p<0.001; 
Figure 4.40). The mutation significantly increased the Hill coefficient (2.57 ± 
0.18, n = 5 for WT, and 3.97 ± 0.13, n = 4 for Y155H; p<0.001; Figure 4.4E). 
The effect of Y155H mutation on BzA TP-evoked currents was also 
investigated (Figure 4.5). Cells expressing the WT rat P2X7 receptor responded 
to BzA TP with a maximal current amplitude of 294 ± 28 pA/pF (n = 7), an ECso 
of 1.7 ± 0.06 J.1M (n = 7), and a Hill coefficient of 3.56 ± 0.19 (n = 7). The Y155H 
mutation reduced the maximal current amplitude (129 ± 15 pA/pF, n = 5; 
p<0.01; Figure 4.5C). The Y155H mutant responded to BzATP with an ECso 
value of 8.0 ± 1.3 J.1M (n = 5). The mutation conferred a decrease in sensitivity 
to BzATP (pECso 5.78 ± 0.01, n = 7 forWT, and 5.12 ± 0.06, n = 5 for Y155H; 
p<0.001; Figure 4.50) and decreased the Hill coefficient (2.78 ± 0.11, n = 5 for 
Y155H; p<0.01; Figure 4.5E). 
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Figure 4.3 Effect of the Y155H mutation on ATP-evoked currents of the rat 
P2X7 receptor recorded in low divalent extracellular solution 
(A) Representative ATP-evoked currents recorded from a HEK293 cell 
expressing WT (rP2X7 WT; left) or Y155H mutant rat P2X7 receptors (right) at -
60 mV. The dashed line indicates the maximal current for WT. (8) Mean ATP 
dose-response curves summarising the data shown in A: WT (squares) or 
Y155H (triangles). Smooth lines show the best fits to the Hill equation. (C-E) 
Mean maximal current amplitudes (I MAX) , pEC50 and Hill coefficients. The 
number of cells recorded is indicated. *** p<0.001, compared to WT. 
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Figure 4.4 Effect of the Y155H mutation on AlP-evoked currents of the rat 
P2X7 receptor recorded in standard extracellular solution 
(A) Representative ATP-evoked currents recorded from a HEK293 cell 
expressing WT (left) or Y155H mutant rat P2X7 receptors (right) in standard 
extracellular solution at -60 mV. The dashed line indicates the maximal current 
for WT. (8) Mean ATP dose-response curves summarising the data shown in A: 
WT (squares) or Y155H (triangles). Smooth lines show the best fits to the Hill 
equation. (C-E) Mean maximal current amplitudes (IMAX), pEC50 and Hill 
coefficients. The number of cells recorded is indicated. *** p<0.001, compared 
toWT. 
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Figure 4.5 Effect of the Y155H mutation on BzATP-evoked currents of the 
rat P2X7 receptor recorded in low divalent extracellular solution 
(A) Representative BzATP-evoked currents (6 s) recorded from a HEK293 cell 
expressing WT (left) or Y155H mutant rat P2X7 receptors (right) at -60 mV. The 
dashed line indicates the maximal current for WT. (B) Mean BzA TP dose-
response curves summarising the data shown in A: WT (squares) or Y155H 
(triangles). Smooth lines show the best fits to the Hill equation. (C-E) Mean 
maximal current amplitudes (I MAX) , pECso and Hill coefficients. The number of 
cells recorded is indicated. ** p<0.01, *** p<0.001, compared to VVT. 
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4.2.3 Effect of the T348A mutation on agonist-induced current responses 
of the rat P2X7 receptor 
In chapter 3, it was shown that the A348T mutation confers increased 
ATP-evoked maximal current amplitudes (Figure 3.5). This mutation changes 
the residue at 348 to that of the Wf rat P2X7 receptor. Because the ATP-
evoked current amplitudes mediated by the rat P2X7 receptor were higher than 
the human receptor (Figure 4.1), the effect of the reciprocal mutation T348A on 
agonist-evoked receptor currents was investigated (Figure 4.6). Cells 
expressing the Wf rat P2X7 receptor responded to ATP with a maximal current 
amplitude of 444 ± 24 pA/pF (n = 10) in low divalent extracellular solution, which 
was reduced by the T348A mutation (326 ± 23, n = 7; p<0.01; Figure 4.6C). The 
Wf receptor responded to ATP with an ECso value of 104 ± 5.2 IJM (n = 10), 
and 105 ± 5.4 IJM for T348A, (n = 7). However, the T348A mutation does not 
alter the sensitivity to ATP (pECso 3.99 ± 0.02, n = 10 for Wf, and 3.98 ± 0.02 
for T348A, n = 7; p>0.05; Figure 4.60). The Hill coefficient was unaffected (2.54 
± 0.07, n = 10 for Wf, and 2.51 ± 0.18, n = 7 for T348A; p>0.05; Figure 4.6E). 
These experiments were also performed using standard extracellular 
solution (Figure 4.7). Similarly, the T348A mutation conferred a decrease in 
ma~imal current amplitude (411 ± 21 pA/pF, n = 5 for Wf, and 230 ± 8.1 pA/pF, 
n = 3 for T348A; p<0.001; Figure 4.7C). The Wf receptor responded to ATP 
with an ECso of 1470 ± 33 /-lM (n = 5), and the T348A mutant 1386 ± 142 ~lM. 
There was no significant effect on sensitivity to ATP (pECso 2.83 ± 0.01, n = 5 
for Wf, and 2.86 ± 0.04, n = 3 for T348A; p>0.05; Figure 4.70). The Hill 
coefficient was unaltered (2.57 ± 0.18, n = 5 for WT, and 2.56 ± 0.26, n = 3 for 
T348A; p>0.05; Figure 4.7E). 
The effect of the T348A mutation on rat P2X7 receptor currents was 
further investigated using BzA TP as the agonist and using low divalent 
extracellular solution (Figure 4.8). The T348A mutation decreased maximal 
current amplitude (294 ± 28 pA/pF, n = 7 for Wf, and 191 ± 24 pA/pF, n = 5 for 
T348A; p<0.05; Figure 4.80). The ATP ECso value was 1.7 ± 0.06 /-lM (n = 7) for 
the WT receptor, and 1.7 ± 0.05 /-lM (n = 5) for T348A mutant. Receptor 
sensitivity to BzATP was unaltered (pECso 5.78 ± 0.01 /-lM, n = 7 for Wf, and 
5.77 ± 0.01, n = 5 for T348A; p>0.05; Figure 4.80), and the Hill coefficient was 
also unaffected (3.56 ± 0.19, n = 7 for Wf, and 3.48 ± 0.14, n = 5 for T348A; 
p>0.05; Figure 4.8E). 
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4.2.4 Effects of the Y155HIT348A mutation on A TP-induced current 
responses of the rat P2X7 receptor 
The Y155HfT348A double mutation was introduced to the rat P2X7 
receptor (Figure 4.9). Cells expressing the WT rat P2X7 receptor responded to 
ATP with a maximal current amplitude of 444 ± 24 pA/pF (n = 10), which was 
reduced by the Y155HfT348A mutation (114 ± 18 pA/pF, n = 3; p<0.001). The 
maximal current amplitude for the Y155HfT348A double mutant receptor was 
significantly lower than that for the Y155H or T348A single mutant receptor. The 
ATP ECso value was 104 ± 5.2 /-lM (n = 10) for WT, and 500 ± 161 /-lM (n = 3) 
for the Y155HfT348A mutant. The sensitivity to ATP was decreased by 
Y155HfT348A mutation in comparison to WT (pECso 3.99 ± 0.02, n = 10 for WT, 
and 3.34 ± 0.13, n = 3 for Y155HfT348A; p<0.001; Figure 4.90). The Hill 
coefficient was decreased by the double mutation (2.54 ± 0.07, n = 10 for WT, 
and 1.72 ± 0.26, n = 3 for Y155HfT348A; p<0.001; Figure 4.9E). 
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Figure 4.6 Effect of the T348A mutation on ATP-evoked currents of the rat 
P2X7 receptor recorded in low divalent extracellular solution 
(A) Representative ATP-evoked currents recorded from a HEK293 cell 
expressing WT (left) or T348A mutant rat P2X7 receptors (right) at -60 mV. The 
dashed line indicates the maximal current for WT. (8) Mean ATP dose-
response curves summarising the data shown in A: WT (squares) or T348A 
(triangles). Smooth lines show the best fits to the Hill equation. (C-E) Mean 
maximal current amplitudes (IMAX), pEC50 and Hill coefficients. The number of 
cells recorded is indicated. ** p<0.01, compared to WT. 
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Figure 4.7 Effect of the T348A mutation on ATP-evoked currents of the rat 
P2X7 receptor recorded in standard extracellular solution 
(A) Representative ATP-evoked currents recorded from a HEK293 cell 
expressing WT (left) or T348A mutant rat P2X7 receptors (right) in standard 
extracellular solution at -60 mV. The dashed line indicates the maximal current 
for WT. (8) Mean ATP dose-response curves summarising the data shown in A: 
wr (squares) or T348A (triangles). Smooth lines show the best fits to the Hill 
equation. (C-E) Mean maximal current amplitudes (I MAX) , pEC50 and Hill 
coefficients. The number of cells recorded is indicated. *** p<0.001, compared 
toWT. 
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Figure 4.8 Effect of the T348A mutation on BzATP-evoked currents of the 
rat P2X7 receptor recorded in low divalent extracellular solution 
(A) Representative 8zATP-evoked currents (6 s) recorded from a HEK293 cell 
expressing WT (left) or T348A mutant rat P2X7 receptors (right) at -60 mV. The 
dashed line indicates the maximal current for WT rat P2X7 receptor. (8) Mean 
8zATP dose-response curves summarising the data shown in A: WT (squares) 
or T348A (triangles). Smooth lines show the best fits to the Hill equation. (C-E) 
Mean maximal current amplitudes (I MAX) , pEC50 and Hill coefficients. The 
number of cells recorded is indicated. * p<0.05, compared to WT. 
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Figure 4.9 Effect of the Y155H/T348A mutation on ATP-evoked currents of 
the rat P2X7 receptor recorded in low divalent extracellular solution 
(A) Representative ATP-evoked currents recorded from a HEK293 cell 
expressing WT (left) or Y155Hff348A mutant rat P2X7 receptors (right) at -60 
mV. The black dashed line indicates the maximal current for the WT receptor, 
and in grey indicates the representative maximal currents for the Y155H (Figure 
4.3A) and T348A (Figure 4.6A) single mutants. (8) Mean ATP dose-response 
curves summarising the data shown in A: WT (squares) or Y155Hff348A 
(triangles). Smooth lines show the best fits to the Hill equation. (C-E) Mean 
maximal current amplitudes (I MAX) , pECso and Hill coefficients. The number of 
cells recorded is indicated. ** p<0.01, *** p<0.001, compared to WT; A p<0.05, 
AM p<0.001 , compared to Y155Hff348A double mutant. 
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4.3 Discussion 
The results presented in this chapter show that the ATP-induced 
maximal currents mediated by the rat P2X7 receptor are greater than the human 
P2X7 receptor (Figure 4.1), Furthermore, mutations Y155H and T348A of the rat 
P2X7 receptor decrease agonist-induced maximal currents, with little or mild 
effect on agonist sensitivity (Figures 4.3 to 4.8). 
Direct comparison of human and rat P2X7 receptors shows that the rat 
P2X7 receptor exhibits significantly greater sensitivity to ATP and BzA TP than 
the human P2X7 receptor (Figures 4.1 and 4.2), a finding that was reported by 
previous studies (Rassendren et a/., 1997, Roman et a/., 2009). Previous 
studies found that the amplitude of BzA TP-evoked maximal currents mediated 
by the rat P2X7 receptor was increased, in comparison to the human, but in this 
study there was no statistical difference detected (Figure 4.2) (Rassendren et 
a/., 1997). This is in striking contrast with the observation that BzATP-evoked 
YO-PRO-1 uptake was greater for cells expressing the rat P2X7 receptor 
compared to the human receptor (Rassendren et a/., 1997). On the other hand, 
the results from this study have provided the first evidence that the amplitude of 
ATP-induced maximal currents was significantly greater in cells expressing the 
rat P2X7 receptor than the human P2X7 receptor (Figure 4.1). These 
observations suggest there is a species difference in functional expression of 
the P2X7 receptors between human and rat, although such a difference only 
becomes apparent when ATP is used as the agonist. BzATP differs structurally 
from ATP due to the attachment of two benzoyls to the ribose group, and may 
interact with different sets of residues in the agonist-binding site. Therefore, it is 
likely the conformational changes that occur upon agonist binding differ 
depending on whether ATP or BzATP is bound. Indeed, Young et a/. found that 
one residue (Asp284) accounts for the difference in ATP sensitivity between rat 
and mouse P2X7 receptors. However, two residues (Lys 127 and Asn284) are 
responsible for the difference in BzATP sensitivity (Young et al., 2007). The 
finding in this study that BzA TP was a full agonist at the human P2X7 receptor, 
but only a partial agonist at the rat receptor, may also provide an explanation for 
the finding that a species difference in functional expression of the P2X7 
receptors between human and rat is only detectable when ATP is used as the 
agonist. 
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Results in chapter 3 show mutations H155Y and A348T, which change 
residues at 155 and 348 to those of the WT rat receptor, increase the amplitude 
of agonist-induced maximal currents mediated by the human P2X7 receptor, 
with modest effects on agonist sensitivity. The results in this chapter show that 
reciprocal mutations, Y155H and T348A, of the rat P2X7 receptor decrease the 
maximal current amplitude (Figures 4.3 to 4.8). Taken together, these results 
strongly suggest that residues at positions 155 and 348 are important for the 
differential functional expression of human and rat P2X7 receptors. In summary, 
the study described in this chapter shows that ATP-induced maximal responses 
are greater for rat P2X7 receptor than human P2X7 receptor. Furthermore, the 
Y155H and T348A mutations of the rat P2X7 receptor attenuates the functional 
expression. This provides further evidence that residues at positions 155 and 
348 are important in determining the functional expression of the P2X7 receptor, 
and particularly the species differences in functional expression of rat and 
human P2X7 receptors. 
Human and rat P2X7 receptor sequences are 80% identical (Rassendren 
et al., 1997). A number of species differences in the function of human and rat 
P2X7 receptors have been reported (see general introduction, section 1.6.10). 
For example, the rat P2X7 receptor sequence contains a CaM binding domain, 
which is not present in the human P2X7 receptor sequence (Roger et al., 
2010b). Therefore, whilst the rat P2X7 receptor has a Ca2+/CaM component to 
current facilitation, the human P2X7 receptors does not. Furthermore, the 
antagonist AZ11645373 has a greater potency at human than rat P2X7 
receptors (Michel et al., 2009; Stokes et al., 2006). Mutation F95L of the human 
P2X7 receptor (changes the residue to that of the WT rat receptor) reduces the 
potency of AZ11645373 (Michel et al., 2008; Michel et al., 2009). Residues at 
positions 155 and 348 of the human and rat P2X7 receptors adds to the list of 
sequence dissimilarities between these species that lead to differences in the 
functional expression of the receptors. 
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Chapter 5 
Contribution of residues in microdomains surrounding 
155 and 348 to the functional expression of human and 
rat P2X7 receptors 
113 
5.1 Introduction 
The results presented in the previous two chapters show that mutations 
H 155Y and A348T of the human P2X7 receptor lead to gain of receptor function 
and reciprocal mutations Y155H and T348A of the rat P2X7 receptor reduce 
receptor function. This demonstrates residues at positions 155 and 348 are 
important in determining the species-specific functional expression of human 
and rat P2X7 receptors. 
According to the structural model of the human P2X7 receptor, His 155 is 
located in the head region of the extracellular domain (Figure 3.1) (Kawate et 
al., 2009; Roger et al., 2010a). Alignment of P2X7 amino acid sequences shows 
that the six residues immediately surrounding 155 are not conserved between 
species (Figure 5.1). Results in chapter 3 found that mutation E156Y of the 
human P2X7 receptor reduced ATP-evoked maximum currents (Figure 3.9), 
providing evidence that residues in the region surrounding position 155 may be 
important in P2X7 receptor function. 
The structural model of the human P2X7 receptor indicates Ala348 is 
located in the TM2 region, on the ihtracellular side of the ion channel gate 
(Figure 3.1) (Kawate et al., 2009; Roger et al., 2010a)). The zebrafish P2X4 
structure shows that TM2 forms the ion conducting pathway and that, on the 
intracellular side of the gate, the TM2 a-helices spread out (Figure 1.5) (Kawate 
et al., 2009). This region of TM2 is predicted to undergo substantial movement 
during channel opening (Browne et al., 2010). Therefore, other residues in this 
region of the P2X7 receptor may be important for receptor function, as 
demonstrated by the residue at 348. Alignment of P2X7 receptor amino acid 
sequences shows all residues N-terminal to position 348 in TM2 are conserved 
(Figure 5.1). However, a number of residues C-terminal to position .348 in, or 
close to, the TM2 domain, are not conserved. 
The potential contributions of the non-conserved residues in the 
microdomains surrounding positions 155 and 348 to the species-specific 
functional expression of human and rat P2X7 receptors have been investigated. 
To this end, each of these residues of the human P2X7 receptor were replaced 
in turn with the corresponding residue of the rat P2X7 receptor, and the 
mutational effects on ATP-evoked currents have been examined in this chapter. 
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Figure 5.1 Microdomains surrounding positions 155 and 348 of P2X7 
receptors 
Sequence alignments of the microdomains surrounding positions 155 and 348 
in five cloned mammalian P2X7 receptors. Conserved residues are highlighted 
in grey, residues 155 and 348 of the human P2X7 receptor in pink, and residues 
studied in this chapter in green. The accession numbers are Y09561, X95882, 
AJ009823, EU275201 and EU334661 , respectively. Aligned using ClustalW. 
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5.2 Results 
5.2.1 Effect of the mutation of residues surrounding His155 in the human 
P2X7 receptor on A TP-induced currents 
Each of the six amino acid residues surrounding His 155 in human P2X7 
receptor was replaced with the corresponding residue of the rat P2X7 receptor, 
generating the following mutants: V1531, V154P, E1560, G157Q, N158K and 
Q159R. Figure 5.2A shows examples of ATP-elicited inward whole-cell currents 
in cells expressing individual mutants in HEK293 cells and Figure 5.28 shows 
the ATP dose-current response curves. Cells expressing WT human P2X7 
receptors responded to ATP with a maximal current amplitude of 276 ± 15 
pA/pF (n = 23). Three mutations (V154P, E1560 and Q159R) had no effect, but 
three other mutations (V1531, G157Q and Q159R) led to a reduction in maximal 
current amplitude (215 ± 19 pA/pF, n = 4; 197 ± 24 pA/pF, n = 5 and 184 ± 25 
pA/pF, n = 6 respectively; p<0.05; Figure 5.2C). The WT EC50 value for ATP 
was 347 ± 24 /-lM (n = 24), and none of the mutations altered the sensitivity to 
ATP (pEC50 3.48 ± 0.03, n = 24 for WT; Figure 5.20) or Hill coefficient (2.04 ± 
0.08, n = 24 for WT; Figure 5.2E). 
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Figure 5.2 Effect of the mutation of residues in the microdomain 
surrounding His 155 of human P2X7 receptor on AlP-evoked currents 
(A) Representative ATP-evoked currents recorded from a HEK293 cell 
expressing WT or mutant human P2X7 receptors at -60 mV. The dashed line 
indicates the maximal current for the WT receptor. (8) Mean ATP dose-
response curves summarising the data from experiments shown in A: WT 
(squares) or mutant (triangles). Smooth lines show the best fits to the Hill 
equation. (C-E) Mean maximal current amplitudes (IMAX), pECso and Hill 
coefficients. The number of cells recorded is indicated. * p<0.05, ** p<0.01, 
compared to WT. 
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5.2.2 Effect of the mutation of residues surrounding Ala348 in human P2X7 
receptor on A TP-induced currents 
Each of the four non-conserved amino acids in the close vicinity of 
residue Ala348 in the human P2X7 receptor was individually mutated to the 
corresponding residue in rat P2X7 receptor. This lead to generation of four 
mutants: F350C, F353L, L3541 and D356N. Individual mutants were expressed 
in HEK293 cells the ATP-induced whole-cell currents were recorded (Figure 
5.3). Cells expressing the WT human P2X7 receptor responded to ATP with a 
maximal current amplitude of 257 ± 13 pA/pF (n = 18), an EC50 of 392 ± 15 ~lM 
(n = 18), and a Hill coefficient of 2.14 ± 0.06 (n = 18). The F353L and D356N 
mutations had opposing effects on maximal current amplitude: F353L caused 
an increase (318 ± 23 pA/pF, n = 5; p<0.05), whilst D356N resulted in a 
decrease (191 ± 16 pA/pF, n = 4; p<0.05; Figure 5.3C). The maximal current 
amplitude was not altered by F350C or L3541 mutations. The ATP EC50 values 
were 291 ± 32 ~M (n = 4) and 291 ± 31 ~M (n = 4) for the F350C and D356N 
mutants, respectively, and both mutations conferred an increase in receptor 
sensitivity to ATP (pEC50 3.41 ± 0.02, n = 18 for WT, and 3.54 ± 0.05, n = 4 and 
3.54 ± 0.05 for F350C and D356N, respectively; p<0.01; Figure 5.3D). The Hill 
coefficient was decreased by the F350C mutation (1.71 ± 0.20, n = 4; p<0.05; 
Figure 5.3E). For all other mutants, the EC50 and Hill coefficients were 
unaltered. 
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Figure 5.3 Effect of mutating residues close to Ala348 of the human P2X7 
receptor on ATP-evoked currents 
(A) Representative ATP-evoked currents recorded from a HEK293 cell 
expressing WT (left) or mutant human P2X7 receptors (right) at -60 mV. The 
dashed line indicates the maximal current for the WT receptor. (8) Mean ATP 
dose-response curves summarising the data from experiments shown in A: WT 
(squares) or mutant (triangles). Smooth lines show the best fits to the Hill 
equation. (C-E) Mean maximal current amplitudes (I MAX) , pECso and Hill 
coefficients. The number of cells recorded is indicated. * p<0.05, compared to 
WT. 
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5.2.3 Effect of the L353F mutation in the rat P2X7 receptor on A TP-induced 
currents 
Like A348T (Figures 3.5 and 5.3), mutation of Phe353 in the human P2X7 to the 
corresponding leucine residue in the rat P2X7 receptor increased the ATP-
evoked maximal current amplitudes (Figure 5.3). The reciprocal mutation, 
L353F, was introduced to the rat P2X7 receptor to see if this residue contributes 
to the species dependent functional expression in a similar way to 348 (chapter 
4). Cells expressing WT rat P2X7 receptors responded to ATP with a maximal 
current amplitude of 316 ± 29 pA/pF (n = 4), and was not significantly altered by 
the L353F mutation (371 ± 52 pA/pF, n = 4; p>0.05; Figure 5.4C). EC50 values 
were 108 ± 7 ~M (n = 4) for WT, and 89 ± 13 ~M (n = 4) for L353F. Receptor 
sensitivity to ATP was not altered by the mutation (pEC50 3.97 ± 0.03, n = 4 for 
WT, and 4.07 ± 0.07, n = 4 for L353F; p>0.05; Figure 5.40). The Hill coefficient 
was also not significantly altered by the L353F mutation (2.39 ± 0.13, n = 4 for 
WT, and 2.43 ± 0.15, n = 4 for L353F; p>0.05; Figure 5.4E). 
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Figure 5.4 Effect of the L353F mutation in the rat P2X7 receptor on ATp· 
evoked currents 
(A) Representative AlP-evoked currents recorded from a HEK293 cell 
expressing WT (left) or L353F mutant rat P2X7 receptors (right) at -60 mV. The 
dashed line indicates the maximal current for the WT receptor. (8) Mean ATP 
dose-response curve summarising the data from experiments shown in A: WT 
(squares) or L353F (triangles). Smooth lines show the best fits to the Hi" 
equation. (C-E) Mean maximal current amplitudes (IMAX), pEC50 and Hi" 
coefficients. The number of cells recorded is indicated. No significant 
differences, compared to WT. 
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5.3 Discussion 
In this chapter, the non-conserved residues in the microdomains 
surrounding residues His 155 and Ala348 (Figure 5.1) in human P2X7 receptor 
were investigated by individually mutating to the corresponding residues in rat 
P2X7 receptor. 
Among the six mutations introduced in the microdomain surrounding 
His155 of human P2X7 receptor, V1531, G157Q and Q159R led to a significant 
reduction in the amplitude of maximal ATP-induced currents (Figure 5.2), 
suggesting Va1153, Gly157 and Gin 159, as well as His 155, in this microdomain are 
important for the human P2X7 receptor functional expression. However, unlike 
H155Y, none of these six mutations increased the maximal current amplitude. 
Together, these results demonstrate that residue at position 155 has a unique 
role in this microdomain in contributing to the difference in functional expression 
between human and rat P2X7 receptors. 
For the four mutations in the microdomain close to Ala348, F353L was 
interesting as, similar to A348T, this mutation conferred a significanfincrease in 
the amplitude of ATP-evoked maximal currents mediated by human P2X7 
receptor (Figure 5.3). However, the reciprocal mutation, L353F, did not alter the 
amplitude of ATP-induced maximal currents mediated by the rat P2X7 receptor 
(Figure 5.4). Therefore, Leu353 is important for human P2X7 receptor function, 
but it has little contribution to the species difference in P2X7 receptor function 
between human and rat species. Furthermore, D356N mutation of the human 
P2X7 receptor had the opposite effect to A348T, and decreased the maximal 
currents (Figure 5.3). Therefore, ASp356 also plays a role in determining the 
human P2X7 receptor function. 
Another approach to studying the contribution of the two microdomains to 
human P2X7 receptor function and to the species differences between human 
and rat P2X7 responses would be to use chimeras in which residues Val
153 to 
Gin 159 or Ala348 to ASp356 of the human P2X7 receptor are replaced with the 
corresponding residues of the rat receptor. This would allow the contribution of 
the entire microdomains to the species-specific functional expression of the 
P2X7 receptor to be determined. This technique, in conjunction with point 
mutations, proved useful in determining that Asn284 of the rat P2X7 receptor 
accounts for the difference in ATP sensitivity between rat and mouse species, 
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and that Lys 127 and Asn284 account for the differences in BzA TP sensitivity 
(Young et al., 2007). 
In summary, the study presented in this chapter has identified residues 
Va1153, Gly157 and Gin 159 in the microdomain surrounding His 155 in the 
extracellular part and Phe353 and ASp356 close to Ala348 in TM2 are important for 
determining the human P2X7 receptor function. However, none of the non-
conserved residues in these microdomains contribute significantly to the 
species differences in ATP-evoked maximal currents or the functional 
expression of the P2X7 receptors described in chapter 4. 
127 
Chapter 6 
Effect of mutations at positions 155 and 348 on human 
and rat P2X7 receptor protein expression 
128 
6.1 Introduction 
The results presented in previous chapters show that H 155Y and A348T 
mutations of the human P2X7 receptor increase (chapter 3), whereas the 
reciprocal mutations Y155H and T348A of the rat P2X7 receptor decrease 
(chapter 4), agonist-evoked maximal currents. The whole-cell currents are 
determined by the sum of the number of the functional receptors at cell surface 
(surface expression) and single channel conductance together with channel 
opening probability (single channel properties). Therefore, mutations of residues 
at these positions could alter surface expression of the P2X7 receptor, or the 
single channel properties of the P2X7 receptor, or both. In this chapter, the 
potential roles of the residues at positions 155 and 348 on the surface 
expression of human and rat P2X7 receptor were investigated using 
immunocytochemistry and biotinylation. 
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6.2 Results 
6.2.1. Effect of reciprocal mutations at position 155 on human and rat P2X7 
receptor protein expression and sub-cellular distribution 
Both WT and mutant human and rat P2X7 receptors contained a C-
terminal EE tag. Thus the effect of mutations at position 155 on the sub-cellular 
localisation of human and rat P2X7 receptors were studied by 
immunocytochemistry using an anti-EE antibody. 
Figure 6.1 shows representative immunofluorescent confocal images. 
The immunoreactivity for the WT human P2X7 receptor was diffuse throughout 
the cell, and for the WT rat receptor was more concentrated towards the cell 
surface. The H155Y mutant immunoreactivity was more concentrated towards 
the cell surface in comparison to WT. Conversely, the Y155H reciprocal 
mutation of the rat P2X7 receptor reduced the surface localisation. 
To further investigate the effect of mutations at position 155 on human 
and rat P2X7 receptor total and surface expression, biotin labelling and Western 
blotting were performed. Figure 6.2 shows representative results. Strong 
expression of the WT receptor was consistently observed, and there was no 
detectable protein in cells transfected with the empty vector pcONA3.1. WT and 
mutant P2X7 receptors were co-expressed with eGFP, which was used as an 
internal control. Band sizes for eGFP were similar within experiments, indicating 
little variation in cell preparation, transfection efficiency, and sample handling. 
Biotin labelled eGFP was not detectable in any of the experiments, indicating 
that the biotin had not crossed the plasma membrane and labelled intracellular 
proteins. Both the human and rat P2X7 receptor protein bands are close to the 
58 kOa protein marker, and two protein bands are detected for the rat P2X7 
receptor (Figures 6.2A and B). 
The H155Y mutation conferred a 74 ± 22% increase (n = 5; p<O.001; 
Figure 6.20) in surface expression of the human P2X7 receptor, and a 43 ± 8% 
increase (n = 5, p<O.01; Figure 6.2C) in total expression. The H155L mutation, 
which significantly decreased ATP-induced maximal currents of the human 
P2X7 receptor (Figure 3.8), decreased both cell surface and total expression 
(Figure 6.2A). In contrast with the effect of H155Y in the human P2X7 receptor, 
the reciprocal mutation Y155H of rat P2X7 receptor decreased surface 
expression by 46 ± 2 % (n = 4; p<O.01; Figure 6.20), and total expression by 27 
± 8 % (n = 4; p<O.05; Figure 6.2C). 
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Figure 6.1 Effect of reciprocal mutations at position 155 on subcellular 
localisation of human and rat P2X7 receptors 
Representative immunofluorescent confocal images of HEK293 cells 
expressing the indicated EE-tagged WT or mutant human (hP2X7) and rat 
(rP2X7) P2X7 receptors. The scale is 10 f...lm. Similar results were observed in 
three independent experiments. 
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Figure 6.2 Effect of mutations at position 155 on surface and total protein 
expression of human and rat P2X7 receptors 
(A) and (B) Representative Western blots showing biotin labelled (surface) and 
whole-cell lysate (total) protein of the human (hP2X7; A) or rat (rP2X7; B) 
receptors. Total protein expression of GFP is also shown. Numbers on the right 
in each panel indicate the protein markers (kOa). (C) and (0) Relative total and 
surface expression of human (C) and rat (0) P2X7 receptors, calculated from 
measurements of band intensities and normalised to that of the respective WT 
receptors in parallel experiments. The numbers in the ·bars indicate the number 
of experiments. * p<0.05, ** p<0.01 and ***, p<0.001, compared to WT. 
132 
6.2.2. Effect of reciprocal mutations at position 348 on human and rat P2X7 
receptor protein expression and sub-cellular distribution 
The effects of reciprocal mutations at position 348 of the human and rat 
P2X7 receptor on the sub-cellular localisation of the protein have also been 
investigated. Figure 6.3 shows representative immunofluorescent confocal 
images. Immunoreactivity for the WT human P2X7 receptor is largely unaffected 
by the A348T mutation. Furthermore, the WT rat P2X7 receptor 
immunoreactivity is only slightly disrupted by the T348A mutation. 
Biotin labelling and Western blotting were performed (Figure 6.4). The 
A348T mutation of the human P2X7 receptor and reciprocal mutation T348A of 
the rat P2X7 receptor had no obvious effect on their surface or total expression. 
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Figure 6.3 Effects of reciprocal mutations at position 348 on sub-cellular 
localisation of human and rat P2X7 receptors 
Representative immunofluorescent confocal images of HEK293 cells 
expressing the EE-tagged WT or mutant human (hP2X7) and rat (rP2X7) 
receptors. The scale is 10 Jlm. Similar results were observed in three 
independent experiments. 
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Figure 6.4 Effects of mutations at position 348 on surface and total protein 
expression of human and rat P2X7 receptors 
Representative Western blots showing biotin labelled (surface) and whole-cell 
lysate (total) protein of the wr or mutant human and rat P2X7 receptors using 
an anti-EE antibody. Total protein expression of GFP is also shown. Numbers 
on the right in each panel indicate the protein markers (kOa). Representative of 
2 experiments. 
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6.3. Discussion 
The results described in this chapter show that mutations at position 155, 
but not position 348 of human and rat P2X7 receptors alter sub-cellular 
localisation, and total and surface protein expression. 
The results from immunofluorescent confocal imaging indicate that, 
under the same experimental conditions, the WT human P2X7 receptor is 
evenly distributed across the cell (both on the cell surface and inside the cell) 
and, in contrast, the WT rat P2X7 receptor is predominantly present on the cell 
surface (Figure 6.1). These results are consistent with those previously reported 
(Jiang et a/., 2005; Liu et a/., 2008). The H155Y mutation enriched the human 
P2X7 receptor immunoreactivity on the cell surface, whereas the reciprocal 
Y155H mutation of rat P2X7 receptor resulted in the opposite effect (Figure 6.1). 
These results therefore suggest that H155Y and Y155H mutations of the human 
and rat P2X7 receptor alter their sub-cellular distribution. 
In separate biotin labelling experiments, the H 155Y mutation significantly 
increased surface expression of the human P2X7 receptor, whereas the 
reciprocal mutation Y155H conferred a decrease in surface expression of the 
protein (Figure 6.2). These results provide consistent evidence suggesting that 
residue at position 155 is important in determining surface expression of the 
human and rat P2X7 receptors. This appears to be, at least in part, due to 
changes in total protein expression, because Western blotting analysis showed 
that H155Y mutation of human P2X7 receptor enhanced, whereas Y155H 
mutation of rat P2X7 receptor reduced total protein expression, and to a 
comparable degree to surface expression. Thus, the change in total and 
particularly surface expression provides a reasonable explanation for the 
opposite effects resulting from reciprocal mutations of residue at position 155 on 
ATP-induced maximal current responses that are described in chapters 4 and 5. 
In addition, H 155L mutation of the human P2X7 receptor, which confers 
reduction in functional expression (Figure 3.8), attenuated the total and surface 
protein expression (Figure 6.2). This result provides further supporting 
evidence. It is worth mentioning the finding that the H155Y mutation of the 
human P2X7 receptor increases surface expression . of the protein is in 
disagreement with a previous study reporting no change in surface expression 
of H155Y mutant of the human P2X7 receptor using flow cytometry (Cabrini et 
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a/., 2005). Such differences may be due to the different assays used, which 
have different detection sensitivities. 
Further experiments are required to determine the underlying 
mechanisms resulting in altered protein and surface expression conferred by 
mutations at position 155. Experiments should be performed to investigate 
possible changes in transcription and translation, protein folding and quality 
control in the ER and degradation, which contribute to total protein expression, 
as well as forward trafficking and endocytic retrieval that are important in' 
determining the sub-cellular distribution and surface expression. For example, 
deletion mutation of Phe508 of CFTR (cystic fibrosis transmembrane 
conductance regulator) results in a dramatic reduction in total protein 
expression, due to protein misfolding in the ER and rapid degradation, and 
thereby surface expression (Cyr, 2005). The effects of mutating residue 155 
could also change the single channel properties of the receptor. Although such 
a possibility cannot be completely ruled out, the contribution should be at most 
minor, considering the location of residue 155 is away from the ATP binding 
site, the channel gate and the ion conducting pore (Figure 3.1) (Kawate et a/., 
2009; Roger et a/., 2010a)). 
This study has shown that reciprocal mutations at position 348 of human 
and rat P2X7 receptors have little detectable effect on receptor sub-cellular 
distribution (Figure 6.3). Furthermore, these mutations had little effect on the 
total and surface expression of the protein (Figure 6.4). Therefore, the changes 
in agonist-induced maximal current amplitudes conferred by these mutations 
(chapters 3 and 4) cannot be attributed to changes in surface expression of the 
protein. According to the model of the human P2X7 receptor (Figure 3.1), 
residue 348 is located in TM2, and on the intracellular side of the ion channel 
gate. Considering this location, the next logical step would be to assess the 
single channel properties these mutants. 
In this study, the P2X7 receptor had a lower molecular weight (-58 kOa) 
than reported in the literature (-70-78 kOa) (Collo et a/., 1997; Sim et a/., 2004; 
Young et a/., 2007). An inaccuracy in the protein marker used in this study may 
be a possible reason for the discrepancy. The P2X7 receptor is glycosylated 
(Young et a/., 2007; Lenertz et a/., 2010), and the two protein bands detected 
for the rat P2X7 receptor may reflect two different glycosylation states of the 
receptor (Figure 6.2). 
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In conclusion, the results in this chapter support a significant role of 
residue at position 155 in determining the surface expression of the P2X7 
receptor, particularly human and rat P2X7 receptors, and show that residue at 
position 348 have no or little effect on surface expression. 
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Chapter 7 
Functional characterisation of the monkey P2X7 
receptor 
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7.1 Introduction 
P2X7 receptors are an attractive therapeutic target due to their role in 
release of the pro-inflammatory cytokine IL-1 (3, and their critical involvement in 
for example, inflammatory, neuropathic pain and rheumatoid arthritis (Chessell 
et al., 2005; Ferrari et al., 1997a; Labasi et al., 2002; Solie et aI., 2001). 
Pharmaceutical industries are therefore making huge efforts to develop novel, 
highly potent and selective P2X7 receptor antagonists (Donnelly-Roberts and 
Jarvis, 2007; Gunosewoyo and Kassiou, 2010). However, a number of 
compounds, including KN-62 and AZ11645373, show species specificity in 
inhibition of P2X7 receptor responses (see sections 1.6.5 and 1.6.10) (Donnelly-
Roberts et al., 2009; Humphreys et al., 1998; Stokes et al., 2006). These 
species differences are useful in identifying the regions of the receptor that are 
important in P2X7 receptor sensitivity to antagonists. More precisely, mutation of 
residue 95 of the human P2X7 reduces sensitivity of the human P2X7 receptor 
to KN-62 (Michel et al., 2008). Furthermore, there are species differences in the 
potency and maximal responses to agonists (chapter 4 and section 1.6.10). 
However, the species-specificity of P2X7 ligands is problematic as it hinders the 
development of compounds to treat human diseases based on rodent P2X7 
receptors or rodent disease models. 
The human, rat, mouse, guinea pig and dog P2X7 receptors have 
previously been cloned and their pharmacological properties characterised 
(Chessell et al., 1998; Fonfria et al., 2008; Rassendren et al., 1997; Roman et 
al., 2009; Surprenant et al., 1996). Of these species, the human P2X7 receptor 
shares the highest sequence homology of 85% to the dog P2X7 receptor 
(Roman et al., 2009). It is expected that primate P2X7 receptors will share even 
higher sequence homology with the human P2X7 receptor. 
In this study, the monkey P2X7 receptor has been characterised in terms 
of its sensitivity to agonists (ATP and BzA TP) and antagonists (KN-62, 
AZ11645373 and A-438079). Comparisons between human and monkey 
responses have been made to determine whether their pharmacological profiles 
are similar between these species. 
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7.2 Results 
7.2.1 Sequence similarity between monkey and other P2X7 receptors 
The monkey P2X7 receptor is predicted to comprise of 595 amino acid 
residues. Figure 7.1 shows the sequence of the monkey P2X7 receptor aligned 
with those of mammalian P2X7 receptors that have previously been cloned 
(Chessell et a/., 1998; Fonfria et a/., 2008; Rassendren et a/., 1997, Roman et 
a/., 2009; Surprenant et a/., 1996). The monkey P2X7 receptor shows the 
highest sequence similarity to the human P2X7 receptor (96%; Table 7.1). 
Indeed, only 19 amino acids are different between these two species, five of 
which are in the extracellular domain where the agonist or antagonist binds 
(Figure 7.1). Chapters 4, 5 and 6 have investigated the contribution of residues 
at positions 155 and 348 to the species differences in the functional expression 
of human and rat P2X7 receptors. Like the rat P2X7 receptor, the monkey P2X7 
receptor has a tyrosine at 155 (Tyr155) and a threonine at position 348 (Thr348). 
The following experiments were designed to determine the pharmacological 
properties of the monkey P2X7 receptor, and comparisons were also made to 
the properties of the human P2X7 receptor. 
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Figure 7.1 Amino acid sequence alignment of monkey, human, rat, mouse, 
guinea pig and dog P2X7 receptors 
Conserved cysteines are in grey, residues that differ between human and 
monkey are highlighted pink, and residues 155 and 348 are in green. TM1 and 
TM2 are indicated. The accession numbers for human, rat, mouse, guinea pig 
(gp) and dog are Y09561, X95882, AJ009823, EU275201 and EU334661, 
respectively. Aligned using ClustalW. 
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Table 7.1 Amino acid similarity between P2X7 receptors 
Monkey Human Dog Rat Mouse Guinea pig 
Monkey 100 96 85 80 80 78 
Human 100 85 80 80 77 
Dog 100 76 76 73 
Rat 100 84 74 
Mouse 100 75 
Guinea pig 100 
Amino acid similarity (%) was determined uSing ClustalW. 
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7.2.2 Agonist-induced monkey P2X7 receptor mediated currents 
Firstly, cONA encoding the monkey P2X7 receptor was transfected into 
HEK293 cells, and agonist-evoked whole-cell currents were recorded in low 
divalent extracellular solution at -60 mV. Figure 7.2A shows representative 
inward currents induced by ATP and BzATP. Both ATP and BzATP activated 
the receptor dose-dependently. The receptor showed moderately fast activation 
and deactivation kinetics and little desensitisation during the 4 s agonist 
application. Dose-response analysis revealed that the ECso for ATP was 802 ± 
87 f-lM (n = 11), and for BzA TP was 58 ± 4.2 f-lM (n = 6). BzA TP was a 
significantly more potent agonist than ATP (pECso 4.24 ±0.03, n = 6 for BzATP, 
and 3.12 ± 0.04, n = 11 for ATP; p < 0.001; Figure 7.20). The Hill coefficient 
was higher when BzATP was used as the agonist (1.23 ± 0.06, n = 11 for ATP, 
and 1.91 ± 0.08, n = 6 for BzATP; p<0.001; Figure 7.2E). The maximal 
amplitudes of currents evoked by ATP and BzA TP were not significantly 
different (160 ± 22 pA/pF, n = 11 for ATP, and 220 ± 27 pA/pF, n = 4 for BzATP; 
p>0.05; Figure 7.2C). 
The sensitivity of the monkey P2X7 receptor to agonists was compared to 
that of the human P2X7 receptor (Figures 7.3 and 7.4). The human P2X7 
receptor ECso for ATP was 314 ± 24 f-lM, and the monkey P2X7 receptor was 
significantly less sensitive to ATP than the human P2X7 receptor (pECso 3.52 ± 
0.04, n = 12 for human, and 3.12 ± 0.04, n = 11 for monkey; p<0.001; Figure 
7.3C). The Hill coefficient was smaller for the monkey P2X7 than the human 
P2X7 receptor (1.92 ± 0.06, n = 12 for human; p<0.001; Figure 7.30). ATP-
induced maximal current amplitudes were larger for the human than the monkey 
P2X7 receptor (330 ± 22 pA/pF, n = 12 for human, and 160 ± 22 pA/pF, n = 11 
for monkey; p<0.001). 
The ECso for BzATP was 30 ± 2.0 f-lM (n = 5) for human P2X7 receptor, 
and the monkey P2X7 receptor was slightly, yet significantly, less sensitive to 
BzATP than the human P2X7 receptor (pECso 4.52 ± 0.03, n = 5 for human, and 
4.24 ± 0.03, n = 6 for monkey; p<0.001; Figure 7.4C). There was no difference 
in the Hill coefficients (2.19 ± 0.16, n = 5 for the human P2X7; p>0.05; Figure 
7.40). BzATP-induced maximal current amplitudes were not significantly 
different (310 ± 36 pA/pF, n = 5 for human, and 220 ± 27 pA/pF, n = 4 for 
monkey; p>0.05). 
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Figure 7.2 Agonist-evoked currents mediated by the monkey P2X7 
receptor 
(A) Representative ATP- (left) and BzA TP- (right) evoked currents recorded 
from a HEK293 cell expressing monkey P2X7 receptors at -60 mV. (B) Mean 
dose-response curves summarising data from experiments shown in A: ATP 
(squares) or BzATP (circles). Smooth lines show the best fits to the Hill 
equation. (C-E) Mean maximal current amplitudes (IMAX), pEC50 and Hill 
coefficients. The number of cells recorded is indicated. *** p<0.001, compared 
to ATP. 
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Figure 7.3 AlP-evoked monkey and human P2X7 receptor mediated 
currents 
(A) Representative AlP-evoked currents recorded from a HEK293 cell 
expressing human (left) or monkey (right) P2X7 receptors at -60 mV. (8) Mean 
AlP dose-response curves summarising the data from experiments shown in A: 
human (squares) or monkey (diamonds). Smooth lines show the best fits to the 
Hill equation. (C-D) Mean pECso and Hill coefficients. The number of cells 
recorded is indicated. *** p<0.001, compared to human P2X7. 
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Figure 7.4 BzATP-evoked monkey and human P2X7 receptor mediated 
currents 
(A) Representative BzA TP-evoked currents recorded from a HEK293 cell 
expressing human (left) or monkey (right) P2X7 receptors at -60 mV. (B) Mean 
BzA TP dose-response curves summarising the data from experiments shown in 
A: human (squares) or monkey (diamonds). Smooth lines show the best fits to 
the Hill equation. (C-D) Mean pECso and Hill coefficients. The number of cells 
recorded is indicated. *** p<0.001, compared to human P2X7. 
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7.2.3 Inhibition of A TP-induced monkey P2X7 receptor mediated currents 
byKN-62 
The monkey P2X7 receptor was also characterised in terms of its 
sensitivity to P2X7 antagonists. KN-62 is a potent antagonist at human P2X7 
receptors (Humphreys et al., 1998). KN-62 dose-dependently inhibited monkey 
P2X7 receptor mediated currents and was largely irreversible following a 20 min 
washout (Figure 7.5A). However, the inhibition was noticeably incomplete; 16.8 
± 6.6% (n = 3) of ATP-induced current remained in the presence of the highest 
concentration of KN-62 used (3 JlM). The data can be fit to the Hill equation 
using two parameters (see section 2.3.5), yielding an IC50 value of 86 ± 19 nM 
(n = 3; Figure 7.58, grey line). However, because the inhibition is incomplete, it 
is more appropriate to fit using three parameters, resulting in an IC50 value of 54 
± 8.3 nM (n = 3; Figure 7.58). However, there is no significant difference 
between the plC50 values calculated using two or three parameters (p>0.05; 
Figure 7.5C). 
Under the same experimental conditions, KN-62 was a potent antagonist 
of human P2X7 receptor, with an IC50 value of 127 ± 38 nM (n = 3). The 
sensitivity to KN-62 is not significantly different between the monkey and human 
P2X7 receptors (plC5o 6.93 ± 0.12, n = 3 for human, and 7.28 ± 0.07, n = 3 for 
monkey; p>0.05; Figure 7.5C). There was no significant difference in the Hill 
coefficient between monkey and human P2X7 receptors (p>0.05; Figure 7.50). 
To determine the nature of antagonism, monkey P2X7 mediated ATP 
dose-current responses were recorded before and after a 4 min application of 
KN-62 (100 nM; Figure 7.6). The maximal current amplitude was significantly 
reduced (81 ± 1.2%; 192 ± 58 pA/pF for control, and 32 ± 7 pA/pF in the 
presence of KN-62, n = 3; p<0.05). The EC50 values were 0.68 ± 0.13 mM for 
control, and 0.46 ± 0.16 mM in the presence of KN-62 (n = 3). The sensitivity to 
ATP was not changed (pEC50 3.18 ± 0.08 for control, and 0.40 ± 0.16 in the 
presence of KN-62, n = 3; p>0.05; Figure 7.6E). There was no significant 
difference in the Hill coefficients in the presence and absence of KN-62 (1.14 ± 
0.02 for control, and 1.33 ± 0.22 in the presence of KN-62, n = 3; p>0.05; Figure 
7.6F). These data point to KN-62 acting as a non-competitive antagonist at the 
monkey P2X7 receptor. 
The maximal current amplitude for the human P2X7 receptor was also 
significantly reduced by the presence of KN-62 (344 ± 44 pA/pF for control, and 
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119 ± 18 pA/pF in the presence of KN-62, n = 6; p<0.001). However, the 
magnitude of inhibition was slightly less than for monkey P2X7 receptors (65 ± 
2.8%, n = 6; p<0.01; Figure 7.60). The ECso values were 0.28 ± 0.03 mM for 
control, and 0.25 ± 0.04 mM in the presence of KN-62 (n = 6). The sensitivity of 
the human P2X7 receptors to ATP was unaffected by the presence of KN-62 
(pECso 3.56 ± 0.06 for control, and 3.63 ± 0.06 in the presence of KN-62, n = 6; 
p>0.05; Figure 7.6E). The Hill coefficient was slightly reduced in the presence of 
KN-62 (1.83 ± 0.10 for control, and 1.43 ± 0.18 in the presence of KN-62, n = 6; 
p<0.05; Figure 7.6F). 
149 
A Human P2X7 \NT 
e a a g [KN-62] (nM)"E ~ g ~ g ~ 
o ~()-----1 mM~ - - - - - -
a 
a .£: 
a (/) 
.: ~ 
--
Monkey P2X7 \NT ~ a a g g § § .£: 
C ...- ('I') ...- ('I') ...- ('I') ~ 
8 -----III!U:5: 
-----.- --ATP 
B 
lrUlru~ UVUu---~ 
100 pA/pF L 120 .-~ 
........-
..... 100 c 
4s 
Q) 
.... 80 .... 
::J 
0 60 
"'0 
Q) 
.~ 40 
ro 
E 20 
.... 
a 
Z 0 
10 100 1000 10000 
[KN-62] (nM) 
C 8- 2.5 
r-=- .............- ,......-.-
2 6- 3 3 3 3 
0 1.5 3 It) I 0 4- c 
a. 1 3 
2- 0.5 
0 0 
.-
.- .-
.-
.- .-
0- 0- 0- 0- 0- 0-
N N (of) N N (of) 
........-
........- ........-
........-
........- ........-
c >. >. c >. >. 
ell Q) Q) ell Q) Q) 
E ~ ~ E ~ ~ c c c C 
::J a a ::J a a 
I ~ ~ I ~ ~ 
Figure 7.5 Inhibition of ATP-evoked monkey P2X7 receptor currents by KN-
62 
(A) Representative ATP-evoked currents (1 mM ATP for human, 3 mM for 
monkey) recorded from a HEK293 cell expressing human (left) or monkey 
(right) P2X7 receptors in the absence and presence of KN-62 at indicated 
concentrations at -60 mV (wash 20 min). (B) Mean KN-62 inhibition curve 
summarising the data from experiments in A: human (squares) and monkey 
(diamonds). Black smooth lines show the best fits to the Hill equation using 2 
parameters (2P), and grey using 3 parameters (3P; for monkey P2X7). (C-D) 
Mean plC50 values and Hill coefficients from the data shown in B. The number 
of cells recorded is indicated. There are no differences among the three groups. 
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Figure 7.6 ATP-evoked human and monkey P2X7 receptor mediated 
currents before and after of KN-62 treatment 
(A) Representative ATP-evoked currents recorded from a HEK293 cell 
expressing human or monkey P2X7 receptors before (left) and after (right) a 4 
min application of 100 nM KN-62 at -60 mV. (8 and C) Mean ATP dose-
response curves summarising the data from experiments shown in A. Smooth 
lines show the best fits to the Hill equation. (D-F) Mean % inhibition, pEC50 and 
Hill coefficients. The number of cells recorded is indicated. In 0: ** p<0.01, 
compared to human P2X7. In E and F: * p<0.05 between control and presence 
of KN-62. 
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7.2.4 Inhibition of A TP-induced monkey P2X7 receptor mediated currents 
by AZ11645373 
Figure 7.7 shows that AZ11645373 was a potent antagonist inhibiting 
dose-dependently the ATP-induced currents (3 mM) in cells expressing monkey 
P2X7 receptors (IGso 23 ± 3.0 nM, n = 3). The compound also inhibited human 
P2X7 receptor mediated currents with an equal potency to monkey P2X7 
currents (ICso 31 ± 2.6 nM, n = 3) (plCso 7.52 ± 0.04, n = 3 for human, and 7.64 
± 0.06, n = 3 for monkey; p>0.05; Figure 7.7C). Inhibition was partly reversible 
following washout (Figure 7.7A). 
To examine the mechanism of inhibition, the effect of AZ11645373 on 
ATP dose-response curves was determined (Figure 7.8). AZ11645373 (30 nM) 
dramatically reduced the maximal currents for monkey P2X7 receptor (74 ± 
8.1 %; 214 ± 9 pAlpF for control, and 56 ± 19 pAlpF in the presence of 
AZ11645373, n = 3; p<0.01). The ECso values were 0.70 ± 0.11 mM for control, 
and 1.67 ± 1.3 mM in the presence of AZ11645373 (n = 3). There was no effect 
on the receptor sensitivity to ATP (pECso 3.18 ± 0.08 for control, and 3.40 ± 
0.16 in the presence of AZ11645373, n = 3; p>0.05; Figure 7.8E). The Hill 
coefficient was also unaffected (Figure 7.8F). AZ11645373 reduced the ATP-
induced maximal current amplitude for human P2X7 receptor (57 ± 12%; 329 ± 
32 pA/pF for control, and 148 ± 52 pA/pF in the presence of AZ11645373, n = 3; 
p<0.01). The ECso values for the human receptor were 0.29 ± 0.05 mM for 
control, and 0.36 ± 0.09 mM in the presence of AZ11645373 (n = 3). Moreover, 
the sensitivity of the human P2X7 receptor to ATP was not changed by the 
presence of AZ11645373 (pECso 3.56 ± 0.06 for control, and 3.63 ± 0.06 in the 
presence of AZ11645373, n = 3; p>0.05; Figure 7.8E). The extent of inhibition 
of ATP-evoked maximal current amplitude by AZ11645373 was not significantly 
different between cells expressing human and monkey P2X7 receptors (p>0.05; 
Figure 7.80). 
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Figure 7.7 Inhibition of ATP-evoked monkey P2X7 receptor currents by 
AZ11645373 
(A) Representative ATP-evoked currents (1 mM ATP for human, 3 mM for 
monkey) recorded from a HEK293 cell expressing human (left) or monkey 
(right) P2X7 receptors in the absence and presence of AZ11645373 at -60 mV 
(wash 15 min). (8) Mean AZ11645373 inhibition curve summarising the data 
from experiments shown in A: human (squares) and monkey (diamonds). 
Smooth lines show the best fits to the Hill equation. (C and D) Mean plCso and 
Hill coefficients. The number of cells recorded is indicated. No significant 
differences, compared to human P2X7. 
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Figure 7.8 AlP-evoked human and monkey P2X7 receptor mediated 
currents before and after of AZ11645373 treatment 
(A) Representative ATP-evoked currents recorded from a HEK293 cell 
expressing human (top) or monkey (bottom) P2X7 receptors at -60 mV before 
(control, left) and after (right) 4 min application of 30 nM AZ11645373 (AZ). (8 
and C) AZ11645373 inhibition curves summarising the data from experiments 
shown in A. Smooth lines show the best fits to the Hill equation. (D-F) Mean % 
inhibition, pEC50 and Hill coefficients. The number of cells recorded is indicated. 
In 0: no difference, compared to human P2X7. In E and F: no differences 
between control and presence of AZ11645373. 
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7.2.5 Inhibition of A TP-induced monkey P2X7 receptor mediated currents 
by A-438079 
A-438079 is reported as an antagonist at both human and rat P2X7 
receptors responses (McGaraughty et al., 2007; Nelson et al., 2006). The 
compound dose-dependently and completely inhibited ATP-evoked monkey 
P2X7 receptor mediated currents (Figure 7.9). The monkey P2X7 receptor was 
highly sensitive to A-438079 (IC5o 297 ± 24 nM, n = 6), and was equally potent 
at human P2X7 receptors (IC5o 493 ± 94 nM, n = 6) (plC5o 6.35 ± 0.09, n = 6 for 
human, and 6.53 ± 0.03, n = 6 for monkey; p>0.05; Figure 7.9C). 
7.2.6 Total and surface expression of the monkey P2X7 receptor 
Monkey and human P2X7 receptors contained a C-terminal EE tag. 
Therefore, biotin labelling and Western blotting were performed using an anti-
EE antibody to assess total and surface expression of the monkey P2X7 
receptor. The expression of the human P2X7 receptor was assessed for 
comparison. P2X7 receptors were co-expressed with eGFP, used as an internal 
control for possible variations in cell preparation, transfection efficiency, and 
sample handling. Figure 7.10 shows representative results. There was 
significant surface and protein expression of the monkey P2X7 receptor, and no 
obvious difference in the levels of expression between monkey and human 
P2X7 receptors. 
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Figure 7.9 Inhibition of ATP-evoked monkey P2X7 receptor currents by A-
438079 
(A) Representative ATP-evoked currents recorded from a HEK293 cell 
expressing human (left) or monkey (right) P2X7 receptors in the absence and 
presence of A-438079 at -60 mV. (8) Mean A-438079 inhibition curve 
summarising the data from experiments shown in A: human (squares) and 
monkey (diamonds). Smooth lines show the best fits to the Hill equation. (C and 
D) Mean plCso and Hill coefficient. The number of cells recorded is indicated. 
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Figure 7.10 Total and surface expression of monkey P2X7 receptors 
Representative Western blots showing biotin labelled (surface) and whole-cell 
lysate (total) protein of the human or monkey P2X7 receptors. Total protein 
expression of GFP is also shown. Numbers on the left in each panel indicate 
the protein markers (kDa). Similar results were observed in two independent 
experiments. 
160 
7.3 Discussion 
This study found that both ATP and BzA TP dose-dependently activate 
the monkey P2X7 receptor (Figure 7.2). Furthermore, the receptor hac! a 14-fold 
higher sensitivity for BzATP over ATP. This was a significant finding because 
the higher potency of BzA TP compared to ATP is a useful tool for distinguishing 
P2X7 receptor mediated responses (Anderson and Nedergaard, 2006; North, 
2002). The sensitivity of the monkey P2X7 receptor to ATP and BzATP was 
slightly, yet significantly lower in comparison to human P2X7 receptors (2.5- and 
2'-fold, respectively; Figures 7.3 and 7.4). 
Human, rat, mouse, guinea pig and dog P2X7 receptors have previously 
been characterised (Chessell et al., 1998; Fonfria et al., 2008; Rassendren et 
al., 1997; Roman et al., 2009; Surprenant et al., 1996). The results from this 
study allow addition of the monkey P2X7 receptor to this list of mammalian ATP-
and BzA TP-sensitive P2X7 receptors (although the guinea-pig orthologues is 
relatively insensitive to BzATP) (Chessell et al., 1998; Fonfria et al., 2008; 
Rassendren et al., 1997; Roman et al., 2009; Surprenant et al., 1996). 
The present study has also provided insight into the antagonist 
pharmacology of the monkey P2X7 receptor by investigating the sensitivity to 
KN-62, AZ11645373, and A-438079. It has been shown that KN-62 is a potent, 
nanomolar range inhibitor of ATP-induced currents mediated by monkey P2X7 
receptors, although the inhibition is incomplete (Figure 7.5). KN-62 inhibition of 
monkey P2X7 receptor currents appeared to be non-competitive, evidenced by 
the insurmountable nature and lack of effect on the pECso for ATP (Figure 7.6). 
KN-62 was also shown to inhibit ATP-evoked currents mediated by the human 
P2X7 receptor in the same concentration range, as previously reported 
(Humphreys et al., 1998). The sensitivity of human and monkey P2X7 receptors 
to KN-62 was virtually identical. Therefore, of the mammalian P2X7 receptors 
functionally characterised, the rat P2X7 receptor exhibits the lowest sensitivity to 
KN-62 (Donnelly-Roberts et al., 2009; Hibell et al., 2001; Humphreys et al., 
1998; Michel et al., 2008; Roman et al., 2009). 
This work has also shown that AZ11645373 is a potent inhibitor of ATP-
evoked monkey P2X7 receptor currents in the high nanomolar range (Figure 
7.7). The insurmountable nature of the inhibition and lack of effect on sensitivity 
to ATP indicates AZ11645373 is a non-competitive antagonist at the monkey 
P2X7 receptor (Figure 7.8). The sensitivities of monkey and human P2X7 
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receptors to AZ11645373 were identical. This is in agreement with a previous 
study, which found ATP- and BzA TP-induced human P2X7 receptor currents 
were potently inhibited by the compound (Stokes et al., 2006). Furthermore 
AZ11645373 also acted as non-competitive antagonist at human P2X7 
receptors, in agreement with a previous studies showing non-surmountable 
inhibition of ATP-induced ionic currents, or ATP-induced Et+ uptake mediated 
by the human P2X7 receptor (Michel et al., 2009; Stokes et al., 2006). A 
previous study found AZ11645373 was an antagonist at dog P2X7 receptors 
with a similar potency to the human receptor (Michel et al., 2009). Moreover, the 
compound was an antagonist at mouse and guinea pig P2X7 receptors, 
although with a lower potency. However, AZ11645373 a relatively low potency 
at rat P2X7 receptors, with only 50% inhibition of BzA TP-induced currents at 10 
IJM (Michel et al., 2009; Stokes et al., 2006). 
In this study, A-438079 was a potent inhibitor of monkey P2X7 receptor 
mediated currents (Figure 7.9). Furthermore, the monkey and human P2X7 
receptors were equally sensitive to inhibition by the compound. Unlike KN-62 
and AZ11645373, A-438079 is an inhibitor of both the human and rat P2X7 
receptors (McGaraughty et al., 2007; Nelson et al., 2006). 
Chapter 4 showed that the rat P2X7 receptor has higher ATP-evoked 
maximal current amplitudes that the human receptor. It was shown that 
mutations H155Y and A348T (which change the amino acids to the 
corresponding one in the rat WT receptor) of the human P2X7 receptor 
increased, whilst reciprocal mutations Y155H and T348A decreased agonist-
evoked maximal current amplitudes. The WT monkey P2X7 receptor, like the rat 
receptor, has tyrosine at position 155 (Tyr155), and threonine at position 348 
(Thr348). Therefore, the finding that the ATP-induced maximal current 
amplitudes of the monkey P2X7 receptor were significantly lower than the 
human was rather unexpected. The conclusion from chapter 6 was that the 
effect of H 155Y and Y155H on maximal current amplitudes was at least in part 
due to changes in surface expression of the protein, and that changes in total 
protein expression contribute to this. However, the biotin labelling experiments 
shown in this chapter (Figure 7.10) found that the surface and total protein 
expression of human and monkey P2X7 receptors were similar. Experiments to 
determine whether the residues at positions 155 and 348 are important in 
162 
determining the functional expression of the monkey P2X7 receptor are 
required. 
In conclusion, in terms of sensitivity to KN-62, AZ11645373 and A-
. 438079, monkey P2X7 receptors are virtually indistinguishable from human 
P2X7 receptors. Sequence comparison showed that only 19 amino acids (5 in 
the extracellular domain) are different between the species orthologues (Figure 
7.1). The results from this study therefore indicate that these 19 residues are 
not important for the antagonistic properties of these compounds at human and 
monkey P2X7 receptors. The next step is to compare the antagonist profiles of 
monkey and dog P2X7 receptors. By these systematic comparisons of 
antagonist profiles at different species orthologues, microdomains and residues 
that are important for antagonist binding could be identified. Furthermore, non-
human primates have closer physiological, neurological and genetic similarities 
with humans than rodents, and therefore research is currently underway to 
develop transgenic non-human primate models for human diseases (Sasaki et 
a/., 2009; Yang et a/., 2008). The substantial similarities in the receptor 
pharmacology between monkey and human P2X7 receptors shown in this study 
indicate the monkey could provide a good model for investigations into the roles 
of the P2X7 receptors in human diseases. 
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Chapter 8 
General discussion and conclusions 
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8.1 General discussion and conclusions 
This study has provided information to improve the understanding of the 
mechanisms underlying the functional expression of P2X7 receptors. WT or 
mutant P2X7 receptors were expressed in HEK293 cells and the mutational 
effects were studied by whole-cell patch-clamp recording of agonist-evoked 
currents (results summarised in tables 8.1 and 8.2), and by assessing surface 
expression using immunostaining and biotin labelling. In this chapter, the main 
findings are summarised and discussed. 
There are numerous ns-SNP mutations of the human P2X7 receptor 
(Barden et aI., 2006; Lucae et aI, 2006; Wiley et al., 2002). Two of these ns-
SNP mutations, H155Y and A348T, are of particular interest because they 
confer· gain-of-function in terms of agonist-induced currents (Roger et al., 
2010a; Stokes et aI., 2010), Ca2+ influx (Cabrini et aI., 2005) and dye uptake 
(Roger et al., 2010a; Stokes et aI., 2010), and were therefore further 
investigated in this thesis. These mutations increased the functional expression 
of the human P2X7 receptor, as evidenced by greater ATP- and BzA TP-evoked 
current amplitudes with no or small change in the agonist sensitivity (chapter 3). 
His 155 and Ala348 in the human P2X7 receptor were mutated to residues with 
different side chain properties. None of the residues introduced at His 155 
mimicked the gain-of-function effect of H155Y, however, in the cases of H155L 
and H155D, the ATP-evoked current amplitudes were reduced. Mutating Ala348 
to bulky residues (A348M and A348F) decreased, whilst mutating to a small 
residue (A348G), increased the amplitude of ATP-evoked currents. Therefore, 
these results taken together with previous findings indicate that residues at 155 
and 348 are important molecular determinants of functional expression of the 
human P2X7 receptor. 
These mutations were also of interest because they change the residues 
in the human P2X7 receptor to the corresponding residues of the rat receptor. 
The results in chapter 4 have shown that ATP-evoked currents mediated by the 
rat P2X7 receptor are larger than those by human P2X7 receptors. Reciprocal 
mutations, Y155H and T348A, were introduced in the rat P2X7 receptor and 
both mutations reduced the amplitude of ATP-evoked currents. The reciprocal 
mutations at 155 and 348 of human and rat P2X7 receptors had opposite effects 
on BzA TP-induced currents, as observed for ATP-induced currents. These 
results provide consistent evidence to show that residues at 155 and 348 are 
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important in determining the functional expression of human and rat P2X7 
receptors. In addition, the results suggest that the distinct residues at these two 
positions contribute to the difference in ATP-induced currents mediated by 
human and rat P2X7 receptors. 
It was shown in chapter 7 that the monkey P2X7 receptor has smaller 
ATP-induced maximal current amplitudes than the human receptor. This was a 
surprising finding because the monkey P2X7 receptor, like the rat P2X7 
receptor, has a tyrosine at position 155 (Tyr155), and a threonine at position 348 
(Thr348). Further experiments are required to determine whether the particular 
residues at 155 and 348 are important in determining the functional expression 
of the monkey P2X7 receptor. 
The non-conserved residues in the microdomains surrounding positions 
His 155 and Ala348 of the human P2X7 receptor were investigated by mutating to 
the corresponding residues of the rat P2X7 receptor (chapter 5). Four mutations, 
V1531, G157Q, Q159R and D356N reduced, whereas F353L increased, ATP-
induced currents, indicating the importance of these residues in human P2X7 
receptor functional expression. The reciprocal mutation L353F was introduced 
into the rat P2X7 receptor, however, the mutations conferred no significant 
effect on ATP-evoked currents. Therefore the residues 155 and 348 are unique 
in these microdomains in that the particular residues at these positions are 
important in determining the species differences between human and rat P2X7 
receptors. 
There are three major mechanisms underlying changes in functional 
expression of an ion channel or agonist-induced currents. These are alterations 
to the single channel properties (open probability and conductance), and the 
number of functional receptors on the cell surface. A major advancement in the 
P2X receptor field was the determination of the zebrafish P2X4 receptor crystal 
structure (Kawate et al., 2009), which has greatly increased our understanding 
of the mechanisms underlying mutational effects on the receptor functions 
(Browne et al., 2010, Evans, 2010; Young, 2010). A model of the human P2X7 
receptor, based on the zebrafish P2X4 structure, indicates that His 155 is located 
in the head region of the dolphin-like structure, and distant from the ion 
permeating pathway (Figure 3.1) (Kawate et al., 2009; Roger et al., 2010a), 
suggesting that this residue is unlikely to be critical in determining the single 
channel conductance. His 155 is also away from the proposed agonist-binding 
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site. Consistent with such predictions, mutation of residue at 155 had little or 
minor effect on the sensitivity of both human and rat P2X7 receptor to agonists 
(chapters 3 to 5). Furthermore, the human WT and H155Y mutant receptors are 
equally sensitive to KN-62, a potent human P2X7 receptor antagonist 
(Humphreys et al., 1998). These observations, taken together, strongly suggest 
mutations of residues at position 155 of P2X7 receptors have little effect on the 
receptor conformation and channel gating properties. On the other hand, 
immunostaining and biotin labelling studies, shown in chapter 6, clearly 
demonstrated that H155Y mutation increased the expression level of human 
P2X7 receptor at the cell surface, whilst reciprocal mutation Y155H decreased 
the membrane expression of rat receptor. The changes in surface expression 
appear to result from disrupted trafficking to the membrane as revealed by 
immunostaining, and altered total protein expression, as shown in Western 
blotting analysis. Furthermore, in comparison to WT, H155L mutation, which 
reduced ATP-evoked current amplitudes of the human P2X7 receptor, had a 
reduced protein and surface expression. Therefore, the alterations in surface 
expression conferred by mutations at position 155 play a major role in 
determining the functional expression of P2X7 receptors or the agonist-evoked 
currents. Further experiments are required to elucidate whether the effects of 
such mutations change protein folding and degradation. Additionally, it would be 
interesting to examine whether the mutations also affect the mechanisms of 
forward trafficking and endocytic retrieval. 
The human P2X7 receptor model predicts that Ala348 is located in the 
TM2 region, on the intracellular side of the ion channel gate (Figure 3.1) 
(Kawate et al., 2009; Roger et al., 2010a). TM2 forms the ion-permeating 
pathway, and residues on the intracellular side of the gate are proposed to, 
undergo substantial movement during gating (Browne et al., 2010; Kawate et 
al., 2009). This concept is consistent with the observations described in this 
thesis (chapter 3) that the effects of mutating Ala348 in human P2X7 receptors on 
ATP-evoked current amplitude were strongly dependent on the side chain size 
of the introduced residues. Immunostaining and biotin labelling showed that 
mutation A348T in the human P2X7 receptor and reciprocal mutation T348A in 
rat P2X7 receptor had little effect on the receptor surface expression (chapter 
6). Taken together, these results suggest that residue 348 has an important role 
in defining the channel open probability and/or single channel conductance of 
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the P2X7 receptor ion channel, and thereby ATP-induced currents. Single 
channel recording analysis of the WT and mutant receptors should provide 
direct evidence to confirm or refute such an interpretation. 
The monkey P2X7 receptor has been characterised of its 
pharmacological properties (chapter 7). ATP and BzATP activated the monkey 
P2X7 receptor in a dose-dependent manner. Like human, rat, mouse and dog 
P2X7 receptors, the monkey P2X7 receptor is more sensitive to BzA TP than 
ATP (Chessell et al., 1998; Rassendren et al., 1997; Roman et al., 2009; 
Surprenant et al., 1996). The monkey P2X7 receptor was slightly, yet 
significantly less sensitive to ATP and BzA TP than the human P2X7 receptor, 
compared under the same experimental conditions. The sensitivity to P2X7 
receptor antagonists KN-62 (Humphreys et al., 1998), AZ11645373 (Stokes et 
al., 2006) and A-438079 (McGaraughty et al., 2007; Nelson et al., 2006) was 
also investigated. All three were potent antagonists at monkey P2X7 receptors 
with ICsc values in the nanomolar range, and, in the case of AZ11645373 and 
A-438079, the inhibition was complete. Furthermore, the sensitivity of the 
monkey P2X7 receptor to these compounds was not different from that of the 
human P2X7 receptor. This receptor orthologue shares 96% amino acid 
sequence identity with the human P2X7 receptors. There are 5 residues in the 
extracellular domain that are different between monkey and human P2X7 
receptors. Based on the results presented in this thesis, it can be concluded 
that these residues are not critically engaged in interacting with KN-62, 
AZ11645373 and A-438079. Additionally, the similar pharmacological profile of 
monkey and human P2X7 receptors suggests that the monkey provides a good 
model for future studies of P2X7 receptor involvement in human diseases. Non-
human primates have closer physiological, neurological and genetic similarities 
with humans than rodents, and therefore research is currently underway to 
develop generate transgenic non-human primate models for human diseases 
(Sasaki et al., 2009; Yang et al., 2008). 
In conclusion, the results presented in this thesis provide consistent and 
convincing evidence to suggest that residues at position 155 and 348 are 
important in determining the functional expression of human and rat P2X7 
receptors. Furthermore, the results suggest differential mechanisms underlie 
the contribution of these two residues; residue 155 is involved in determining 
surface expression of the P2X7 receptor proteins, and residue 348 in single 
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channel properties of the P2X7 receptors. The study has functionally 
characterised the pharmacological properties of the monkey P2X7 receptor. 
Such information is useful in further studies to decipher the molecular basis 
underlying species-dependent properties. Comparisons made to human P2X7 
receptors have revealed similar agonist and antagonist properties between 
monkey and human P2X7 receptors, suggesting that the monkey may provide a 
suitable model for the study of roles for P2X7 receptors in human diseases. 
8.2 Summary of future directions for the project 
This work has increased our understanding of the expression and 
functional properties of human, rat and monkey P2X7 receptors. However, there 
are a number of experiments that could be performed to enhance the 
conclusions that can be drawn, and these are summarised below. 
In chapter 3 is was shown that the effects of mutating Ala348 of the 
human P2X7 receptor on maximal current amplitude was dependent on the side 
chain size of the introduced residue, with larger side chains reducing and 
smaller side chains increasing maximal current amplitudes. According to the 
human P2X7 receptor model (Figure 3.1), Ala348 is located in the TM2 domain of 
the receptor (Kawate et al., 2009; Roger et al., 2010a), and it was therefore 
hypothesised that mutation of Ala348 may affect the single channel properties of 
the human P2X7 receptor. Single channel recording to assess the affect of 
mutation of Ala348 on single channel conductance and/or channel open 
probability of the human P2X7 receptor would determine if this is indeed the 
case. 
In chapter 6, it was shown using biotin labelling that the H155Y mutation 
of the human P2X7 receptor increased, whilst the reciprocal mutation Y155H of 
the rat receptor decreased surface expression, and this appeared to be largely 
due to the changes in total protein expression. It would be useful to determine 
the mechanism by which mutation of residue 155 affects the total protein 
expression of the P2X7 receptor. One possible mechanism is that the mutations 
affect the protein assembly in the ER. This could be tested by the use on BN-
PAGE to determine whether the ratio of monomers: dimers: trimers is affected 
by mutations at position 155. Another possibility is changes in the level of 
protein degradation due to changes in rate of successful protein folding. Lower 
temperatures facilitate protein folding, and so cells could be incubated at a 
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lower temperature prior to Western blotting experiments to determine whether 
the total expression of the WT and mutant proteins are affected to a similar 
degree. For example, if the Y155H mutation of the rat P2X7 receptor increases 
protein misfolding, it would be expected that a lower temperature would 
increase the total protein expression of the mutant. 
The immunostaining experiments in chapter 6 showed that the WT rat 
P2X7 receptor immunoreactivity was concentrated towards the cell surface, 
whereas the WT human receptor immunoreactivity was diffuse throughout the 
cell. It would be interesting to determine the subcellular compartments in which 
the human P2X7 receptor is located. To achieve this, double immunostaining 
could be performed using markers for intracellular organelles, such as 
calreticulin (an ER protein marker), TGN46 (a trans-Golgi network protein 
marker), or LAMP1 (a lysosomal marker). 
Based on the results shown in chapter 7, it can be concluded that the 
residues that are not conserved between human and monkey P2X7 receptors 
are not critically engaged in interacting with KN-62, AZ11645373 and A-438079. 
The next step is to compare the antagonist profiles of monkey and dog P2X7 
receptors, which share 85% amino acid identity. This systematic comparison of 
antagonist profile between species will allow microdomains and residues 
important for antagonist binding to be identified. 
The WT monkey P2X7 receptor, like the rat receptor, has tyrosine at 
position 155 (Tyr155), and threonine at position 348 (Thr348). The finding that the 
ATP-induced maximal current amplitudes of the monkey P2X7 receptor were 
significantly lower than the human was rather unexpected. It was shown in 
chapter 4 that mutations H 155Y and A348T (which change the amino acids to 
the corresponding one in the rat WT receptor) of the human P2X7 receptor 
increased, whilst reciprocal mutations Y155H and T348A decreased agonist-
evoked maximal current amplitudes. Experiments to determine the effects of 
Y155H and T348A mutations of the monkey P2X7 receptors are required to 
ascertain whether the particular residues at 155 and 348 are important 
determinants of the ATP-induced functional expression of the monkey P2X7 
receptor. 
H155Y and A348T are ns-SNP mutations in the human P2RX7 gene and 
have not yet been associated with disease conditions. However, a recent study 
has found that monocytes from individuals carrying the A348T SNP showed 
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enhanced ATP-evoked secretion of pro-inflammatory cytokine Il-1P (Stokes et 
al., 2010). Further studies should be performed to determine the effect of these 
ns-SNP mutations on other ATP-evoked cell functions of the human P2X7 
receptor such as apoptosis, cell proliferation, neuron-glia interactions and bone 
remodelling (Baricordi et al., 1999; Chen et al., 2008; Ferrari et al., 1999; Ke et 
al., 2003; Zhang et al., 2009). Furthermore, there is evidence for roles of the 
P2X7 receptor in number of pathological conditions, including arthritis, Cll and 
pain (Chessell et al., 2005; labasi et al., 2002; Wiley et al., 2002). Thus, it 
would be interesting to examine by genetic linkage studies whether these ns-
SNP mutations are associated with human diseases. The information provided 
by this study should be useful in understanding the pathological functions of the 
P2X7 receptors and development suitable therapeutics. 
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Table 8.1 Summary of ECso1 pECso1 Hill coefficient and maximal current amplitudes 
Chapter Agonist and EC P2X7 receptor EC50 (IJM) pECso Hill IMAX (pNpF) n 
used coefficient 
3 ATP and LDEC hP2X7WT 397 ± 19 3.42 + 0.02 2.08 + 0.06 268 ± 12 29-30 
H155Y 313 ± 14 * 3.51 + 0.02 * 2.03 + 0.07A 391 + 19 *** A 10 
A348T 354 ± 26 3.46 + 0.03 1.80 + 0.08 * 324 + 17 * AM 12 
H155Y/A348T 360 ± 47 3.47 + 0.06 1.73 + 0.09 * 473 + 31 *** 7 
BzA TP and LDEC hP2X7 WT 36 ± 4.7 4.46 ± 0.05 2.06 ± 0.27 244 +4.5 4 
H155Y 27 ± 6.6 4.60 ± 0.11 2.09 ± 0.14 . 392±51* 4 
A348T 31 ± 3.9 4.51 ± 0.05 1.94 ± 0.14 447 ± 72 * 3 
ATP and LDEC hP2X7 WT 348 ± 14 3.47 + 0.02 1.89 + 0.04 293 + 13 28 
H155Y 324 ± 15 3.49 ± 0.02 1.95 ± 0.11 434 ± 19 *** 4 
H155F 402 ± 42 3.41 ± 0.05 1.95 ± 0.08 339 ± 27 7 
H155A 364 ± 52 3.46 ± 0.06 2.20 ± 0.09 ** 333 ± 68 5 
H155R 228 ± 29 *** 3.66 + 0.06 *** 1.83 + 0.04 325 + 48 6 
H155L 368 ± 31 3.44 ± 0.04 1.70 ± 0.13 171 ± 29 *** 5 
H155D 388 ± 43 3.42 ± 0.05 1.82 ± 0.04 214 ± 25 * 5 
ATP and LDEC hP2X7 WT 348 ± 14 3.47 ± 0.02 1.89 ± 0.04 293 ± 13 28 
H155Y 324 ± 15 3.49 ± 0.02 1.95 ± 0.11 434 ± 19 *** 4 
V154Y 365 ± 22 3.44 ± 0.03 2.01 ±0.10 260 ± 15 5 
E156Y 387 ± 30 3.42 ± 0.04 1.72 ± 0.09 137 ± 30 *** 6 
ATP and LDEC hP2X7 WT 392 ± 15 3.41 ± 0.02 2.14 ± 0.06 257 ± 13 18 
A348T 335 + 34 3.49 + 0.04 1.91 + 0.10 318+18* 7 
A348G 280 ± 25 ** 3.56 + 0.04 ** 1.94 + 0.12 394 ± 19 *** 4 
A348F 568 ± 74 ** 3.26 ± 0.05 ** 1 .71 + O. 11 ** 143 ± 42 ** 4 
A348M 580 ± 77 *** 3.25 ± 0.07 ** 1.91 ± 0.19 178±55* 4-5 
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4 ATP and LDEC hP2X7 Wf 304 ± 49 3.54 ± 0.07 2.03 ± 0.13 281 ± 18 5 
rP2X7 Wf 110 ± 6.1 ** 3.96 ± 0.02 *** 2.67 ± 0.18 * 458 ± 27 *** 5 
BzA TP and LDEC hP2X7 Wf 31 ± 3.7 4.53 ± 0.05 2.73 ± 0.29 234 ± 24 11 . 
rP2X7 Wf 1.9 ± 0.1 *** 5.72 ± 0.02 *** 3.59 ± 0.28 * 282 ± 21 12 
ATP and LDEC rP2X7 Wf 104 ± 5.2 3.99 ± 0.02 2.54 ± 0.07 444 ± 24 10 
Y155H 286 ± 10 *** 3.55 ± 0.02 *** A 2.40 ± 0.13 A 211 ± 25 *** A 7 
T348A 105 ± 5.4 M 3.98 ± 0.02 AM 2.51 ±0.18 A 326 ± 23 ** AM 7 
Y155HIT348A 500 ± 16 *** 3.34 ± 0.13 *** 1.72 ± 0.26 *** 114 ± 18 *** 3 
A TP and standard rP2X7 Wf 1470 ± 33 2.83 ± 0.01 2.57 ± 0.18 411 ± 21 5 
EC Y155H 2513 ± 114 *** 2.60 ± 0.02 *** 3.97 ± 0.13 *** 189 ± 37 *** 4-5 
T348A 1386 ± 142 2.86 ± 0.04 2.56 ± 0.26 230±8.1 *** 3 
BzA TP and LDEC rP2X7 Wf 1.7 ± 0.06 5.78 ± 0.02 3.56 ± 0.19 294 ± 28 7 
Y155H 8.0 ± 1.3 *** 5.12 ± 0.06 *** 2.78 ± 0.11 ** 129 ± 15 ** 5 
T348A 1.7±0.05 5.77 ± 0.01 3.48 ± 0.14 191 ± 24 * 5 
-- -- -- --- -
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5 ATP and LDEC hP2X7WT 347 ± 24 3.48 ± 0.03 2.04 ± 0.08 276 ± 15 23-24 
H155Y 285 ± 10 3.55 ± 0.02 2.08 ± 0.10 357 ± 29 * 5 
V1531 316 ± 32 3.51 ± 0.04 1.81 ± 0.05 215±19* 4 
V154P 314 ± 34 3.51 ± 0.05 1.86 ± 0.07 279 ± 74 3 I 
E156D 307 ± 65 3.55 ± 0.09 1.93 ± 0.19 240 ±47 5 
G1570 437 ± 47 3.37 ± 0.05 1.70 ± 0.03 197 ± 24 * 5 
N158K 400 ± 40 3.41 ± 0.05 1.83 ± 0.12 212 ± 40 4 
0159R 415 ± 34 3.39 ± 0.04 1.82 ± 0.07 184 ± 25** 6 
ATP and LDEC hP2X7WT 392 ± 15 3.41 ± 0.02 2.14 ± 0.06 257 ± 13 18 
A348T 335 ± 34 3.49 ± 0.04 1.91 ± 0.10 318±18* 7 
F350C 291 ± 32 * 3.54 ± 0.05 ** 1.71 ± 0.20 * 257 ± 63 4 
F353L 408 ± 56 3.40 ± 0.05 1.90 ± 0.06 318 ± 23 * 5 
L3541 357 ± 42 3.46 ± 0.05 1.96±0.12 278 ± 41 7 
D356N 291 ± 31 * 3.54 ± 0.05 ** 2.16 ± 0.14 191 ±16* 4 
ATP and LDEC rP2X7WT 108 ± 7 3.97 ± 0.03 2.39 ± 0.13 316 ± 29 4 
L353F 89 ± 13 4.07 ± 0.07 2.43 ± 0.15 371 ± 52 4 
7 ATP and LDEC hP2X7 314 ± 24 3.52 ± 0.04 1.92 ± 0.07 330 ± 22 12 
mP2X7 802 ± 87 *** 3.12 ± 0.04 *** 1.23 ± 0.06 *** 160 ± 22 *** 11 
BzA TP and LDEC hP2X7 30 ± 2.0 4.52 ± 0.03 2.19 ± 0.16 310 ± 36 5 
mP2X7 58 ± 4.2 *** 4.24 ± 0.03 *** 1.91 ± 0.08 220 ± 27 4-6 
---
Summary of all the values calculated in the thesis. * p<0.05, ** p<0.01, and *** p<0.001, compared to WT. A p<0.05, All p<0.01, and AAII 
p<0.001, compared to double mutant. EC: extracellular recording solution. LDEC: low divalent extracellular solution. 
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Table 8.2 Summary of ICso, plCso and Hill coefficients 
Chapter Antagonist P2X7 receptor IC50 (nM) plC50 Hill coefficient n 
13 KN-62 hP2X7 WT 127 ± 38 6.93±0.12 1.63±O.15 3 
H155Y 129 ± 20 6.90 ± 0.06 1.34 ± 0.07 3 
7 KN-62 hP2X7 WT 127 ± 38 6.93±0.12 1.63 ± 0.15 3 
mP2X7 WT 54 ± 8.3 7.28 ± 0.07 1.93±0.17 3 
AZ11645373 hP2X7 WT 31 ± 2.6 7.52 ± 0.04 1.77 ± 0.45 3 
mP2X7 WT 24 ± 3.0 7.64 ± 0.06 1.17 ± 0.14 3 
A-438079 hP2X7 WT 493 ± 94 6.35 ± 0.09 1.13 ± 0.05 6 
mP2X7 WT 297 ± 24 6.53 ± 0.03 0.85 ± 0.06 ** 6 
** p<0.01. Summary of all the values calculated in the thesis. Low divalent extracellular solution was used. 
175 
References 
ABBRACCHIO, M. P., BURNSTOCK, G., VERKHRATSKY, A. & 
ZIMMERMANN, H. (2009). Purinergic signalling in the nervous system: 
an overview. Trends Neurosci, 32: 19-29. 
ADINOLFI, E., CALLEGARI, M. G., FERRARI, D., BOLOGNESI, C., MINELLI, 
M., WIECKOWSKI, M. R, PINTON, P., RIZZUTO, R. & DI VIRGILIO, F. 
(2005). Basal activation of the P2X7 ATP receptor elevates mitochondrial 
calcium and potential, increases cellular ATP levels, and promotes 
serum-independent growth. Mol BioI Cell, 16: 3260-3272. 
ADINOLFI, E., MELCHIORNI, L., FALZONI, S., CHIOZZI, P., MORELLI, A., 
TIEGHI, A., CUNEO, A., CASTOLDI, G., DI VIRGILIO, F. & BARICORDI, 
O. R (2002). P2X7 receptor expression in evolutive and indolent forms of 
chronic B lymphocytic leukemia. Blood, 99: 706-708. 
ADRIOUCH, S., BANNAS, P., SCHWARZ, N., FLiEGERT, R, GUSE, A. H., 
SEMAN, M., HAAG, F. & KOCH-NOLTE, F. (2007). ADP-ribosylation at 
Arg 125 gates the P2X7 ion channel by presenting a covalent ligand to its 
nucleotide binding site. FASEB J, 22: 861-869. 
AGBOH, K. C., WEBB, T. E., EVANS, R. J. & ENNION, S. J. (2004). Functional 
characterisation of a P2X receptor from Schistosoma mansoni. J BioI 
Chern, 279: 41650-41657. 
ALCARAZ, L., BAXTER, A., BENT, J., BOWERS, K., BRADDOCK, M., 
CLADINGBOEL, D., DONALD, D., FAGURAi M., FURBER, M., 
LAURENT, C., LAWSON, M., MORTIMORE, M., MCCORMICK, M., 
ROBERTS, N. & ROBERTSON, M. (2003). Novel P2X7 receptor 
antagonists. Bioorg Med Chern Lett, 13: 4043-4046. 
ANDERSON, C. M. & NEDERGAARD, M. (2006). Emerging challenges of 
assigning P2X7 receptor function and immunoreactivity in neurons. 
Trends Neurosci, 29: 257-262. 
APOLLONI, S., MONTILLI, C., FINOCCHI, P. & AMADIO, S. (2009). Membrane 
compartments and purinergic signalling: P2X receptors in 
neurodegenerative and neuroinflammatory events. FEBS J, 27: 354-364. 
ARMSTRONG, J. N., BRUST, T. B., LEWIS, R G. & MACVICAR, B. A. (2002). 
Activation of presynaptic P2Xrlike receptors depresses mossy fiber-CA3 
176 
synaptic transmission through p38 mitogen-activated protein kinase. J 
Neurosci, 22: 5938-5945. 
ASTBURY, C., BLAKEY, G. E., SPRAY, H. E., PERRETT, J. H. & LAWRENCE, 
P. (2007). Single dose safety, tolerability, pharmacokinetics and 
pharmacodynamics of AZD9056, a novel P2X7 receptor antagonist, in 
healthy volunteers. Proceedings Annual Scientific Meeting of Am Coli 
Rheum Abtract 954: S397. 
BARALDI, P. G., DEL CARMEN NUA±EZ, M., MORELLI, A., FALZONI, S., DI 
VIRGILIO, F. & ROMAGNOLI, R (2003). Synthesis and biological 
activity of N-arylpiperazine-modified analogues of KN-62, a potent 
antagonist of the purinergic P2X7 receptor. J Med Chern, 46: 1318-1329. 
BARDEN, N., HARVEY, M., GAGNE, B., SHINK, E., TREMBLAY, M., 
RAYMOND, C., LABBE, M., VILLENEUVE, A., ROCHETIE, D., 
BORDELEAU, L., STADLER, H., HOLSBOER, F. & MULLER-MYHSOK, 
B. (2006). Analysis of single nucleotide polymorph isms in genes in the 
chromosome 12Q24.31 region points to P2X7 as a susceptibilty gene to 
bipolar defective disorder. Am J Med Gen B Neuropsychiatr Genet, 
141 B: 374-382. 
BARICORDI, O. R, MELCHIORRI, L., ADINOLFI, E., FALZONI, S., CHIOZZI, 
P., BUELL, G. & 01 VIRGILIO, F. (1999). Increased proliferation rate of 
lymphoid cells transfected with the P2X7 ATP receptor. J BioI Chern, 274: 
33206-33208. 
BARRERA, N. P., ORMOND, S. J., HENDERSON, R M., MURRELL-
LAGNADO, R D. & EDWARDSON, J. M. (2005). Atomic force 
microscopy imaging demonstrates that P2X2 receptors are trimers but 
that P2X6 receptor subunits do not oligomerise. J BioI Chern, 280: 
10759-10765. 
BEAN, B. P. (1990). ATP-activated channels in rat and bullfrog sensory 
neurons: concentration dependence and kinetics. J Neurosci, 10: 1-10. 
BIANCHI, B. R, LYNCH, K. J., TOUMA, E., NIFORATOS, W., BURGARD, E. 
C., ALEXANDER, K. M., PARK, H. S., YU, H., METZGER, R., 
KOWALUK, E., JARVIS, M. F. & VAN BIESEN, T. (1999). 
Pharmacological characterisation of recombinant human and rat P2X 
receptor subtypes. EurJ Pharmacal, 376: 127-138. 
177 
BO, X., JIANG, L.-H., WILSON, H. L., KIM, M., BURNSTOCK, G., 
SURPRENANT, A & NORTH, R. A (2003). Pharmacological and 
biophysical properties of the human P2X5 receptor. Mol Pharmacol, 63: 
1407-1416. 
BO, X., ZHANG, Y., NASSAR, M., BURNSTOCK, G. & SCHOEPFER, R. 
(1995). A P2X purinoceptor cDNA conferring a novel pharmacological 
profile. FEBS Lett, 375: 129-133. 
BODIN, P. & BURNSTOCK, G. (2001). Purinergic signalling: ATP release. 
Neurochem Res, 26: 959-969. 
BOLDT, W., KLAPPERSTUCK, M., BUDNER, C., SADTLER, S., 
SCHMALZING, N. & MARKWARDT, F. (2003). Glu496 Ala polymorphism 
of human P2X7 receptor does not affect its electrophysiological 
phenotype. Am J Physiol Cell Physiol, 284: C749-C756. 
BOUE-GRABOT, E., AKIMENKO, M. A & SEGUELA, P. (2000). Unique 
functional properties of a sensory neuronal P2X ATP-gated channel from 
zebrafish. J Neurochem, 75: 1600-1607. 
BOUMECHACHE, M., MASIN, M., EDWARDSON, J. M., GARECKI, D. C. & 
MURRELL-LAGNADO, R. (2009). Analysis of assembly and trafficking of 
native P2X4 and P2X7 receptor complexes in rodent immune cells. J BioI 
Chem, 284: 13446-13454. 
BRAKE, A J., WAGENBACH, M. J. & JULIUS, D. (1994). New structural motif 
for ligand-gated ion channels defined by an ionotropic ATP receptor. 
Nature, 371: 519-523. 
BROWNE, L. E, JIANG, L.-H. & NORTH, R. A (2010). New structure enlivens 
interest in P2X receptors. Trends Pharmacol Sci, 31: 229-237. 
BUELL, G., LEWIS, C., COLLO, G., NORTH, R. A & SURPRENANT, A 
(1996). An antagonist-insensitive P2X receptor expressed in epithelia 
and brain. EMBO J, 15: 55-62. 
BUELL, G. N., TALABOT, F., GOS, A, LORENZ, J., LAI, E, MORRIS, M. A & 
ANTONARAKIS, S. E. (1998). Gene structure and chromosomal 
localisation of the human P2X7 receptor. Receptors Channels, 5: 347-
354. 
BURGARD, E C., NIFORATOS, W., VAN BIESEN, T., LYNCH, K. J., KAGE, K. 
L., TOUMA, E, KOWALUK, E. A & JARVIS, M. F. (2000). Competitive 
antagonism of recombinant P2X2/3 receptors by 2',3'-0-(2,4,6-
178 
trinitrophenyl} adenosine 5'-triphosphate (TNP-ATP). Mol Pharmacol, 58: 
1502-1510. 
BURNSTOCK, CAMPBELL, G., SATCHELL, D. & SMYTHE, A (1970). 
Evidence that adenosine triphosphate or a related nucleotide is the 
transmitter substance released by non-adrenergic inhibitory nerves in the 
gut. Br J Pharmacol, 40: 668-688. 
BURNSTOCK, G. (1972). Purinergic nerves. Pharmacol Rev, 24: 509-581. 
BURNSTOCK, G. (1978). A basis for distinguishing two types of purinergic 
receptor. Cell membrane receptors for drugs and hormones: A 
multidisciplinary approach: 107-118. 
BURN STOCK, G. (2007). Purine and pyrimidine receptors. Cell Mol Life Sci, 64: 
1471-1483. 
CABRINI, G., FALZONI, S., FORCHAP, S. L., PELLEGATTI, P., BALBONI, A, 
AGOSTINI, P., CUNEO, A., CASTOLDI, G., BARICORDI, O. R. & DI 
VIRGILIO, F. (2005). A His 155 to Tyr polymorphism confers gain-of-
function to the human P2X7 receptor of human leukemic lymphocytes. J 
Immunol, 175: 82-89. 
CAO, L., BROOMHEAD, H. E., YOUNG, M. T. & NORTH, R. A (2009). Polar 
residues in the second transmembrane domain of the rat P2X2 receptor 
that affect spontaneous gating, unitary conductance, and rectification. J 
Neurosci, 29: 14257-14264. 
CAO, L., YOUNG, M. T., BROOMHEAD, H. E., FOUNTAIN, S. J. & NORTH, R. 
A (2007). Thr339-to-Ser sUbstitution in rat P2X2 receptor second 
transmembrane domain causes constitutive opening and indicates a 
gating role for Lys308. J Neurosci, 27: 12916-12923. 
CHEN, C.-C., AKOPIAN, A. N., SIVILOTTIT, L., COLQUHOUN, D., 
BURNSTOCK, G. & WOOD, J. N. (1995). A P2X purinoceptor expressed 
by a subset of sensory neurons. Nature, 377: 428-431. 
CHEN, L. & BROSNAN, C. F. (2006). Exacerbation of experimental 
autoimmune encephalomyelitis in P2X7R-1- mice: evidence for loss of 
apoptotic activity in lymphocytes. J Immunol, 176: 3115-3126. 
CHEN, Y., ZHANG, X., WANG, C., LI, G., GU, Y. & HUANG, L.-Y. M. (2008). 
Activation of P2X7 receptors in glial satellite cells reduces pain through 
downregulation of P2X3 receptors in nociceptive neurons. Proc Nat! Acad 
Sci USA, 105: 16773-16778. 
179 
CHESSELL, I. P., HATCHER, J. P., BOUNTRA, C., MICHEL, A D., HUGHES, 
J. P., GREEN, P., EGERTON, J., MURFIN, M., RICHARDSON, J., 
PECK, W. L., GRAHAMES, C. B. A, CASULA, M. A, YIANGOU, Y., 
BIRCH, R., ANAND, P. & BUELL, G. N. (2005). Disruption of the P2X7 
purinoceptor gene abolishes chronic inflammatory and neuropathic pain. 
Pain, 114: 386-396. 
CHESSELL, I. P., SIMON, J., HIBELL, A D., MICHEL, A D., BARNARD, E. A 
& HUMPHREY, P. P. A (1998). Cloning and functional characterisation 
of the mouse P2X7 receptor. FEBS Lett, 439: 26-30. 
CHOY, E. H. & PANAYI, G. S. (2001). Cytokine pathways and joint 
inflammation in rheumatoid arthritis. N Engl J Med, 344: 907-916. 
CLYNE, J. D., WANG, L.-F. & HUME, R. I. (2002). Mutational Analysis of the 
Conserved Cysteines of the Rat P2X2 Purinoceptor. J Neurosci, 22: 
3873-3880. 
COCKAYNE, D. A, HAMILTON, S. G., ZHU, Q.-M., DUNN, P. M., ZHONG, Y., 
NOVAKOVIC, S., MALMBERG, A B., CAIN, G., BERSON, A, 
KASSOTAKIS, L., HEDLEY, L., LACHNIT, W. G., BURNSTOCK, G., 
MCMAHON, S. B. & FORD, A P. D. W. (2000). Urinary bladder 
hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. 
Nature, 407: 1011-1015. 
COLLO, G., NEIDHART, S., KAWASHIMA, E., KOSCO-VILBOIS, M., NORTH, 
R. A & BUELL, G. (1997). Tissue distribution of the P2X7 receptor. 
Neuropharmacology, 36: 1277-1283. 
COLLO, G., NORTH, R. A, KAWASHIMA, E., MERLO-PICH, E., NEIDHART, 
S., SURPRENANT, A & BUELL, G. (1996). Cloning of P2Xs and P2X6 
receptors and the distribution and properties of an extended family of 
ATP-gated ion channels. J Neurosci, 16: 2495-2507. 
COX, J. A, BARMINA, O. & VOIGT, M. M. (2001). Gene structure, 
chromosomal localisation, cDNA cloning and expression of the mouse 
ATP-gated ionotropic receptor P2Xs subunit. Gene, 270: 145-152. 
CYR, D. M. 2005. Arrest of CFTR[Delta]F508 folding. Nat Struct Mol BioI, 12: 2. 
DAMER, S., NIEBEL, B., CZECHE, S., NICKEL, P., ARDANUY, U., 
SCHMALZING, G., RETTINGER, J., MUTSCHLER, E. & LAMBRECHT, 
G. (1998). NF279: a novel potent and selective antagonist of P2X 
receptor-mediated responses. Eur J Pharmacol, 350, R5-6. 
180 
DENLINGER, L. C., ANGELINI, G., SCHELL, K., GREEN, D. N., 
GUADARRAMA, A G., PRABHU, U., COURSIN, D. 8., BERTICS, P. J. 
& HOGAN, K. (2005). Detection of human P2X7 nucleotide receptor 
polymorph isms by a novel monocyte pore assay predictive of alterations 
in lipopolysaccharide-induced cytokine production. J Immunol, 174: 
4424-4431. 
DENLINGER, L. C., SOMMER, J. A, PARKER, K., GUDIPATY, L., FISETTE, 
P. L., WATTERS, J. W., PROCTOR, R. A, DUBYAK, G. R. & BERTICS, 
P. J. (2003). Mutation of a dibasic amino acid motif within the C-terminus 
of the P2X7 receptor results in trafficking defects and impaired function. J 
Immunol, 171: 1304-1311. 
DEUCHARS, S. A, ATKINSON, L., BROOKE, R. E., MUSA, H., MILLIGAN, C. 
J., BATTEN, T. F. C., BUCKLEY, N. J., PARSON, S. H. & DEUCHARS, 
J. (2001). Neuronal P2X7 receptors are targeted to presynaptic terminals 
in the central and peripheral nervous systems. J Neurosci, 21: 7143-
7152. 
01 VIRGILIO, F. (1995). The P2Z purinoceptor: an intriguing role in immunity, 
inflammation and cell death. Immunol Today, 16: 524-528. 
DIAZ-HERNANDEZ, M., COX, J. A, MIGITA, K., HAINES, W., EGAN, T. M. & 
VOIGT, M. M. (2002). Cloning and characterisation of two novel 
zebrafish P2X receptor subunits. Biochem Biophys Res Comm, 295: 
849-853. 
DONNELLY-ROBERTS, D. L., NAMOVIC, M. T., HAN, P. & JARVIS, M. F. 
(2009). Mammalian P2X7 receptor pharmacology: comparison of 
recombinant mouse, rat and human P2X7 receptors. Br J Pharmacol, 
157: 1203-1214. 
DONNELLY-ROBERTS, D. L. JARVIS, M. F. (2007). Discovery of P2X7 
receptor-selective antagonists offers new insights into P2X7 receptor 
function and indicates a role in chronic pain states. Br J Pharmacol, 
151:571-579. 
DORN, G., PATEL, S., WOTHERSPOON, G., HEMMINGS-MIESZCZAK, M., 
BARCLAY, J., NATT, F. J. C., MARTIN, P., BEVAN, S., FOX, A, 
GANJU, P., WISHART, W. & HALL, J. (2004). siRNA relieves chronic 
neuropathic pain. Nucleic Acids Res, 32: e49. 
181 
DRURY, A. N. & SZENT-GYORGYI, A. (1929). The physiological activity of 
adenine compounds with especial reference to their action upon the 
mammalian heart. J Physiol, 68: 213-237. 
DUAN, S., ANDERSON, C. M., KEUNG, E. C., CHEN, Y., CHEN, Y. & 
SWANSON, R. A. (2003). P2X7 receptor-mediated release of excitatory 
amino acids from astrocytes. J Neurosci, 23: 1320-1328. 
DUNN, P. & BLAKELEY, A. (1988). Suramin: a reversible P2-purinoceptor 
antagonist in the mouse vas deferens. Brit J Pharmacol, 93: 243-245. 
ENNION, S., HAGAN, S. & EVANS, R. J. (2000). The role of positively charged 
amino acids in ATP recognition by human P2X1 receptors. J BioI Chem, 
275: 29361-29367. 
ENNION, S. J. & EVANS, R. J. (2002). Conserved cysteine residues in the 
extracellular loop of the human P2X1 receptor form disulfide bonds and 
are involved in receptor trafficking to the cell surface. Mol Pharmacal, 61: 
303-311. 
EVANS, R. J. (2010). Structural interpretation of P2X receptor mutagenesis 
studies on drug action. Brit J Pharmacal, ahead of print. 
EVANS, R. J., LEWIS, C., BUELL, G., VALERA, S., NORTH, R. A. & 
SURPRENANT, A. (1995). Pharmacological characterisation of 
heterologously expressed ATP-gated cation channels (P2X 
Purinoceptors). Mol Pharmacal, 48: 178-183. 
FAIRBAIRN, I. P., STOBER, C. B., KUMARARATNE, D. S. & LAMMAS, D. A. 
(2001). ATP-mediated killing of intracellular Mycobacteria by 
macrophages is a P2X7-dependent process inducing bacterial death by 
phagosome-lysosome fusion. J Immunal, 167: 3300-3307. 
FERNANDO, S. L., SAUNDERS, B. M., SLUYTER, R., SKARRATI, K. K., 
GOLDBERG, H., MARKS, G. B., WILEY, J. S. & BRITTON, W. J. (2007). 
A polymorphism in the P2X7 gene increases susceptibility to 
extrapulmonary tuberculosis. Am J Respir Crit Care Med, 175: 360-366. 
FERRARI, D., CHIOZZI, P., FALZONI, S., DAL SUSINO, M., MELCHIORRI, L., 
BARICORDI, O. R. & DI VIRGILIO, F. (1997a). Extracellular ATP triggers 
IL-1 p release by activating the purinergic P2Z receptor of human 
macrophages. J Immunol, 159: 1451-1458. 
FERRARI, D., LOS, M., BAUER, M. K. A., VANDENABEELE, P., 
WESSELBORG, S. & SCHULZE-OSTHOFF, K. (1999). P2Z 
182 
purinoreceptor ligation induces activation of caspases with distinct roles 
in apoptotic and necrotic alterations of cell death. FEBS Lett, 447: 71-75. 
FERRARI, D., PIZZIRANI, C., ADINOLFI, E., LEMOLl, R. M., CURTI, A, 
IDZKO, M., PANTHER, E. & DI VIRGILIO, F. (2006). The P2X7 receptor: 
A key player in IL-1 processing and release. J Immunol, 176: 3877-3883. 
FERRARI, D., WESSELBORG, S., BAUER, M. K. A & SCHULZE-OSTHOFF, 
K. (1997b). Extracellular ATP activates transcription factor NF-KB 
through the P2Z purinoreceptor by selectively targeting NF-KB p65 
(ReIA). J Cell Bioi, 139: 1635-1643. 
FONFRIA, E., CLAY, W. C., LEVY, D. S., GOODWIN, J. A, ROMAN, S., 
SMITH, G. D., CONDREAY, J. P. & MICHEL, A D. (2008). Cloning and 
pharmacological characterisation of the guinea pig P2X7 receptor 
orthologue. Brit J Pharmacol, 153: 544-556. 
FOUNTAIN, S. J. & BURNSTOCK, G. (2009). An evolutionary history of P2X 
receptors. Purinergic Signal, 5: 269-272. 
FOUNTAIN, S. J., CAO, L., YOUNG, M. T. & NORTH, R. A (2008). Permeation 
properties of a P2X receptor in the green algae Ostreococcus tauri. J Bioi 
Chern, 283: 15122-15126. 
FOUNTAIN, S. J., PARKINSON, K., YOUNG, M. T., CAO, L., THOMPSON, C. 
R. L. & NORTH, R. A (2007). An intracellular P2X receptor required for 
osmoregulation in Dictyostelium discoideum. Nature, 448: 200-203. 
GARCIA-GUZMAN, M., SOTO, F., GOMEZ-HERNANDEZ, J. M., LUND, P.-E. 
& STAHMER, W. (1997a). Characterisation of recombinant human P2X4 
receptor reveals pharmacological differences to the rat homologue. Mol 
Pharmacol, 51: 109-118. 
GARCIA-GUZMAN, M., SOTO, F., LAUBE, 8. & STUHMER, W. (1996). 
Molecular cloning and functional expression of a novel rat heart P2X 
purinoceptor. FEBS Lett, 388: 123-127. 
GARCIA-GUZMAN, M., STOHMER, W. & SOTO, F. (1997b). Molecular 
characterisation and pharmacological properties of the human P2X3 
purinoceptor. Brain Res Mol Brain Res, 47: 59-66. 
GARGETT, C. E. & WILEY, J. S. (1997). The isoquinoline derivative KN-62 a 
potent antagonist of the P2Z-receptor of human lymphocytes. Br J 
Pharmacol, 120: 1483-1490. 
183 
GARTLAND, A, BUCKLEY, K. A, BOWLER, W. B. & GALLAGHER, J. A 
(2003). Blockade of the pore-forming P2X7 receptor inhibits formation of 
multinucleated human osteoclasts. Calcif Tissue Inti, 73: 361-369. 
GREEN, E. K., GROZEVA, D., RAYBOULD, R, ELVIDGE, G., MACGREGOR, 
S., CRAIG, I., FARMER, A, MCGUFFIN, P., FORTY, L., JONES, L., 
JONES, I., O'DONOVAN, M. C., Owen, M. J., KIROV, G. & 
CRADDOCK, N. (2009). P2RX7: A bipolar and unipolar disorder 
candidate susceptibility gene? Am J Med Gen B Neuropsychiatr Gen, 
150: 1063-1069. 
GODING, J. W., GROBBEN, B. & SLEGERS, H. (2003). Physiological and 
pathophysiological functions of the ecto-nucleotide 
pyrophosphatase/phosphodiesterase family. Biochim Biophys Acta, 
1638: 1-19. 
GONNORD, P., DELARASSE, C., AUGER, R, BENIHOUD, K., PRIGENT, M., 
CUIF, M. H., LAMAZE, C. & KANELLOPOULOS, J. M. (2009). 
Palmitoylation of the P2X7 receptor, an ATP-gated channel, controls its 
expression and association with lipid rafts. FASEB J, 23: 795-805. 
GRIGOROIU-SERBANESCU, M., HERMS, S., MOHLEISEN, T. W., GEORGI, 
A, DIACONU, C. C., STROHMAIER, J., CZERSKI, P., HAUSER, J., 
LESZCZYNSKA-RODZIEWICZ, A, JAMRA, R A, BABADJANOVA, G., 
TIGANOV, A, KRASNOV, V., KAPILETTI, S., NEAGU, A I., VOLLMER, 
J., BREUER, R, RIETSCHEL, M., NOTHEN, M. M., CICHON, S. & 
PROPPING, P. (2009) Variation in P2RX7 candidate gene (rs2230912) 
is not associated with bipolar I disorder and unipolar major depression in 
four European samples. Am J Med Gen B Neuropsychiatr Gen, 150B: 
1017-1021. 
GROSSMANN, M., NAKAMURA, Y., GRUMONT, R & GERONDAKIS, S. 
(1999). New insights into the roles of ReUNF-KB transcription factors in 
immune function, hemopoiesis and human disease. Inti J Biochem Cell 
BioI, 31: 1209-1219. 
GU, B. J., SLUYTER, R, SKARRATI, K. K., SHEMON, AN., DAO-UNG, L. P., 
FULLER, S. J., BARDEN, J. A, CLARKE, A L., PETROU, S. & WILEY, 
J. S. (2004). An Arg307 to Gin polymorphism within the ATP-binding site 
causes loss of function of the human P2X7 receptor. J BioI Chem, 279: 
31287-31295. 
184 
GU, B. J., ZHANG, W. Y., WORTHINGTON, R. A, SLUYTER, R, DAO-UNG, 
P., PETROU, S., BARDEN, J. A & WILEY, J. S. (2001). A Glu496 to Ala 
polymorphism leads to loss of function of the human P2X7 receptor. J 
BioI Chem, 276: 11135-11142. 
GUDIPATY, L., HUMPHREYS, B. D., BUELL, G. & DUBYAK, G. R (2001). 
Regulation of P2X7 nucleotide receptor function in human monocytes by 
extracellular ions and receptor density. Am J Physiol Cell Physiol, 280: 
C943-953. 
GUIMARAES, C. A & LINDEN, R (2004). Programmed cell deaths. Eur J 
Biochem, 271: 1638-1650. 
GUNOSEWOYO, H. & KASSIOU, M. (2010). P2X purinergic receptor ligands: 
recently patented compounds. Exp Opin Ther Pat, 20: 625-646. 
GUO, C., MASIN, M., QURESHI, O. S. & MURRELL-LAGNADO, R. D. (2007). 
Evidence for functional P2X4/P2X7 heteromeric receptors. Mol 
Pharmacol, 72: 1447-1456. 
HAINES, W. R, MIGITA, K., COX, J. A, EGAN, T. M. & VOIGT, M. M. (2001). 
The first transmembrane domain of the P2X receptor subunit participates 
in the agonist-induced gating of the channel. J BioI Chem, 276: 32793-
32798. 
HAINES, W. R, TORRES, G. E., VOIGT, M. M. & EGAN, T. M. (1999). 
Properties of the novel ATP-gated ionotropic receptor composed of the 
P2X1 and P2Xs isoforms. Mol Pharmacol, 56: 720-727. 
HAMILL, O. P., MARTY, A, NEHER, E., SAKMANN, B. & SIGWORTH, F. J. 
(1981). Improved patch-clamp techniques for high-resolution current 
recording from cells and cell-free membrane patches. Pflugers Arch, 391: 
85-100. 
HANAHAN, D. (1983). Studies on transformation of Escherichia coli with 
plasm ids. J Mol BioI, 166: 557-580. 
HECHLER, B. A, LENAIN, N. G., MARCHESE, P., VIAL, C., HElM, V. R, 
FREUND, M., CAZENAVE, J.-P., CATTANEO, M., RUGGERI, Z. M., 
EVANS, R & GACHET, C. (2003). A role of the fast ATP-gated P2X1 
cation channel in thrombosis of small arteries in vivo. J Expt Med, 198: 
661-667. 
185 
HIBELL, A D., KIDD, E. J., CHESSELL, I. P., HUMPHREY, P. P. A & MICHEL, 
A D. (2000). Apparent species differences in the kinetic properties of 
P2X7 receptors. Br J Pharmacol, 130: 167-173. 
HIBELL, A. D., THOMPSON, K. M., XING, M., HUMPHREY, P. P. A & 
MICHEL, A D. (2001). Complexities of measuring antagonist potency at 
P2X7 receptor orthologs. J Pharmacol Exp Ther, 296: 947-957. 
HOLTON, P. (1959). The liberation of adenosine triphosphate on antidromic 
stimulation of sensory nerves. J Physiol, 145: 494-504. 
HONORE, P., DONNELLY-ROBERTS, D., NAMOVIC, M. T., HSIEH, G., ZHU, 
C. Z., MIKUSA, J. P., HERNANDEZ, G., ZHONG, C., GAUVIN, D. M., 
CHANDRAN, P., HARRIS, R, MEDRANO, A P., CARROLL, W., 
MARSH, K., SULLIVAN, J. P., FAL TYNEK, C. R & JARVIS, M. F. 
(2006). A-740003 [N-(1-{[(Cyanoimino)(5-quinolinylamino) 
methyl]amino }-2,2 -dimethylpropyl)-2-(3 ,4-d imethoxyphenyl)acetamide], a 
novel and selective P2X7 receptor antagonist, dose-dependently reduces 
neuropathic pain in the rat. J Pharmacol Exp Ther, 319: 1376-1385. 
HULSMANN, M., NICKEL, P., KASSACK, M., SCHMALZING, G., 
LAMBRECHT, G. & MARKWARDT, F. (2003). NF449, a novel picomolar 
potency antagonist at human P2X1 receptors. Eur J Pharmacol, 470: 1-7. 
HUMPHREYS, B. D. & DUBYAK, G. R (1996). Induction of the P2Z1P2X7 
nucleotide receptor and associated phospholipase D activity by 
lipopolysaccharide and IFN-y in the human THP-1 monocytic cell line. J 
Immunol, 157: 5627-5637. 
HUMPHREYS, B. D., VIRGINIO, C., SURPRENANT, A, RICE, J. & DUBYAK, 
G. R. (1998). Isoquinolines as antagonists of the P2X7 nucleotide 
receptor: High selectivity for the human versus rat receptor homologues. 
Mol Pharmacal, 54: 22-32. 
JACOBSON, K. A, KIM, Y. C., WILDMAN, S. S., MOHANRAM, A, HARDEN, 
T. K., BOYER, J. L., KING, B. F. & BURNSTOCK, G. (1998). A 
pyridoxine cyclic phosphate and its 6-azoaryl derivative selectively 
potentiate and antagonise activation of P2X1 receptors. J Med Chem, 41: 
2201-2206. 
JARVIS, M. F., BIANCHI, B., UCHIC, J. T., CARTMELL, J., LEE, C.-H., 
WILLIAMS, M. & FALTYNEK, C. (2004). [3H]A-317491, a novel high-
186 
affinity non-nucleotide antagonist that specifically labels human P2X2/3 
and P2X3 receptors. J Pharmacol Exp Ther, 310: 407-416. 
JARVIS, M. F., BURGARD, E. C., MCGARAUGHTY, S., HONORE, P., LYNCH, 
K., BRENNAN, T. J., SUBIETA, A., VAN BIESEN, T., CARTMELL, J., 
BIANCHI, B., NIFORATOS, W., KAGE, K., YU, H., MIKUSA, J., 
WISMER, C. T., ZHU, C. Z., CHU, K., LEE, C.-H., STEWART, A. 0., 
POLAKOWSKI, J., COX, B. F., KOWALUK, E., WILLIAMS, M., 
SULLIVAN, J. & FAL TYNEK, C. (2002). A-317491, a novel potent and 
selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, 
reduces chronic inflammatory and neuropathic pain in the rat. Proc Nat 
Acad Sci USA, 99: 17179-17184. 
JIANG, L.-H., KIM, M., SPELTA, V., BO, X., SURPRENANT, A. & NORTH, R. 
A. (2003). Subunit arrangement in P2X receptors. J Neurosci, 23: 8903-
8910. 
JIANG, L.-H., MACKENZIE, A. B., NORTH, R. A. & SURPRENANT, A. (2000a). 
Brilliant blue G selectively blocks ATP-gated rat P2X7 receptors. Mol 
Pharmacol, 58: 82-88. 
JIANG, L.-H., RASSENDREN, F., MACKENZIE, A., ZHANG, Y.-H., 
SURPRENANT, A. & NORTH, R. A. (2005). N-methyl-D-glucamine and 
propidium dyes utilise different permeation pathways at rat P2X7 
receptors. Am J Physiol Cell Physiol, 289: C1295-1302. 
JIANG, L.-H., RASSENDREN, F., SURPRENANT, A. & NORTH, R. A. (2000b). 
Identification of amino acid residues contributing to the ATP-binding site 
of a purinergic P2X receptor. J BioI Chem, 275: 34190-34196. 
JIANG, L.-H., RASSENDREN, F. 0., SPELTA, V., SURPRENANT, A. & 
NORTH, R. A. (2001). Amino acid residues involved in gating identified in 
the first membrane-spanning domain of the rat P2X2 receptor. J BioI 
Chem, 276: 14902-14908. 
JIANG, L.-H., RASSENDREN, F., MACKENZIE, A., ZHANG, Y.-H, 
SURPRENANT, A . & NORTH, A. (2005). N-methyl-D-glucamine and 
propidium dyes utilise different permeation pathways at rat P2X7 
receptors. Am J Physiol Cell Physiol, 289: 1295-1302. 
JONES, C. A., CHESSELL, I. P., SIMON, J., BARNARD, E. A., MILLER, K. J., 
MICHEL, A. D. & HUMPHREY, P. P. A. (2000). Functional 
187 
characterisation of the P2X4 receptor orthologues. Br J Pharmacol, 129: 
388-394. 
JONES, C. A, VIAL, C., SELLERS, L. A, HUMPHREY, P. P. A, EVANS, R. J. 
& CHESSELL, I. P. (2004). Functional regulation of P2X6 receptors by N-
linked glycosylation: Identification of a novel up-methylene ATP-sensitive 
phenotype. Mol Pharmacol, 65: 979-985. 
JURANKA, P. F., HAGHIGHI, A P., GAERTNER, T., COOPER, E. & MORRIS, 
C. E. (2001). Molecular cloning and functional expression of Xenopus 
laevis oocyte ATP-activated P2X4 channels. Biochim Biophys Acta, 1512: 
111-124. 
KAWATE, T., MICHEL, J. C., BIRDSONG, W. T. & GOUAUX, E. (2009). Crystal 
structure of the ATP-gated P2X4 ion channel in the closed state. Nature, 
460: 592-598. 
KE, H. Z., QI, H., WEIDEMA, A F., ZHANG, Q., PANUPINTHU, N., 
CRAWFORD, D. T., GRASSER, W. A, PARALKAR, V. M., LI, M., 
AUDOL Y, L. P., GABEL, C. A, JEE, W. S. S., DIXON, S. J., SIMS, S. M. 
& THOMPSON, D. D. (2003). Deletion of the P2X7 nucleotide receptor 
reveals its regulatory roles in bone formation and resorption. Mol 
Endocrinol, 17: 1356-1367. 
KHAKH, B. S. & NORTH, R. A (2006). P2X receptors as cell-surface ATP 
sensors in health and disease. Nature, 442: 527-532. 
KIM, M., JIANG, L. H., WILSON, H. L., NORTH, R. A & SURPRENANT, A 
(2001). Proteomic and functional evidence for a P2X7 receptor signalling 
complex. EMBO J, 20: 6347-58. 
KING, B. F., LlU, M., PINTOR, J., GUALlX, J., MIRAS-PORTUGAL, M. T. & 
BURNSTOCK, G. (1999). Diinosine pentaphosphate (IP51) is a potent 
antagonist at recombinant rat P2X1 receptors. Br J Pharmacol, 128: 981-
988. 
KUKLEY, M., STAUSBERG, P., ADELMANN, G., CHESSELL, I. P. & 
DIETRICH, D. (2004). Ecto-nucleotidases and nucleoside transporters 
mediate activation of adenosine receptors on hippocampal mossy fibers 
by P2X7 receptor agonist 2'-3'-O-(4-Benzoylbenzoyl)-ATP. J Neurosci, 
24: 7128-7139. 
188 
KUSNER, D. J. & ADAMS, J. (2000). ATP-induced killing of virulent 
Mycobacterium tuberculosis within human macrophages requires 
phospholipase D. J Immunol, 164: 379-388. 
LABASI, J. M., PETRUSHOVA, N., DONOVAN, C., MCCURDY, S., LIRA, P., 
PAYETTE, M. M., BRISSETTE, W., WICKS, J. R., AUDOLY, L. & 
GABEL, C. A (2002). Absence of the P2X7 receptor alters leukocyte 
function and attenuates an inflammatory response. J Immunol, 168: 
6436-6445. 
LAMBRECHT, G., FRIEBE, T., GRIMM, U., WINDSCHEIF, U., BUNGARDT, E., 
HILDEBRANDT, C., BAUMERT, H. G., SPATZ-KUMBEL, G. & 
MUTSCHLER, E. (1992). PPADS, a novel functionally selective 
antagonist of P2 purinoceptor-mediated responses. Eur J Pharmacol, 
217: 217-219. 
LAMBRECHT, G., RETTINGER, J., BAUMERT, H. G., CZECHE, S., DAMER, 
S., GANSO, M., HILDEBRANDT, C., NIEBEL, B., SPATZ-KUMBEL, G., 
SCHMALZING, G. & MUTSCHLER, E. (2000). The novel pyridoxal-5'-
phosphate derivative PPNDS potently antagonises activation of P2X1 
receptors. Eur J Pharmacol, 387: R 19-21. 
LE, K.-T., PAQUET, M., NOUEL, D., BABINSKI, K. & SEGUELA, P. (1997). 
Primary structure and expression of a naturally truncated human P2X 
ATP receptor subunit from brain and immune system. FEBS Lett, 418: 
195-199. 
LENERTZ, L. Y., WANG, Z., GUADARRAMA, A, HILL, L. M., GAVALA, M. L. & 
BERTICS, P. J. (2010). Mutation of putative N-Iinked glycosylation sites 
on the human nucleotide receptor P2X7 reveals a key residue important 
for receptor function. Biochemistry, 49: 4611-4619. 
LEWIS, C., NEIDHART, S., HOLY, C., NORTH, R. A, BUELL, G. & 
SURPRENANT, A (1995). Coexpression of P2X2 and P2X3 receptor 
subunits can account for ATp-gated currents in sensory neurons. Nature, 
377: 432-435. 
L1, M., CHANG, T.-H., SILBERBERG, S. D. & SWARTZ, K. J. (2008). Gating 
the pore of P2X receptor channels. Nat Neurosci, 11: 883-887. 
LISTER, M., SHARKEY, J., SAWATZKY, D., HODGKISS, J., DAVIDSON, D., 
ROSSI, A & FINLAYSON, K. (2007). The role of the purinergic P2X7 
receptor in inflammation. J Inflamm, 4: 5. 
189 
LlU, L., ZOU, J., LlU, X., JIANG, L.-H. & LI, J. (2010). Inhibition of ATP-induced 
macrophage death by emodin via antagonising P2X7 receptor. Eur J 
Pharmacol, 640: 15-19. 
LlU, X., MA, W., SURPRENANT, A. & JIANG, L.-H. (2009). Identification of the 
amino acid residues in the extracellular domain of rat P2X7 receptor 
involved in functional inhibition by acidic pH. Br J Pharmacol, 156: 135-
142. 
LlU, X., SURPRENANT, A, MAO, H.-J., ROGER, S., XIA, R., BRADLEY, H. & 
JIANG, L.-H. (2008). Identification of key residues coordinating functional 
inhibition of P2X7 receptors by zinc and copper. Mol Pharmacol, 73: 252-
259. 
L6PEZ-CASTEJ6N, G., YOUNG, M. T., MESEGUER, J., SURPRENANT, A. & 
MULERO, V. (2007). Characterisation of ATP-gated P2X7 receptors in 
fish provides new insights into the mechanism of release of the 
leaderless cytokine interleukin-1j3. Mollmmunol, 44: 1286-1299. 
LUCAE, S., SAL YAKINA, D., BARDEN, N., HARVEY, M., GAGNE, B., LABBE, 
M., BINDER, E. B., UHR, M., PEAEZ-PEREDA, M., SILLABER, I., 
ISING, M., BRUCKL, T., L1EB, R., HOLSBOER, F. & MULLER-
MYHSOK, 8. (2006). P2X7, a gene coding fora purinergic ligand-gated 
ion channel, is associated with major depressive disorder. Human Mol 
Genet, 15: 2438-2445. 
LUSTIG, K. D., SHIAU, A K., BRAKE, A. J. & JULIUS, D. (1993). Expression 
cloning of an ATP receptor from mouse neuroblastoma cells. Proc Nat! 
Acad Sci USA, 90: 5113-5117. 
LYNCH, K. J., TOUMA, E., NIFORATOS, W., KAGE, K. L., BURGARD, E. C., 
VAN BIESEN, T., KOWALUK, E. A. & JARVIS, M. F. (1999). Molecular 
and functional characterisation of human P2X2 receptors. Mol 
Pharmacol, 56: 1171-1181. 
MACKENZIE, A 8., YOUNG, M. T., ADINOLFI, E. & SURPRENANT, A. (2005). 
Pseudoapoptosis induced by brief activation of ATP-gated P2X7 
receptors. J Bioi Chem, 280: 33968-33976. 
MARQUEZ-KLAKA, B., RETTINGER, J., BHARGAVA, Y., EISELE, T. & NICKE, 
A (2007). Identification of an intersubunit cross-link between substituted 
cysteine residues located in the putative ATP binding site of the P2X1 
receptor. J Neurosci, 27: 1456-1466. 
190 
MATUTE, C., TORRE, I., PEREZ-CERDA, F., PEREZ-SAMARTIN, A, 
AlBERDI, E., ETXEBARRIA, E., ARRANZ, AM., RAVID, R, 
RODRIGUEZ-ANTIGUEDAD, A, SANCHEZ-GOMEZ, M. & DOMERCQ, 
M. (2007). P2X7 receptor blockade prevents ATP excitotoxicity in 
oligodendrocytes and ameliorates experimental autoimmune 
encephalomyelitis. J Neurosci, 27: 9525-9533. 
MATUTES, E., OWUSU-ANKOMAH, K., MORlllA, R, GARCIA MARCO, J., 
HOULIHAN, A, QUE, T. H. & CATOVSKY, D. (1994). The 
immunological profile of B-cell disorders and proposal of a scoring 
system for the diagnosis of ClL. Leukemia, 8: 1640-1645. 
MCGARAUGHTY, S., CHU, K. L., NAMOVIC, M. T., DONNEllY-ROBERTS, 
D. L., HARRIS, R R., ZHANG, X. F., SHIEH, C. C., WISMER, C. T., 
ZHU, C. Z., GAUVIN, D. M., FABIYI, A C., HONORE, P., GREGG, R J., 
KORT, M. E., NELSON, D. W., CARROll, W. A, MARSH, K., 
FAl TYNEK, C. R & JARVIS, M. F. (2007). P2X7-related modulation of 
pathological nociception in rats. Neuroscience, 146: 1817-1828. 
MClARNON, J. G., RYU, J. K., WALKER, D. G. & CHOI, H. B. (2006). 
Upregulated expression of purinergic P2X7 receptor in Alzheimer disease 
and amyloid-P peptide-treated microglia and in peptide-injected rat 
hippocampus. J Neuropath Expt Neurol, 65,1090-1097. 
MCQUilLIN, A, BASS, N. J., CHOUDHURY, K., PURl, V., KOSMIN, M., 
LAWRENCE, J., CURTIS, D. & GURLlNG, H. M. D. (2008). Case-control 
. studies show that a non-conservative amino-acid change from a 
glutamine to arginine in the P2X7 purinergic receptor protein is 
associated with both bipolar- and unipolar-affective disorders. Mol 
psychiatry, 14: 614-620. 
MICHEL, A D., CLAY, W. C., NG, S. W., ROMAN, S., THOMPSON, K., 
CONDREAY, J. P., HAll, M., HOLBROOK, J., LIVERMORE, D. & 
SENGER, S. (2008). Identification of regions of the P2X7 receptor that 
contribute to human and rat species differences in antagonist effects. Br 
J Pharmacol, 155: 738-751. 
MICHEL, A D., NG, S. W., ROMAN, S., CLAY, W. C., DEAN, D. K. & WALTER, 
D. S. (2009). Mechanism of 'action of species-selective P2X7 receptor 
antagonists. BrJ Pharmacol, 156: 1312-1325. 
191 
MULRYAN, K., GIDERMAN, D. P., LEWIS, C. J., VIAL, C., LECKIE, B. J., 
COBB, A L., BROWN, J. E., CONLEY, E. C., BUELL, G., PRITCHARD, 
C. A & EVANS, R. J. (2000). Reduced vas deferens contraction and 
male infertility in mice lacking P2X1 receptors. Nature, 403: 86-89. 
MURGIA, M., HANAU, S., PIZZO, P., RIPPA, M. & DIVIRGILIO, F. (1993). 
Oxidized ATP - an irreversible inhibitor of the macrophage purinergic 
P2Z receptor. J BioI Chern, 268: 8199-8203. 
MURRELL-LAGNADO, R. D. & QURESHI, O. S. (2008). Assembly and 
trafficking of P2X purinergic receptors. Mol Mernbr BioI, 25: 321 - 331. 
NAWA, G., URANO, T., TOKINO, T., OCHI, T. & MIYOSHI, Y. (1998). Cloning 
and characterisation of the murine P2XM receptor gene. J Hurn Genet. , 
43: 262-267. 
NELSON, D. W., GREGG, R. J., KORT, M. E., PEREZ-MEDRANO, A, 
VOIGHT, E. A, WANG, Y., GRAYSON, G., NAMOVIC, M. T., 
DONNELLY-ROBERTS, D. L., NIFORATOS, W., HONORE, P., JARVIS, 
M. F., FAL TYNEK, C. R. & CARROLL, W. A (2006). Structure-activity 
relationship studies on a series of novel, substituted 1-benzyl-5-
phenyltetrazole P2X7 antagonists. J Med Chern, 49: 3659-3666. 
NICKE, A, BAUMERT, H. G., REDINGER, J., EICHELE, A, LAMBRECHT, 
G., MUTSCHLER, E. & SCHMALZING, G. (1998). P2X1 and P2X3 
receptors form stable trimers: a novel structural motif of ligand-gated ion 
channels. EMBO J, 17: 3016-3028. 
NICKE, A (2008). Homotrimeric complexes are the dominant assembly state of 
native P2X7 subunits. Biochem Biophys Res Commun, 377:803-808. 
NICKE, A (2009). A Functional P2X7 splice variant with an alternative 
transmembrane domain 1 escapes gene inactivation in P2X7 knock-out 
mice. J BioI Chern, 284:25813-25822. 
NOGUCHI, T., ISHII, K., FUKUTOMI, H., NAGURO, I., MATSUZAWA, A, 
TAKEDA, K. & ICHIJO, H. (2008). Requirement of reactive oxygen 
species-dependent activation of ASK1-p38 MAPK pathway for 
extracellular ATP-induced apoptosis in macrophage. J BioI Chern, 283: 
7657-7665. 
NORTH, R. A (2002). Molecular physiology of P2X receptors. Physiol Rev, 82: 
1013-1067. 
192 
PARVATHENANI, L. K., TERTYSHNIKOVA, S., GRECO, C. R., ROBERTS, S. 
B., ROBERTSON, B. & POSMANTUR, R. (2003). P2X7 mediates 
superoxide production in primary microglia and is up-regulated in a 
transgenic mouse model of Alzheimer's disease. J BioI Chern, 278: 
13309-13317. 
PAUKERT, M., HIDAYAT, S. & GRONDER, S. (2002). The P2X7 receptor from 
Xenopus laevis: formation of a large pore in Xenopus oocytes. FEBS 
Lett, 513: 253-258. 
PELEGRIN, P. & SURPRENANT, A (2006). Pannexin-1 mediates large pore 
formation and interleukin-1 release by the ATP-gated P2X7 receptor. 
EMBO J, 25: 5071-5082. 
RALEVIC, V. & BURNSTOCK, G. (1998). Receptors for purines and 
pyrimidines. Pharmacol Rev, 50: 413-492. 
RASSENDREN, F., BUELL, G. N., VIRGINIO, C., COLLO, G., NORTH, R A & 
SURPRENANT, A (1997b). The permeabilising ATP receptor, P2X7. 
CLONING AND EXPRESSION OF A HUMAN cDNA J BioI Chern, 272: 
5482-5486. 
REDINGER, J., BRAUN, K., HOCHMANN, H., KASSACK, M. U., ULLMANN, 
H., NICKEL, P., SCHMALZING, G. & LAMBRECHT, G. (2005). Profiling 
at recombinant homomeric and heteromeric rat P2X receptors identifies 
the suramin analogue NF449 as a highly potent P2X1 receptor 
antagonist. Neuropharmacology, 48: 461-468. 
REDINGER, J., SCHMALZING, G., DAMER, S., MULLER, G., NICKEL, P. & 
LAMBRECHT, G. (2000). The suramin analogue NF279 is a novel and 
potent antagonist selective for the P2X1 receptor. Neuropharmacology, 
39: 2044-2053. 
ROBERTS, J. A, DIGBY, H. R, KARA, M., AJOUZ, S. E., SUTCLIFFE, M. J. & 
EVANS, R. J. (2008). Cysteine substitution mutagenesis and the effects 
of methanethiosulfonate reagents at P2X2 and P2X4 receptors support a 
core common mode of ATP action at P2X receptors. J BioI Chern, 283: 
20126-20136. 
ROBERTS, J. A & EVANS, R J. (2004). ATP Binding at Human P2X1 
Receptors: CONTRIBUTION OF AROMATIC AND BASIC AMINO 
ACIDS REVEALED USING MUTAGENESIS AND PARTIAL AGONISTS. 
J BioI Chern, 279: 9043-9055. 
193 
ROBERTS, J. A & EVANS, R. J. (2006). Contribution of conserved polar 
glutamine, asparagine and threonine residues and glycosylation to 
agonist action at human P2X1 receptors for ATP. J Neurochem, 96: 843-
852. 
ROBERTS, J. A & EVANS, R. J. (2007). Cysteine substitution mutants give 
structural insight and identify ATP binding and activation sites at P2X 
receptors. J Neurosci, 27: 4072-4082. 
ROBERTS, J. A, VALENTE, M., ALLSOPP, R. C., WATT, D. & EVANS, R. J. 
(2009). Contribution of the region Glu 181 to Val200 of the extracellular loop 
of the human P2X1 receptor to agonist binding and gating revealed using 
cysteine scanning mutagenesis. J Neurochem, 109: 1042-1052. 
ROGER, S., MEl, Z.-Z., BALDWIN, J. M., DONG, L., BRADLEY, H., BALDWIN, 
S. A, SURPRENANT, A & JIANG, L.-H. (2010a). Single nucleotide 
polymorph isms that were identified in affective mood disorders affect 
ATP-activated P2X7 receptor functions. J Psych Res, 44: 347-355. 
ROGER, S., PELEGRIN, P. & SURPRENANT, A (2008). Facilitation of P2X7 
receptor currents and membrane blebbing via constitutive and dynamic 
calmodulin binding. J Neurosci, 28: 6393-6401. 
ROGER, S. B., GILLET, L., BAROJA-MAZO, A, SURPRENANT, A & 
PELEGRIN, P. (2010b). C-terminal calmodulin-binding motif differentially 
controls human and rat P2X7 receptor current facilitation. J Bioi Chem, 
285: 17514-17524. 
ROMAN, S., CUSDIN, F., FONFRIA, E., GOODWIN, J., REEVES, J., LAPPIN, 
S., CHAMBERS, L., WALTER, D., CLAY, W. & MICHEL, A (2009). 
Cloning and pharmacological characterisation of the dog P2X7 receptor. 
Brit J Pharmacal, 158: 1513-1526. 
RONG, W., GOURINE, A V., COCKAYNE, D. A, XIANG, Z., FORD, A P. D. 
W., SPYER, K. M. & BURNSTOCK, G. (2003). Pivotal role of nucleotide 
P2X2 receptor subunit of the ATP-gated ion channel mediating ventilatory 
responses to hypoxia. J Neurosci, 23: 11315-11321. 
RYTEN, M., DUNN, P. M., NEARY, J. T. & BURNSTOCK, G. (2002). ATP 
regulates the differentiation of mammalian skeletal muscle by activation 
of a P2X5 receptor on satellite cells. J Cell Bioi, 158: 345-355. 
194 
RYU, J. K. & MCLARNON, J. G. (2008). Block of purinergic P2X7 receptor is 
neuroprotective in an animal model of Alzheimer's disease. NeuroReport, 
19: 1715-1719. 
SAlMI, Y. & KUNG, C. (2002). Calmodulin as an ion channel subunit. Ann Rev 
Physiol, 64: 289-311. 
SANCHEZ-NOGUEIRO, J., MARIN-GARCIA, P. & MIRAS-PORTUGAL, M. T. 
(2005). Characterisation of a functional P2Xr like receptor in cerebellar 
granule neurons from P2X7 knockout mice. FEBS Lett, 579: 3783-3788. 
SASAKI, E., SUEMIZU, H., SHIMADA, A, HANAZAWA, K., OIWA, R, 
KAMIOKA, M., TOMIOKA, I., SOTOMARU, Y., HIRAKAWA, R, ETO, T., 
SHIOZAWA, S., MAEDA, T., ITO, M., ITO, R, KITO, C., YAGIHASHI, C., 
KAWAI, K., MIYOSHI, H., TANIOKA, Y., TAMAOKI, N., HABU, S., 
OKANO, H. & NOMURA, T. (2009). Generation of transgenic non-human 
primates with germline transmission. Nature, 459: 523-527. 
SAUNDERS, B. M., FERNANDO, S. L., SLUYTER, R., BRITTON, W. J. & 
WILEY, J. S. (2003). A loss-of-function polymorphism in the human P2X7 
receptor abolishes ATP-mediated killing of mycobacteria. J Immunol, 
171: 5442-5446. 
SHARP, A, POLAK, P., SIMONINI, V., LIN, S., RICHARDSON, J., 
BONGARZONE, E. & FEINSTEIN, D. (2008). P2X7 deficiency 
suppresses development of experimental autoimmune 
encephalomyelitis. J Neuroinflammation, 5: 33. 
SHEMON, A N., SLUYTER, R., FERNANDO, S. L., CLARKE, A L., DAO-UNG, 
L. P., SKARRATT, K. K., SAUNDERS, B. M., TAN, K. S., GU, B. J., 
FULLER, S. J., BRITTON, W. J., PETROU, S. & WILEY, J. S. (2006). A 
Thr357 to Ser polymorphism in homozygous and compound heterozygous 
subjects causes absent or reduced P2X7 function and impairs ATP-
induced mycobacterial killing by macrophages. J BioI Chem, 281: 2079-
2086. 
SHINK, E., HARVEY, M., TREMBLAY, M., GAGNE, B., BELLEAU, P., 
RAYMOND, C., LABBE, M., DUBE, M. P., LAFRENIERE, R. G. & 
BARDEN, N. (2005). Analysis of microsatellite markers and single 
nucleotide polymorph isms in candidate genes for susceptibility to bipolar 
affective disorder in the chromosome 12Q24.31 region. American 
195 
Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 135: 50-
58. 
SIM, J. A, CHAUMONT, S., JO, J., ULMANN, L., YOUNG, M. T., CHO, K., 
BUELL, G., NORTH, R. A & RASSENDREN, F. (2006). Altered 
hippocampal synaptic potentiation in P2X4 knock-out mice. J Neurosci, 
26: 9006-9009. 
SIM, J. A, YOUNG, M. T., SUNG, H.-Y., NORTH, R. A & SURPRENANT, A 
(2004). Reanalysis of P2X7 receptor expression in rodent brain. J 
Neurosci, 24: 6307-6314. 
SLUYTER, R., DALlTZ, J. G. & WILEY, J. S. (2004a). P2X7 receptor 
polymorphism impairs extracellular adenosine 5 '-triphosphate-induced 
interleukin-18 release from human monocytes. Genes Immunity, 5: 588-
591. 
SLUYTER, R., SHEMON, A N. & WILEY, J. S. (2004b). GIU496 to Ala 
polymorphism in the P2X7 receptor impairs ATP-induced I L-1 ~ release 
from human monocytes. J Immunol, 172: 3399-3405. 
SMART, M. L., GU, B., PANCHAL, R. G., WILEY, J., CROMER, B., WILLIAMS, 
D. A & PETROU, S. (2003). P2X7 receptor cell surface expression and 
cytolytic pore formation are regulated by a distal C-terminal region. J Bioi 
Chem, 278: 8853-8860. 
SaLLE, M., LABASI, J., PERREGAUX, D. G., STAM, E., PETRUSHOVA, N., 
KOLLER, B. H., GRIFFITHS, R. J. & GABEL, C. A (2001). Altered 
cytokine production in mice lacking P2X7 receptors. J Bioi Chem, 276: 
125-132. 
SOMERS, J. M., GOLDNER, E. M., WARAICH, P. & HSU, L. (2006). 
Prevalence and incidence studies of anxiety disorders: a systematic 
review of the literatu re. Can J Psychiatry, 51: 100-113. 
SOTO, F., GARCIA-GUZMAN, M., KARSCHIN, C. & STUHMER, W. (1996). 
Cloning and tissue distribution of a novel P2X receptor from rat brain. 
Biochem Biophys Res Comm, 223: 456-460. 
SOTO, F., GARCIA-GUZMAN, M. & STOHMER, W. (1997). Cloned ligand-
gated channels activated by extracellular ATP (P2X receptors). J Mem 
Bioi, 60: 91-100. 
196 
SOTO, F., KRAUSE, U., BORCHARDT, K. & RUPPELT, A (2003). Cloning, 
tissue distribution and functional characterisation of the chicken P2X1 
receptor. FEBS Lett, 533: 54-58. 
SOTO, F., LAMBRECHT, G., NICKEL, P., STUHMER, W. & BUSCH, A E. 
(1999). Antagonistic properties of the suramin analogue NF023 at 
heterologously expressed P2X receptors. Neuropharmacology, 38: 141-
149. 
SOUSLOVA, V., CESARE, P., DING, Y., AKOPIAN, AN., STANFA, L., 
SUZUKI, R, CARPENTER, K., DICKENSON, A, BOYCE, S., HILL, R, 
NEBENIUS-OOSTHUIZEN, D., SMITH, A J. H., KIDD, E. J. & WOOD, J. 
N. (2000). Warm-coding deficits and aberrant inflammatory pain in mice 
lacking P2X3 receptors. Nature, 407: 1015-1017. 
SOUSLOVA, V., RAVENALL, S., FOX, M., WELLS, D., WOOD, J. N. & 
AKOPIAN, A. N. (1997). Structure and chromosomal mapping of the 
mouse P2X3 gene. Gene, 195: 101-111. 
SPERLAGH, B., KOFALVI, A, DEUCHARS, J., ATKINSON, L., J. MILLIGAN, 
C., BUCKLEY, N. J. & VIZI, E. S. (2002). Involvement of P2X7 receptors 
in the regulation of neurotransmitter release in the rat hippocampus. J 
Neurochem, 81: 1196-1211. 
STOKES, L., FULLER, S. J., SLUYTER, R., SKARRATT, K. K., GU, B. J. & 
WILEY, J. S. (2010). Two haplotypes of the P2X7 receptor containing the 
Ala348 to Thr polymorphism exhibit a gain-of-function effect and 
enhanced interleukin-1p secretion. FASEB J, 24: 2916-2927. 
STOKES, L., JIANG, L. H., ALCARAZ, L., BENT, J., BOWERS, K., FAGURA, 
M., FURBER, M., MORTIMORE, M., LAWSON, M., THEAKER, J., 
LAURENT, C., BRADDOCK, M. & SURPRENANT, A (2006). 
Characterisation of a selective and potent antagonist of human P2X7 
receptors, AZ11645373. Br J Pharmacol, 149: 880-887. 
SURPRENANT, A., RASSENDREN, F., KAWASHIMA, E., NORTH, R A & 
BUELL, G. (1996). The cytolytic P2Z receptor for extracellular ATP 
identified as a P2X receptor (P2X7). Science, 272: 735-738. 
THUNBERG, U., TOBIN, G., JOHNSON, A, SODERBERG, 0., PADYUKOV, 
L., HUL TDIN, M., KLARESKOG, L., ENBLAD, G., SUNDSTROM, C., 
ROOS, G. & ROSENQUIST, R (2002). Polymorphism in the P2X7 
197 
receptor gene and survival in chronic lymphocytic leukaemia. Lancet, 
360: 1935-1939. 
TORRES, G. E., EGAN, T. M. & VOIGT, M. M. (1999). Hetero-oligomeric 
assembly of P2X receptor subunits. SPECIFICITIES EXIST WITH 
REGARD TO POSSIBLE PARTNERS. J BioI Chem, 274: 6653-6659. 
TOWNSEND-NICHOLSON, A,' KING, B. F., WILDMAN, S. S. & BURNSTOCK, 
G. (1999). Molecular cloning, functional characterisation and possible 
cooperativity between the murine P2X4 and P2X4a receptors. Mol Brain 
Res, 64: 246-254. 
TSUDA, M., SHIGEMOTO-MOGAMI, Y., KOIZUMI, S., MIZOKOSHI, A, 
KOHSAKA, S., SALTER, M. W. & INOUE, K. (2003). P2X4 receptors 
induced in spinal microglia gate tactile allodynia after nerve injury. 
Nature, 424: 778-783. 
URANO, T., NISHIMORI, H., HAN, H., FURUHATA, T., KIMURA, Y., 
NAKAMURA, Y. & TOKINO, T. (1997). Cloning of P2XM, a novel human 
P2X receptor gene regulated by p53. Cancer Res., 57: 3281-3287. 
VALERA, S., HUSSY, N., EVANS, R. J., ADAMI, N., NORTH, R. A, 
SURPRENANT, A & BUELL, G. (1994). A new class of ligand-gated ion 
channel defined by P2X receptor for extracellular ATP. Nature, 371: 516. 
VALERA, S., TALABOT, F., EVANS, R. J., GOS, A, ANTONARAKIS, S. E., 
MORRIS, M. A & BUELL, G. N. (1995). Characterisation and 
chromosomal localisation of a human P2X receptor from the urinary 
bladder. Receptors Channels, 3: 283-289. 
VIAL, C. & EVANS, R. J. (2000). P2X receptor expression in mouse urinary 
bladder and the requirement of P2X1 receptors for functional P2X 
receptor responses in the mouse urinary bladder smooth muscle. Brit J 
Pharmacal, 131: 1489-1495. 
VIAL, C. & EVANS, R. J. (2002). P2X1 receptor-deficient mice establish the 
native P2X receptor and a P2Ys-like receptor in arteries. Mol Pharmacal, 
62: 1438-1445. 
VIRGINIO, C., CHURCH, D., NORTH, R. A & SURPRENANT, A (1997). 
Effects of divalent cations, protons and calmidazolium at the rat P2X7 
receptor. Neuropharmacology, 36: 1285-1294. 
VIRGINIO, C., ROBERTSON, G., SURPRENANT, A & NORTH, R. A (1998). 
Trinitrophenyl-substituted nucleotides are potent antagonists selective for 
198 
P2X1, P2X3, and Heteromeric P2X2/3 Receptors. Mol Pharmacol, 53: 969-
973. 
VON KOGELGEN, I. (2006). Pharmacological profiles of cloned mammalian 
P2Y-receptor subtypes. Pharmacol Ther, 110: 415-432. 
WALKER, E., SARASTE, M., RUNSWICK, M. J. & GAY, N. J. (1982). Distantly 
related sequences in the alpha- and beta-subunits of ATP synthase, 
myosin, kinases and other ATP-requiring enzymes and a common 
nucleotide binding fold. EMBO J, 1: 945-951. 
WEBB, T. E., SIMON, J., KRISHEK, B. J., BATESON, A N., SMART, T. G., 
KING, B. F., BURNSTOCK, G. & BARNARD, E. A (1993). Cloning and 
functional expression of a brain G-protein-coupled ATP receptor. FEBS 
Lett, 324: 219-225. 
WILEY, J. S., DAO-UNG, L. P., GU, B. J., SLUYTER, R, SHEMON, AN., LI, 
C. P., TAPER, J., GALLO, J. & MANOHARAN, A (2002). A loss-of-
function polymorphic mutation in the cytolytic P2X7 receptor gene and 
chronic lymphocytic leukaemia: a molecular study. Lancet, 35: 1114-
1119. 
WILEY, J. S., DAO-UNG, L. P., LI, C. P., SHEMON, AN., GU, B. J., SMART, 
M. L., FULLER, S. J., BARDEN, J. A, PETROU, S. & SLUYTER, R 
(2003). An IIe568 to Asn polymorphism prevents normal trafficking and 
function of the human P2X7 receptor. J BioI Chem, 278: 17108-17113. 
WILKINSON, W. J., JIANG, L.-H., SURPRENANT, A & NORTH, R A (2006). 
Role of ectodomain Iysines in the subunits of the heteromeric P2X2/3 
receptor. Mol Pharmacol, 70: 1159-1163. 
WiniNG, A, CHEN, L., CUDABACK, E., STRAIKER, A, WALTER, L., 
RICKMAN, B., MALLER, T., BROSNAN, C. & STELLA, N. (2006). 
Experimental autoimmune encephalomyelitis disrupts endocannabinoid-
mediated neuroprotection. Proc Nat! Acad Sci USA, 103: 6362-6367. 
WORTHINGTON, R A, SMART, M. L., GU, B. J., WILLIAMS, D. A, PETROU, 
S., WILEY, J. S. & BARDEN, J. A (2002). Point mutations confer loss of 
ATP-induced human P2X7 receptor function. FEBS Lett, 512: 43-46. 
www.atrazeneca.com. Homepage. Accessed 14th Jan 2011.· 
www.clinicaltrials.gov. Homepage. Accessed 14th Jan 2011. 
XIAO, J., SUN, L., JIAO, W., LI, Z., ZHAO, S., LI, H., JIN, J., JIAO, A, GUO, Y., 
JIANG, Z., MOKROUSOV, I. & SHEN, A (2009). Lack of association 
199 
between polymorph isms in the P2X7 gene and tuberculosis in a Chinese 
Han population. FEMS Immunol Med Micro, 55: 107-111. 
YAMAMOTO, K., SOKABE, T., MATSUMOTO, T., YOSHIMURA, K., SHIBATA, 
M., OHURA, N., FUKUDA, T., SATO, T., SEKINE, K., KATO, S., 
ISSHIKI, M., FUJITA, T., KOBAYASHI, M., KAWAMURA, K., MASUDA, 
H., KAMIYA, A. & ANDO, J. (2006). Impaired flow-dependent control of 
vascular tone and remodeling in P2X4-deficient mice. Nat Med, 12: 133-
137. 
YANG, S.-H., CHENG, P.-H., BANTA, H., PIOTROWSKA-NITSCHE, K., YANG, 
J.-J., CHENG, E. C. H., SNYDER, B., LARKIN, K., L1U, J., ORKIN, J., 
FANG, Z.-H., SMITH, Y., BACHEVALlER, J., ZOlA, S. M., L1, S.-H., L1, 
X.-J. & CHAN, A. W. S. (2008). Towards a transgenic model of 
Huntington's disease in a non-human primate. Nature, 453: 921-924. 
YEGUTKIN, G. G. 2008. Nucleotide- and nucleoside-converting ectoenzymes: 
Important modulators of purinergic signalling cascade. Biochim Biophys 
Acta, 1783: 673-694. 
YOUNG, M. T. (2010). P2X receptors: dawn of the post-structure era. Trends 
Biochem Sci, 35: 83-90. 
YOUNG, M. T., PElEGRIN, P. & SURPRENANT, A. (2007). Amino acid 
residues in the P2X7 receptor that mediate differential sensitivity to ATP 
and BzATP. Mol Pharmacal, 71: 92-100. 
ZEMKOVA, H., YAN, Z., LIANG, Z., JELINKOVA, I., TOMIC, M. & 
STOJllKOVIC, S. S. (2007). Role of aromatic and charged ectodomain 
residues in the P2X4 receptor functions. J Neurochem, 102; 1139-1150. 
ZHANG, L. Y., IBBOTSON, R. E., ORCHARD, J. A., GARDINER, A. C., 
SEEAR, R. V., CHASE, A. J., OSCIER, D. G. & CROSS, N. C. P. (2003). 
P2X7 polymorphism and chronic lymphocytic leukaemia: lack of 
correlation with incidence, survival and abnormalities of chromosome 12. 
Leukemia, 17: 2097-2100. 
ZHANG, X., CHEN, Y., WANG, C. & HUANG, L. Y. M. (2007). Neuronal 
somatic ATP release triggers neuron-satellite glial cell communication in 
dorsal root ganglia. Proc Nat! Acad Sci USA, 104: 9864-9869. 
200 
